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INVESTIGATION OF PROLIFERATION SUPPRESSORS IN
GENETIC FITNESS SCREENS
Walter Frank Lenoir IV, B.S.
Advisory Professor: G. Traver Hart, Ph.D.
Innovation of CRISPR gene-editing technology has provided scientists genome
manipulation tools that allowed rapid advancement of scientific capabilities and thus
improved our ability to systematically study mammalian genetic functional profiles.
Genome-wide CRISPR knockout screens conducted in collections of human cell lines
can knock out genes at multiple loci, and have provided new insights into functional
roles for independent genes. This method has launched massive efforts in looking
across genetic backgrounds for context specific genetic vulnerabilities within cancer.
Much of the research effort thus far has been spent on optimizing phenotype
distinctions between essential, genes required for cell fitness, and non-essential,
genes exhibiting no effect on cell fitness, gene sets.

Currently, there has been sparse investigation of proliferation suppressor
genes, gene knockouts resulting in increased cellular growth rates, in the vast
collection of genome-wide genetic screens coming from the Sanger and Broad
Institute’s DepMap database. In this dissertation, we conducted a systematic survey
of data coming from these respective databases to study proliferation suppressor
gene measurements of genetic fitness. Our working hypothesis is that we can
leverage the distinct fitness score signature of proliferation suppressor genes in a
screen to identify pathway level proliferation suppressor biology and novel proliferation

xi
suppressor functions for specific genes. Analyses from these projects indicate that we
have identified distinct patterns of genetic growth fitness distributions that are
predicated on a tumor suppressor’s functional status. Additionally, we are able to
leverage the fitness signature and detect other consistent genetic proliferation
suppressors of cancer cells.

We have developed methodologies that can detect proliferation suppressor
behavior within whole genome genetic fitness screens that is confirmed through other
genomic metrics, specifically mutation and expression profiles. We additionally
implemented network methodologies that demonstrate conserved pathways of
proliferation suppression, as well as metabolic adaptation mechanisms. Finally, we
have identified a short list of genes that have not been noted previously to have
proliferation suppressor behavior, representing candidate tumor suppressor genes.
Included in these novel hits are fatty acid synthesis genes demonstrating proliferation
suppressor scores within a select group of acute myeloid leukemia cell lines.
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Chapter 1 – Introduction and Fundamental Concepts
1.1 Background
The completion of the genome project (Lander et al., 2001) signified the
beginning of the “-omics” era, and thus far this era has brought an unprecedented
amount of data that has improved our understanding of genetics and molecular
biology. This increase of data has caused biologists’ focus to shift away from single
gene-objects to groups of genes, pathways, and protein complexes. Within genetics,
it is observed that single genes rarely function independently, but rather function within
genetic modules where they interact with multiple genes involved in similar functional
processes (Hartwell, Hopfield, Leibler, & Murray, 1999). By framing genetic modules
as interlinked components rather than static single entities, we have started to observe
and discover a genetic hierarchy that exists within cells. Systems biology, spurred by
the completion of the genome project (Ideker, Galitski, & Hood, 2001), aims to model
this natural hierarchy in complex biological systems by integrating distinct levels of “omic” data.

System-level methods are appropriate for genome-scale experiments and
investigation of human diseases (Barabasi, Gulbahce, & Loscalzo, 2011) because
disrupted pathways frequently linked to independent diseases have been shown to
overlap (Menche et al., 2015). For cancer specifically, system-level approaches are
necessary as cancer can be caused by a collection of genetic factors (Hanahan &
Weinberg, 2011), thus requiring integration of multiple datatypes to understand
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phenotype associations to genotypes and modular genetic relationships. Further
complicating identification of genotype associations is that the collection of genetic
factors that can cause cancer exists heterogeneously within patients. This
complication suggests that proper experimental development needs to be capable of
both accounting for patient genetic diversity and identifying background specific
genetic targets for therapeutic applications (Behan et al., 2019).

Comprehensive investigation of phenotype inferences linked to specific
genotypes or genetic interactions represents a promising avenue for therapeutics
because it can identify modifications to cellular functions that cancer cells depend on.
These fundamental concepts have given rise to precision medicine based
approaches, which aim to optimize treatment for patients, extending beyond cancer,
based on the patient’s underlying genetic makeup. In general, the approach for
genomic medicine could be summarized as the following; 1) Identify a recurrent
functional aberration leading to or involved with a disease. 2) Identify targetable
pathways that alteration co-occurs with the functional aberration causing the disease.
3) Define cohorts of patients that could be impacted by these observed shifts in genetic
changes.

Pinpointing the critical genetic functional modifications that are causing cancer
manifestation and phenotypes, however, has proven difficult considering the total
complexity of biological systems and adaptive mechanisms that can arise if the system
is perturbed. Further complications have also originated from gene targets that have

3
been identified as false-positives due to off-target effects by preceding technologies
(Lin et al., 2019). This accumulation of complications has led scientists to investigate
for gene-editing tools that are able to identify druggable targets that exist as cellular
functional dependencies. One such gene-editing tool is clustered regularly
interspaced short palindromic repeats (CRISPR), which has shown to outperform its
predecessors in terms of on target precision effects, sample consistency, and
decreasing experimental noise (Evers et al., 2016; Smith et al., 2017).

1.2 Genetic Screening with CRISPR Systems
The potential for CRISPR-based technology was profound when it was first
presented to cleave double stranded DNA with a high degree of precision (Doudna &
Charpentier, 2014; Jinek et al., 2012). Innovation of CRISPR gene-editing technology
has provided scientists genome manipulation tools (Komor, Kim, Packer, Zuris, & Liu,
2016; Sanjana, Shalem, & Zhang, 2014) that have allowed for rapid advancement of
scientific capabilities and thus improved our ability to systematically study mammalian
genetic functional profiles (O. Shalem et al., 2014; Ophir Shalem, Sanjana, & Zhang,
2015). The following are some fundamental features of CRISPR genetic screening in
combination with systems biology approaches that enable evaluation and discovery
of clinically relevant disease biology, specifically cancer biology.

1.2.1 Commonly Used CRISPR Systems

4
Initial developed technology primarily focused on guide RNA combinations with
Cas9 (Doench et al., 2016; Mali, Esvelt, & Church, 2013; Mali, Yang, et al., 2013),
which were primarily intended to make a single modification per cell. In addition to
Cas9, there has been research focus on developing methodologies that use Cas12a
(H. K. Kim et al., 2017; J. Liu et al., 2019), formerly “Cpf1,” as this enzyme enables a
multiplexing experimental design allowing for guide development to target two genetic
loci simultaneously. Combined, the Cas9 and Cas12a enzymes provide scientists
effective functional genomic tools through guide RNA (gRNA) library designs that can
perform concurrent genome-scale knockouts, with Cas9, or select targeted groups of
genes, with Cas9 or Cas12a.

1.2.2 Detectable Phenotypes with CRISPR Screening
Genetic knockout fitness screens with Cas9 or Cas12a, and all library design
sizes, operate similarly. The gRNA library is first designed and made to target multiple
loci of each specified gene of interest. The library is then introduced into a single cell
type with a lentivirus construct or similar gene delivery system. Cas9 or Cas12a is
either included in the lentivirus or is endogenously expressed prior to guide
introduction. These cell batches, with Cas enzyme and gRNAs, then are allowed to
grow over a period of time with each cell cleaving a genetic loci specified by the
inserted gRNA. Following this growth period, cell time point samples are submitted
through next-generation sequencing to quantify each gRNA in the cell populations.
From this experimental design, total gRNA abundance of the final time points can be
compared against the initial time points to demonstrate how cell growth fitness
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changed with respect to the gene knockout caused by the introduced gRNA. This
method has launched massive efforts in looking across genetic backgrounds for
context specific genetic vulnerabilities within cancer (Behan et al., 2019; Doench et
al., 2016; Hart et al., 2015; Meyers et al., 2017; Tsherniak et al., 2017; T. Wang et al.,
2017). The specific phenotypes that can be interpreted from these gene knockout
experimental set ups, and that will be focused on in this dissertation, are:
1) Essential Genes: Gene knockouts that cause deficiency in cell fitness
measured by lower cell counts in final time points relative to initial time
points – representing genes that are necessary for cell viability and survival.
2) Non-Essential Genes: Gene knockouts that cause no change in fitness
measured as cell population remaining relatively constant between time
points – representing genes that are not needed for cellular survival. Often
cells can survive independent knock-out of these genes.
3) Proliferation

suppressor

genes:

Gene

knock

outs

that

cause

improvements to cell fitness measured by higher cell counts in final time
points relative to initial time points – representing genes that are actively
causing cells to grow at slower rates and knockout of these genes
subsequently increases overall cellular growth rate.

Much of the research focus thus far has been spent on matching essential
genes to particular genetic backgrounds, which represent the previously mentioned
avenue for cancer therapeutics through precision medicine. Generally, around 1,500
- 3,000 genes out of 18,000 tested genes will cause a fitness defect in any given single
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screen. While this approach has yielded potential therapeutic targets, many of the
targets coming from these studies are well defined cancer specific proto-oncogenes.
A prime example of this approach in practice was conducted by Behan et al., a study
that identified cell reliance on known oncogenes in specific contexts (cell dependence
on BRAF within BRAF mutated cells, NRAS within NRAS mutated cells, ERBB2 with
amplified ERBB2, among others), and one novel gene dependency context, Werner
syndrome helicase (WRN) with microsatellite instability, after accumulating 324
screens (Behan et al., 2019). This study identified additional unique genetic
dependencies but was unable to connect these observations to a specific cellular
context or cause. This study generated approximately 5.5 million data points, but only
focused on a fraction of data to understand cancer, and highlights that despite the
enormous efforts in finding context specific cancer vulnerabilities, we have not
identified many new genetic targets.

1.3 Analyzing Intrinsic Genetic Functional Relationships
Within CRISPR Screens
In order to identify genetic targets for therapeutic approaches in non-Mendelian
diseases, such as cancer (although genetic predisposition to cancer certainly exists
(Druker et al., 2017)), it is important to understand how genes work together to perform
cellular functions. Alluded to earlier, cellular phenotypes caused by disease frequently
are not caused by single genes, but rather groups of genes with complex associations
that when combined facilitate cellular functions. CRISPR knock-out screens provide a
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conventional approach to identifying genes that cells depend on. With these screen
sets, we have an effective approach to evaluate genetic relationships by either making
direct inferences of gene pairs being frequently observed as co-dependents within cell
lines, or by identifying how cell dependencies change either in the presence of a tested
perturbation or functional status of a gene. A common way to measure genetic and
functional relationships is through genetic interactions, which are defined as
unexpected phenotype measurements resulting from combined functional knockout
of two or more genes. There are two forms of genetic interactions that are commonly
studied:
1) Synthetic lethality:

Measured change of cell fitness that surpasses

expected fitness decrease and is caused by combined functional loss of two
or more genes. Generally, functional loss to either single gene does not
severely impact cell viability.
2) Genetic Suppression: Measured change of cell fitness that is less or
opposite than expected and is caused by combined functional loss of two
or more genes.
From a cancer perspective, genetic interactions are informative as they can
identify evolutionarily conserved gene groups that are responsible for specific
phenotypes such as cell survival and viability, and synthetic lethal interactions provide
alternative gene-targets for clinicians.

Inference of genetic interactions is the current goldrush of precision medicine,
with many groups dedicated to deciphering which genotypes robustly cause observed
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genetic interactions. Many of the initial large-scale genetic interaction studies
conducted focused on particular genetic behavior across large portions of available
datasets (Henkel, Rauscher, & Boutros, 2019). Researchers now focus on dissecting
datasets further in order to limit specific backgrounds, and conduct in silico
comparisons of questions of interest. Identifying context dependent genetic
interactions remains challenging given that gene pair combinations are exponentially
linked to genome size, and testing all gene pair combinations is currently infeasible
with current technology. The following sections are examples of methodologies where
researchers have implemented CRISPR genetic screening to model human genetic
interactions.

1.3.1 Genetic Interaction Maps
A map of genetic relationships can provide a reference of normal functional
genetic behavior, which can simplify research questions that aim to identify
modifications to genetic mechanisms leading to disease manifestation. Genetic
interaction maps require high-throughput studies that allow for evaluation of all
testable genes. One of the first approaches within functional genomics to measure
genetic interactions was through deployment of synthetic genetic arrays in the early
2000s by Tong et al. (Tong et al., 2004). This initial genetic interaction map was
completed in budding yeast, Saccharomyces cerevisiae, and highlighted that genetic
associations were predictive of additional genetic interactions. Two landmark
subsequent papers by Costanzo et al. using similar techniques (Costanzo et al., 2010;
Costanzo et al., 2016), systematically tested almost every combination of gene (~6000
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unique genes) pairs through isogenic knockout query yeast strains and found more
than one million genetic interactions between genes. The results from these studies
found that genes with similar genetic interaction patterns had a high likelihood of being
within the same pathways or complexes. These studies provided valuable insight into
the connections existing between functional groups.

Constructing analogous genetic interaction maps in human cells would be ideal
in order to identify how disease linked pathway disruptions impact neighboring cellular
functions. However, constructing genetic interaction maps by systematically knocking
out two genes at a time, similar to the yeast studies mentioned prior, is nearly
impossible due to the increase in gene set size (more than 20,000 coding genes), and
cellular heterogeneity. To circumvent these experimental complications, inferences of
genetic interactions have been made from collections of whole-genome CRISPR
knock-out screens to identify similar patterns of genetic fitness scores (Boyle,
Pritchard, & Greenleaf, 2018; E. Kim et al., 2019; Pan et al., 2018). Genome-scale
CRISPR genetic fitness screens in cancer cell lines have enormous potential in
evaluating genetic relationships as they can infer genetic interactions using an indirect
approach. With a single genome-scale fitness screen, we can quantify the loss of
every gene’s aberrant effect on cellular viability (Wang et al., 2015; Wang, Wei,
Sabatini, & Lander, 2014). Evaluating multiple screens, allows for identification of
groups of genes that have similar fitness defect patterns across different cancer types
(T. Wang et al., 2017).
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1. Figure 1.1: The coessentiality network, figure created by Eiru Kim, Ph.D., investigators
evaluated genetic fitness patterns within 276 whole-genome CRISPR knockout genetic
screens. Kim et al. demonstrate that network algorithms of genetic fitness profiles provide a
functional interaction map that can be used to identify cancer-specific genetic relationships.
This figure also demonstrates that genetic relationships observed within CRISPR screen sets,
reveal functional similarity. E. Kim, M. Dede, W. Lenoir, G. Wang, S. Srinivasan, M. Colic, T.
Hart, A network of human functional gene interactions from knockout fitness screens in cancer
cells. Life Sci Alliance, 2019. 2(2). Figure used for display purposes with permission from Eiru
Kim, Ph.D. Copyright permissions are not required. This article is available under a Creative
Commons License – https://creativecommons.org/licenses/by/4.0/).
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The conclusions from these studies evaluating genetic fitness correlations from
whole genome CRISPR genetic knockout demonstrate analogous results to the yeast
studies in that they aim to identify gene-pairs with similar patterns of cell fitness, and
found that correlated fitness scores frequently were observed to have shared
biological function – “co-functional.” This indirect approach displayed by these studies
in identifying genetic interactions represents an effective and powerful tool to navigate
cellular functional relationships within the cancer landscape, and to identify new
functions for specific genes given their respective associations (Figure 1.1). In order
to develop cellular functional landscapes, these analyses require large collections of
heterogeneous cell backgrounds. Cell heterogeneity is needed in order to compare
genetic dependencies and infer genetic interactions, because identical backgrounds
would have limited variation in cell fitness making it impossible to identify unique
functional signatures. However, cellular heterogeneity can also complicate the
identification of root causes of observed genetic interactions, as with many genetic
interactions, penetrance is difficult to predict and reproduce experimentally (Ryan,
Bajrami, & Lord, 2018).

1.3.2 Perturbation Genetic Screening
An alternative to large scale data interrogation, which require high-throughput
experimental setups to infer and identify genetic interactions, is perturbation
screening. Perturbation screening is making genetic comparisons between wild-type
cellular conditions and cellular backgrounds in the presence of some form of cellular
alteration or disruption (“perturbation”). Perturbations can exist in many forms, and
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some common applications in combination with genetic screening include but are not
limited to: drug combination screens (Colic et al., 2019), environmental stress
responses (Jain et al., 2020), and isogenic knockouts (Shen et al., 2017). The goal
with many studies using this technique is either to evaluate how cells respond in the
presence of a perturbation or to validate an expected change in response to the tested
perturbation.

Perturbation

screenings

are

useful

techniques

for

scientists

experimentally modeling disease conditions. Examples specific to cancer include
subjecting cells to hypoxic conditions, or understanding drug response mechanisms.

Many oncology drugs have been developed to target recurrent mechanisms of
oncogenic drivers. A common problem with targeting oncogenic drivers however is
that cancer cells frequently adapt to these drugs and develop resistance to the
targeted oncogenes, or cancer cells rely on oncogenes that are currently undruggable.
These situations have driven researchers to identify alternative gene pathways that
can be targeted by therapeutics. One such strategy for precision medicine within
cancer therapy mentioned previously is synthetic lethality. Synthetic lethality as a
therapeutic approach has been proven with PARP inhibition in BRCA1/2 mutated
cancer backgrounds (Bryant et al., 2005; Farmer et al., 2005). This example of
synthetic lethality requires the cancer cells to contain loss of function tumor
suppressor genes (TSGs) that have critical cellular caretaker functions. While the
success of this example has prompted researchers to search for synthetic lethal
relationships, PARP inhibitors remain the only approved drug exploiting this concept
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due to difficulties of experimental reproducibility and synthetic lethal penetrance (Ryan
et al., 2018).

Whole-genome CRISPR Cas9 knockout screens represent an ideal approach
for searching for synthetic lethal relationships in that we are able to make direct
inferences on genetic fitness with profoundly more powerful precision compared to
previous technologies. Identifying genetic dependencies that are specific to cell lines
harboring loss of function tumor suppressor genes, represents candidate synthetic
lethal targets in that they can indicate genes that are required for cell survival in the
absence of tumor suppressor gene caretaker functions. One example of this approach
was conducted by Shen et al. where the authors took two gene knock out
combinations of 73 tumor suppressor genes and common oncological drug targets to
identify conserved genetic interactions (Shen et al., 2017). A striking observation from
this report is that from three distinct cell lines, not a single genetic interaction was
conserved, and roughly 10% of the identified genetic interactions were observed in at
least two cell lines. The results from this study indicate that the cellular context is
critical when identifying viable synthetic lethal relationships for therapeutic purposes,
however perturbation screening remains an effective methodology to identify genetic
interactions.

1.4 Dissertation Overview
This dissertation aims to demonstrate and build upon some of the fundamental
concepts described above for CRISPR genetic screening. The projects described in
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the following chapters demonstrate how to effectively utilize fitness screening data in
combination with additional genomic metrics to learn cancer biology that can have
clinical implications.

Chapter 2 features basic genetic relationships driven by underlying existing
genotypes that can be observed from simple genomic integration of different omic
metrics. This chapter will focus on the utilization of the PICKLES database (Lenoir,
Lim, & Hart, 2017), which provides a visualization toolbox for scientists aiming to ask
questions of interest of specific genes from the large combination of available
datasets. Chapter 3 focuses on the proliferation suppressor phenotype that is
observed within CRISPR genetic screens. This chapter will discuss how genetic
screens can be repurposed to learn new biology about tumor suppressors, and how
the functional status of a tumor suppressor can impact genetic fitness of other genes.
Chapter 4 will primarily be focused on metabolism subtypes observed within Acute
Myeloid Leukemia (AML) cell lines. This subtype was identified through methods
developed from Chapter 3. Chapter 5 demonstrates analyses that were used to
identify genetic interactions in combination with a tested perturbation, in the form of
isogenic knockouts. Finally, Chapter 6 will contain conclusions and final remarks.
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Chapter 2 – Available Data and Integration of
Genomic Metrics with Genetic Fitness

2.1 Background
The recent evolution of CRISPR gene editing technology has led to massive
efforts in producing genome-wide knockout screens in cancer cell lines. Within the last
half-decade, these screening efforts encompass more than 1,000 cell lines of more
than 19 different tissue types, and average more than 17,000 gene fitness profiles
(Aguirre et al., 2016; Behan et al., 2019; Dempster, Rossen, et al., 2019; Hart et al.,
2015; Hart, Tong, et al., 2017; Meyers et al., 2017; O. Shalem et al., 2014; Wang et
al., 2015; Wang et al., 2014; T. Wang et al., 2017). While these screens provide
scientists with a rich opportunity to investigate novel avenues of research on their
genes of interest, interpreting this amount of data is both arduous and time consuming.
Thus, an interactive utility of genetic essentiality profiles would be a useful tool for
scientists examining genes of interest in pan-cancer and tissue specific contexts.

In this chapter, I describe work on a web visualization tool titled “Pooled In-vitro
CRISPR Knockout Library Essentiality Screens” (PICKLES), where users can view
essentiality scores using the Bayesian classifier BAGEL (Hart & Moffat, 2016; Hart,
Tong, et al., 2017; E. Kim & Hart, 2020) from whole genome knockout screens
mentioned in the prior paragraph. This chapter will discuss the utility of PICKLES and
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why it provides researchers an effective method for analyzing genes of interest across
a panel of distinct tissue types. At the time of initial publication, PICKLES was the only
visualization tool that provided easy display of these datasets. Additionally, this
chapter will review the subsequent updates implemented in this database, as well as
discussing its user usage. The following publication is discussed in this chapter:

1. Lenoir, W. F., Lim, T. L., & Hart, T. (2017). PICKLES: the database of pooled
in-vitro CRISPR knockout library essentiality screens. Nucleic Acids Res.
doi:10.1093/nar/gkx993.
Copyright permissions are not required. This is an open access article distributed
under the terms of the Creative Commons CC BY license, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is
properly cited.

2.2 PICKLES Initial Implementation
2.2.1 Background
The ability to knock out a gene and observe the resulting phenotype has been
a foundational tool for functional genomics for decades. The yeast deletion library has
been extensively studied, and recently a near-complete catalog of fitness defects of
all pairwise deletions of yeast genes was published. The tractability of yeast genetics
made Saccharomyces cerevisiae a powerful model system. The discovery of RNA
interference and its adaptation to RNA-guided transcript knockdown brought large-
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scale genetic screens to higher eukaryotes (Moffat et al., 2006; Sonnichsen et al.,
2005) but imprecise targeting, low penetrance, and off-target effects (Echeverri et al.,
2006; Echeverri & Perrimon, 2006; Moffat, Reiling, & Sabatini, 2007) led to a loss of
confidence in this method for large-scale screens (Kaelin, 2012). Recently, the
application of CRISPR/Cas9 technology to generate double strand breaks in target
DNA, whose repair by nonhomologous end joining frequently results in indels, has
been exploited to knock out protein coding genes in a variety of model systems by
targeted introduction of frameshifts or other deleterious mutations (Cong et al., 2013;
Mali, Yang, et al., 2013) .

Genome-scale CRISPR libraries have been adapted to a variety of screening
goals, including knockout libraries for loss of function screens for protein coding genes
(O. Shalem et al., 2014; Wang et al., 2014) and noncoding RNA (S. J. Liu et al., 2017;
S. Zhu et al., 2016). The most commonly used CRISPR-associated endonuclease,
SpCas9, has been modified to disable its endonuclease activity, facilitating protein
fusion with domains for transcriptional activation (Gilbert et al., 2014; Konermann et
al., 2015), transcriptional repression (Gilbert et al., 2014; Qi et al., 2013), and
chromatin modification (Hilton et al., 2015). Multiplexed guide designs have been
engineered to enable pairwise gene perturbation screens to detect synthetic lethal
genetic interactions (Du et al., 2017) and to remove precisely targeted segments of
DNA (S. Zhu et al., 2016).
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Despite this breadth of available technologies, the most common application of
pooled CRISPR libraries is to screen protein coding genes for knockout fitness defects
in cancer and other human cell lines. Pooled library screens in cancer are designed
to identify the essential genes specific to tumors of a given tissue of origin or even
subtype. Early screens demonstrated the power of this differential essentiality
approach (Hart, Koh, & Moffat, 2017; Tzelepis et al., 2016; Wang et al., 2015) and
demonstrated that genotype-specific vulnerabilities could be identified and targeted
(Steinhart et al., 2017), while subsequent efforts expanded the scope of the cell lines
being screened (Aguirre et al., 2016; T. Wang et al., 2017), and vastly more data is in
the pipeline (McDonald et al., 2017; Meyers et al., 2017; Tsherniak et al., 2017).

As this massive screening effort expands, so grows the need for a central
repository where researchers and the public can easily interpret the data. Here we
present PICKLES, the database of Pooled In vitro CRISPR Knockout Library
Essentiality Screens. PICKLES presents an easy to use interface where a user can
visualize how the essentiality of a given gene varies across experiments and across
tissues/cells probed within an experiment. Raw data from large-scale screening efforts
is processed through the BAGEL pipeline (Hart & Moffat, 2016; Hart, Tong, et al.,
2017; E. Kim & Hart, 2020), which generates a log Bayes Factor (BF) that represents
the confidence level of whether a gene is essential in a given cell line screen. Both
raw and normalized BFs are available for download.
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In initial publication, the PICKLES database contained data from four unique
CRISPR knockout libraries applied in screens of over 60 cell lines, performed in at
least six labs. It additionally contained data from genome-scale shRNA knockdown
screens in over 100 cancer cell lines (Marcotte et al., 2012; Marcotte et al., 2016;
Medrano et al., 2017).

2.2.2 Data Source Pipeline and Preprocessing with BAGEL
Viral-mediated, pooled library CRISPR screens involve transducing a large
population of cells with a pooled library of CRISPR reagents (guide RNAs, or gRNA).
Expression of SpCas9 or a related endonuclease, either from prior genetic knock-in
or encoded on the same viral backbone as the gRNA, results in gRNA-mediated
cleavage and, in most cases, error-prone repair of targeted loci. Successful targeting
of a fitness gene results in mutation or indels resulting in frameshift, loss of gene
function, and subsequent cell death, arrest, or severe fitness defect, causing cells
harboring that gRNA to represent an ever smaller fraction of total transduced cells as
generations pass. At an endpoint, typically 8-15 doublings after library transduction,
gRNA sequences are amplified from genomic DNA and sequenced and their relative
abundance is compared to either a control timepoint immediately after infection or to
the original plasmid pool. Guide RNA targeting essential genes will be depleted in the
final pool, resulting in a strong negative fold change relative to genes with no fitness
defect.
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Raw read count data from all datasets was acquired and processed with
BAGEL (Hart & Moffat, 2016; Hart, Tong, et al., 2017; E. Kim & Hart, 2020). BAGEL
is a Bayesian classifier trained using gold standard reference sets of essential and
nonessential genes. The observed fold changes of gRNA targeting uncharacterized
genes are compared to the observed fold change distributions of gRNA targeting
genes in the training sets and a log Bayes Factor (BF) is calculated. The BF represents
the relative confidence that the gene is essential (i.e. that the observed fold changes
were more likely drawn from the red or the blue distribution; Figure 2.1A).

The BF for a given gene in a given screen is a function of the number of gRNA
targeting that gene, the number of replicates screened, and the number of doublings
at the screen endpoint, as well as other global experimental factors. It is therefore
inevitable that major batch effects will arise when comparing screens from different
labs using different libraries. It is also common for BF distributions to vary considerably
even within the same set of experiments/screens conducted in a single lab (Figure
2.1B). For this reason, we have quantile normalized the BF from each experimental
set before generating the display (Figure 2.1C).
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2. Figure 2.1: PICKLES Essentiality Data. A) Density plot of fold changes of gRNA targeting
essential (red) or nonessential (blue) genes. B) Distributions of BAGEL Bayes Factor (BF)
scores in Tzelepis AML dataset.

Cells are screened under uniform conditions but

experimental and biological differences drive variance in results. C) Quantile normalized BFs
of the Tzelepis AML dataset, allowing for direct gene BF comparisons across cell lines. Figure
from Lenoir, W. F., Lim, T. L., & Hart, T. (2017). PICKLES: the database of pooled in-vitro
CRISPR knockout library essentiality screens. Nucleic Acids Res. doi:10.1093/nar/gkx993.
Copyright permissions are not required. This is an open access article distributed under the
terms of the Creative Commons CC BY license, which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.

In addition to CRISPR data, the PICKLES database also contains a large
compendium of pooled library shRNA screen data from (Marcotte et al., 2012;
Marcotte et al., 2016; Medrano et al., 2017). This data has undergone considerably
more thorough preprocessing and filtering, including reducing the number of screens
to 112 high quality screens, ensuring minimal representation of shRNA in T0
populations, and normalizing to the number of shRNA targeting each gene in each
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experiment, in order to yield a robust dataset with minimal false positives. These data
processing steps are described in (Hart, Koh, et al., 2017). Table 2.1 shows a
complete listing of the data available at time of writing.

Number of

Screen/Library

Data Type

Number of Genes

shRNA

Essentiality Score

13,395

112

15,466

33

17,230

10

17,997

5

19,161
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GeCKO

TKOv1

Tzelepis/Yusa

Wang

Quantile Normalized Bayes
Factor
Quantile Normalized Bayes
Factor
Quantile Normalized Bayes
Factor
Quantile Normalized Bayes
Factor

Cell Lines

1. Table 2.1: Fitness screens initially available in PICKLES. Table from Lenoir, W. F., Lim, T.
L., & Hart, T. (2017). PICKLES: the database of pooled in-vitro CRISPR knockout library
essentiality screens. Nucleic Acids Res. doi:10.1093/nar/gkx993. Copyright permissions are
not required. This is an open access article distributed under the terms of the Creative
Commons CC BY license, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.

2.2.3 Original Implementation
PICKLES was originally implemented exclusively in JavaScript, using the
charts.js library for display. A SQLite database containing all gene essentiality and
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gene expression data resides on the web server and is queried through a custom
python web service. The browser-based JavaScript modifies the view in response to
user selection of options and downloads additional data via http request when the user
searches for a new gene. Statistical tests at the time were pre-calculated for the
existing data and loaded as static metadata.

2.3 PICKLES Post Publication Updates
Following initial manuscript publication, we added several subsequent updates
on the interface, including updating the interface to a different web framework from
JavaScript to an R Shiny based application (McPherson) in Spring 2018. Subsequent
updates included additional screen sets from the Broad and Sanger Institute (Behan
et al., 2019; Meyers et al., 2017; Tsherniak et al., 2017), additional genomic metric
types from the Cancer Cell Line Encyclopedia (CCLE) (Barretina et al., 2012; Ghandi
et al., 2019), and visualization of co-essential gene pairs from a network of correlated
genetic fitness profiles (E. Kim et al., 2019).

2.3.1 R-Shiny Interface
The PICKLES database interface was updated to become an R Shiny based
application, as data updates and user capabilities were easier and more feasible to
incorporate. The online database specifically can currently be found at:
https://hartlab.shinyapps.io/pickles/. Code for the current compiled application can be
found at https://github.com/franklenoir/PICKLESv2.
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We additionally updated the database to include filtering features, and
statistical testing of the available genomic metrics; automatic calculations of Pearson
correlations of primary gene BF against secondary metrics either of the primary gene
or equivalent metrics of a secondary gene (normalized BF, CCLE TPM expression,
copy number) (Barretina et al., 2012; Ghandi et al., 2019); Wilcox rank sum test of
normalized BF in cell lines separated by a binary classification of mutated status (1 =
mutated in cell line, 0 = not mutated in cell line) of either the primary or secondary
gene; a tissue filter and selector; and Wilcox rank sum test of normalized BF in cell
lines separated by tissue type, where the output is the tissue type with the lowest
overall p-value from the available set of tissue types. All metrics are calculated and
processed with base R functions (Grolemund, 2016; Wickham et al., 2019).

2.3.2 Database Tutorial Utilization
The left panel on the interface contains all the selection options for the user.
The following summarizes the user options available in the database: selecting the
displayed screen data set; search entry for a primary gene (always normalized BF);
search entry option for a secondary gene to be plotted (if blank, the primary gene’s
secondary genomic metrics will be plotted); selection of secondary genomic metrics
(pink dots for expression, small black boxes distinguishing mutation status, yellow dots
for copy number metrics); tissue type selection; corresponding download buttons for
relevant citation information, plotted gene data, and entire datasets.
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Upon entering a valid gene symbol in the input form, the essentiality profile for
that gene will be plotted for the selected screen data set (Shows et al., 1980). In the
display, the primary y-axis plots the gene BFs (dots colored by their corresponding
tissue type), as well as a solid black line at BF = 5 representing a low-stringency
threshold for gene essentiality (Hart, Tong, et al., 2017) (Figure 2.2). To demonstrate
the utility of the database, Figure 2.2A shows breast cancer oncogene FOXA1 with
high essentiality and high expression only in HER2+ and luminal breast cancer cell
lines. To contrast, Figure 2.2B displays the essentiality profiles for TP53 and its
corresponding mutational status, displaying a distinction in essentiality patterns.
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B

3. Figure 2.2: Example essentiality plots from the PICKLES database. Both plots contain
gene essentiality (primary y-axis, descending orders) scores of a single gene with their
selected genomic metrics plotted on the secondary y-axis. Each dot represents a single
screen (276 total screens on the x-axis) coming from the original DepMap release (Meyers et
al., 2017). The red line corresponds to BF = 5, which has been established as high confidence
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level of essentiality (Hart, Tong, et al., 2017). A) PICKLES essentiality plot for FOXA1 against
FOXA1 log TPM expression (Pearson correlation = 0.44, p = 1.9 X 10-14). Higher expression
is observed in breast cancer (purple) and lung (blue) cell lines. B) PICKLES essentiality plot
for TP53, with boxes representing TP53 mutational status (bottom = mutated TP53, top = no
mutation detected or silent). Blue line indicates a threshold in which tumor suppressors have
high representation. Wilcoxon rank sum test p = 8.4 X 10-20, with null hypothesis that TP53
has the same essentiality distribution when mutated vs not mutated. Figure unpublished, and
taken directly from the PICKLES database at https://hartlab.shinyapps.io/pickles/.

2.3.3 Current Data Available
Following initial publication of PICKLES, the Broad and Sanger institutes
published several large collections of screens at a rapid pace through their individual
Cancer Dependency Map platforms, with the Broad institute specifically releasing
quarter year releases with their Avana library (Behan et al., 2019; Broad, 2018;
Cancer, 2018; Dempster, Rossen, et al., 2019; Meyers et al., 2017). Table 2.2
indicates the additional screen sets added following publication.

Screen/Library

Avana Q3 2017

Avana Q4 2018

Behan 2019

Data Type
Quantile Normalized Bayes
Factor
Quantile Normalized Bayes
Factor
Quantile Normalized Bayes
Factor

Number of

Number of

Genes

Cell Lines

17,184

276

17,427

425

18,009

319
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2. Table 2.2: Fitness screens added to PICKLES following publication.

For each additional screen set we checked the screen quality using precision
recall functions from the BAGEL software (Hart & Moffat, 2016; Hart, Tong, et al.,
2017; E. Kim & Hart, 2020). Screens included in following publication follow the
selection guidelines from Kim et al. (E. Kim et al., 2019). Using a BF essentiality
threshold of 5 (representing high confidence essentiality), each individual screen’s fmeasure is calculated (harmonic mean of precision and recall). Screens included in
the PICKLES database if the screen had an f-measure of 0.85 or higher. This step
filters for cell line screens that perform well at separating known sets of essential and
non-essential gene sets, which directly impacts the essentiality scores computed by
BAGEL (Hart & Moffat, 2016; Hart, Tong, et al., 2017; E. Kim & Hart, 2020), thus
selecting for high data quality. The initial set of Avana data (Q3 2017 in Table 2.2)
was filtered from 338 original cell lines to the 276 listed (Cancer, 2018). The additional
screens have more than quadrupled the number of screens available in the PICKLES
database, with the Sanger and Broad Institutes continuing to produce screens. The
Broad Institute has current plans to produce more than 1,000 screens, with the release
of 2020 Q2 pushing the current data set to 769 total screens conducted with CRISPRCas9.

2.3.4 Coessentiality Network
The interface now includes an interactive copy of the coessentiality network
observed in Figure 1.1 created by Kim et al. (E. Kim et al., 2019). In total the network
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contains 68,000 high confidence co-correlations of more than 3,000 unique gene
essentiality profiles from the Avana set of screens. This study, and several others
(Bayraktar et al., 2020; Boyle et al., 2018; Hart, Koh, et al., 2017; T. Wang et al., 2017),
have indicated that co-correlations of gene essentiality have the capabilities to
represent biological pathways and hierarchy. Gene-gene relationships within this
network represent an indirect approach for identifying genetic interactions from
genome-wide single gene CRISPR knockout screens that allow for navigation of
connections between cellular bioprocesses. Genes with high confidence cocorrelations have been included in the interface. An example of the network utility
observable in the network has been included in Figure 2.3, which demonstrates
correlated profiles to FOXA1’s essentiality patterns (Figure 2.2A).

4. Figure 2.3: Example coessentiality network utility from the PICKLES database. The plot
contains high correlation of essentiality profiles between genes from 276 unique screens.
Edges represent genetic interactions inferred from 276 screens conducted with the Avana
Library from the DepMap database (Cancer, 2018; Meyers et al., 2017). Network visualization
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developed with Cytoscape (Shannon et al., 2003) package designed for Shiny applications
(Luna, 2018). Figure unpublished, and

taken directly from the PICKLES database at

https://hartlab.shinyapps.io/pickles/.

Demonstrated in this cluster are genes (ESR1, GATA3, TRPS1, and SPDEF)
that several studies have indicated direct genetic interactions with FOXA1 or gene
markers that are associated with HER2+ and luminal breast cancer (Campbell,
Castro, Ponder, & Meyer, 2016; J. Z. Huang et al., 2016; Lee, Park, Oh, Kwack, &
Park, 2017; Theodorou, Stark, Menon, & Carroll, 2013).

2.4 User Utilization
Following subsequent updates to the PICKLES database, we incorporated the
Google Analytics webtool (G. M. P. D. Team, 2020) into the R shiny application in
order to follow total usage of the website and to identify which genes users were
commonly searching for. Figure 2.4 provides a complete overview of total usage from
January 1st 2019 – December 31st 2019. In 2019, we observe that PICKLES had
59,401 unique user events, (~163 times a day), representing the number of times that
the database was either opened from a unique device or used to query a specific gene
profile. ERBB2 was filtered from Figure 2.4B considering that it is the default gene
when opening the database. Amongst the top gene searches are well defined
COSMIC cancer census genes such as TP53, KRAS, MYC, BRCA1, and PTEN,
amongst several others (Bamford et al., 2004; Futreal et al., 2004; Sondka et al.,
2018). The second most viewed gene within the database was FASN, however this is
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likely due from internal use by the lab considering its immediate relevance to additional
research our group has performed (see Chapter 3 and 4).
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5. Figure 2.4: PICKLES usage data coming from Google Analytics for 2019. A) The total
unique events (unique gene searches per session) per day. B) Genes exceeding 40 unique
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queries in 2019. ERBB2 is excluded from this plot as it is database’s default. Figure
unpublished.

2.5 Conclusions and Discussion
We present PICKLES (Lenoir et al., 2017), the database of Pooled In vitro
CRISPR Knockout Library Essentiality Screens, where researchers can explore the
gene essentiality profiles of their favorite genes across a large set of CRISPR
knockout and shRNA knockdown fitness screens, mostly in cancer cell lines. Raw
data from seven major data sets of genome-scale screens, for a total of over 800
CRISPR-screened cell lines and over 100 shRNA-screened cell lines, was acquired
and processed with the BAGEL algorithm, resulting in a consistent set of essentiality
scores. This easy to use interface allows users to visualize how gene-specific
essentiality varies across tissue types and, in many cases, whether it correlates with
gene expression levels or is impacted by other genomic features.

PICKLES was one of the first databases compiling the available genetic fitness
data that had been published in the last half decade. Following the data releases
coming from the Achilles Project and Project score, coming from the Broad and
Sanger Institutes respectively (Behan et al., 2019; Dempster, Rossen, et al., 2019;
Meyers et al., 2017; Tsherniak et al., 2017), two other larger and more sophisticated
Cancer Dependency Map databases were produced. These databases surpass
PICKLES in terms of total user capabilities, however differ in terms of the underlying
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essentiality metric used. The DepMap from the Broad Institute contains genetic fitness
scores from their CERES algorithm that applies a copy-number correction adjustment
to gene’s final fitness scores. CERES is an effective methodology and is one of the
most used methods overall, however CERES requires multiple genetic screens in
order to identify poorly performing gRNAs, and potentially can eliminate genetic
signals from independent screens. PICKLES uses the software BAGEL (Hart & Moffat,
2016; Hart, Tong, et al., 2017; E. Kim & Hart, 2020) for genetic fitness scoring in
individual screens. BAGEL has flexibility in that it evaluates and scores screens
independently, allowing for a user to analyze a single screen at a time. Each fitness
scoring algorithm has strengths and weaknesses (Bodapati, Daley, Lin, Zou, & Qi,
2020), and as such the scoring metric utilized is at the discretion of the user.

While the amount of screens published is quite large, researchers will continue
to produce screens that extend from their own research. Providing database tools that
allow researchers to compare internally derived screens to existing data would provide
a customizable approach for independent researchers, and could aid in identifying
connections between published datasets.
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Chapter 3 – Identification of Proliferation
Suppressor Genes and Genetic Modules within
Fitness Screens

3.1 Background
Chapter 2 demonstrates that there have been a substantial number of wholegenome CRISPR Cas9 knockout screens to assess patterns of genetic fitness
published in the last half decade (Aguirre et al., 2016; Behan et al., 2019; Hart, Tong,
et al., 2017; Meyers et al., 2017; Tsherniak et al., 2017; Wang et al., 2015; Wang et
al., 2014; T. Wang et al., 2017). Much of the research effort thus far has been spent
on optimizing phenotype distinctions between essential gene sets, those required for
cell fitness, and non-essential gene sets, those exhibiting no effect on cell fitness (Hart
et al., 2015; Hart, Tong, et al., 2017; Wang et al., 2015). The purpose of these studies
is that this methodology represents an avenue for cancer therapeutics by aiming to
identify genetic dependencies in context specific backgrounds that exist within
patients’ profiles. One interesting finding from an early landmark CRISPR Cas9
screening paper from Shalem et al. (Ophir Shalem et al., 2015) is that chemogenetic
interaction screens demonstrated well-known proliferation suppressor (PS) genes
acting as suppressors of drug activity. A subsequent study from our lab (Colic et al.,
2019), found that cellular PS genes consistently are identified as suppressors of drug
activity in CRISPR chemogenetic screens.
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The observations from Shalem et al. and our own study, of the measured
suppressor interactions to drug activity, we found were caused by growth advantages
of the knocked out PS genes. While the measurements from Shalem et al. would
represent suppressor interactions in other experimental set ups, they represent
experimental artifacts in whole-genome CRISPR knockout screens in combination
with chemotherapeutics. Though this experimental artifact does not represent true
genetic interaction measurements, it does indicate that PS genes within CRISPR
genetic screens give a high and robust fitness score due to growth advantages caused
by genetic knockout. This gene signature was further validated within a report
provided by Brown et al. (Brown, Mair, Soste, & Moffat, 2019) that identified cellular
fitness distinctions as a result of knocked out TP53. The report by Brown et al.
demonstrated that quantified cellular fitness resulting from knocked out TP53 was
dictated by the functional status of TP53. Further, Brown et al. observed that the
functional status of TP53 impacted the fitness scores of related pathway genes,
specifically TP53 negative regulators MDM2 and MDM4. This research indicates that
PS genes, like TP53, have distinct genetic fitness patterns compared to other genes
that are based on the functional status of the PS gene. This concept allows us to work
in reverse and infer the PS gene’s functional status from the quantified fitness score.
Fitness score observations that demonstrate improved cellular fitness due to genetic
knockout indicate wild-type PS function of the knocked out gene.
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There have been several attempts to leverage this signature in identifying
functional insights, and potential tumor suppressor genes, specifically by detecting PS
phenotypes through genetic fitness screens. Specifically, studies have been made
with shRNA technology (Solimini et al., 2012; Xue et al., 2012), where researchers
sought to identify genetic fitness improvements resulting from gene knockdowns, in
HMEC and HCC cells, respectively. Efforts to learn PS growth phenotypes have
additionally been conducted using CRISPR activation technology (Gilbert et al., 2014),
where fitness impacts where compared following increased expression of targeted
tumor suppressors in K562 cell lines. These studies delivered functional insight into
genetic fitness, and also provided a set of observable expectations from genetic
screens. However, these efforts were conducted in a very small selection of cell lines,
compared to data that is publicly available today. As such, there is a lack of knowledge
regarding the PS phenotype within CRISPR knockout genetic screens. Considering
this gap, we investigated the PS phenotype further in a large set of publicly available
genetic screens.

This chapter will discuss computational methodology used to detect PS using
data from the Cancer Dependency Map (Dempster, Rossen, et al., 2019; Meyers et
al., 2017; Tsherniak et al., 2017). These analyses modeled the relationship existing
between PS functional state and observed fitness scores, aimed to determine new
genetic relationships of known PS genes, and identify candidate PS genes. The
majority of analyses found in this chapter are present in the following preprint
manuscript, currently under review:
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Lenoir, W.F., et al., Discovery of novel tumor suppressors from CRISPR
screens reveals lipid-sensitive subtype of AML. bioRxiv, 2020: p. 2020.10.08.332023.

3.2 Computational Detection of the Proliferation
Suppressor Phenotype

3.2.1 Defining the Proliferation Suppressor Phenotype
As noted in the background of this chapter, we previously observed genes
whose knockout leads to overrepresentation in pooled library knockout screens.
These genes, which we term proliferation suppressor (PS) genes, exhibit knockout
phenotypes opposite that of essential genes (Hart et al., 2015; Hart, Tong, et al.,
2017), in that knockout fitness screens show positive selection for these genes – that
is, gene knockout results in increased cell proliferation. In some cases, the phenotype
is clear and consistent with expectations. For example, well-known tumor suppressor
TP53 and other genes in the same pathway (CDKN1A, CHEK2, and TP53BP1) show
positive selection in some cell lines (Figure 3.1A). Unsurprisingly, TP53 knockouts
exhibit positive selection in cell lines where the gene is wildtype but not where it is
mutated (Figure 3.1B). Likewise, cells with a mutated PTEN tumor suppressor show
little PTEN knockout phenotype, while many, but not all, wildtype PTEN cells show the
PS phenotype (Figure 3.1C). These observations are consistent with the role of tumor
suppressor genes (TSG) in cell lines: in wildtype cells, TSG knockout increases the
proliferation rate in cell culture, but when cell lines are derived from tumors where the
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TSG is already lost, gene knockout has no effect. TSGs are therefore context-specific
PS genes, but it is not necessarily the case that genes with a PS phenotype in vitro
act as TSG in vivo; PS genes are at best putative TSGs in the absence of confirmatory
data from tumor profiling.

6. Figure 3.1: Demonstration of the PS phenotype within genetic knockout screens. (A) Foldchange distribution of a typical CRISPR knockout screen has a long left tail of essential genes,
and a small number of genes whose knockout increases fitness (proliferation suppressors,
“PS genes”). (B) and (C) Fold change of known tumor suppressors across 563 cell lines
separated by functional status derived from CCLE (Ghandi et al., 2019) mutation annotation
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calls. P-values are from corresponding Wilcoxon rank-sum tests. Figure adapted from Lenoir,
W. F., Morgado, M., DeWeirdt, P. C., McLaughlin, M., Griffith, A. L., Sangree, A. K., Feeley,
M. N., Kim, E., Colic, M., Dede, M., Doench, J. G., Hart, T., Discovery of novel tumor
suppressors from CRISPR screens reveals lipid-sensitive subtype of AML. bioRxiv, 2020: p.
2020.10.08.332023. Copyright permissions are not required. This article is available under a
Creative Commons International License – https://creativecommons.org/licenses/by/4.0/).

In order to accurately detect proliferation suppressor genes, several factors that
complicate robust detection need to be considered when completing computational
assessment of this phenotype:
1) Genetic signatures are highly background dependent.
As detailed in the previous paragraph, PS phenotype detection of a specific
gene is contingent on the genetic functional status as it exists within the cell.
2) No widely accepted methodology in place for classifying this phenotype.
In our example cell line F5 in Figure 3.1A, TP53 pathway genes are outliers in
four CRISPR bioinformatics pipelines (Allen et al., 2019; Hart & Moffat, 2016;
Meyers et al., 2017) (Figure 3.2 A-D), but COSMIC-defined (Bamford et al.,
2004; Sondka et al., 2018) tumor suppressor genes as a whole show either no
phenotype or signs of negative selection similar to oncogenes. This indicates
that available pipelines are not optimized to detect this phenotype, and
customization might need to be considered.
3) Distinct genetic screen variance.
Genetic screens of independent cell lines demonstrate a wide range of variance
in LFC distributions, making robust outlier detection challenging (Figure 3.3C
& D).
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4) No common gene set of proliferation suppressor genes.
Contrary to essential and non-essential gene sets for genetic fitness, there is
currently no gene set that is expected to unanimously demonstrate this
phenotype.

7. Figure 3.2: Genetic fitness of three different gene sets scored by four different metric
techniques. The gene sets are non-essential fitness genes (Hart, Brown, Sircoulomb,
Rottapel, & Moffat, 2014), expected to have no impact on fitness, and non-overlapping tumor
suppressor and oncogene gene sets defined as defined by COSMIC (Bamford et al., 2004;
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Sondka et al., 2018). The metrics techniques include: A) CERES (Meyers et al., 2017), B)
Bagel (Hart & Moffat, 2016; E. Kim & Hart, 2020), C) Mean log2 Fold-Change, and D) JACKS
(Allen et al., 2019). Figure adapted from Lenoir, W. F., Morgado, M., DeWeirdt, P. C.,
McLaughlin, M., Griffith, A. L., Sangree, A. K., Feeley, M. N., Kim, E., Colic, M., Dede, M.,
Doench, J. G., Hart, T., Discovery of novel tumor suppressors from CRISPR screens reveals
lipid-sensitive subtype of AML. bioRxiv, 2020: p. 2020.10.08.332023. Copyright permissions
are not required. This article is available under a Creative Commons International License –
https://creativecommons.org/licenses/by/4.0/).

3.2.2 Guide Shuffling Approach for Detection of the Proliferation
Suppressor Phenotype in Genetic Fitness Screens
To accommodate the factors listed in the previous section, we developed a
normalization method to detect proliferation suppressor genes based on the mean
log2 fold-change (logFC) of gRNA targeting a gene. This calculates gene-level logFC
Z-scores based on a null distribution generated from all available logFC values of a
given screen. To build the null distribution (Figure 3.3A), we label-shuffled guide-level
logFC values, calculated gene-level mean fold change, and repeated this shuffling
1,000 times. We used the mean and standard deviation (Figure 3.3C-D) of this
randomized distribution of gene-level mean fold changes to calculate a Z-score for
raw gene-level mean fold change.
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8. Figure 3.3: Shuffled Z-score strategy for genetic fitness. A) Representation of gene mean
logFC distributions of original gene guide-level logFC and label-shuffled guide-level logFC. B)
Precision comparison of genetic fitness metrics, and the corresponding number of COSMIC
(Bamford et al., 2004; Sondka et al., 2018) TSGs detected. C) Screen mean logFC and (D)
mean standard deviation of logFC of original and label-shuffled logFC. Figure adapted from
Lenoir, W. F., Morgado, M., DeWeirdt, P. C., McLaughlin, M., Griffith, A. L., Sangree, A. K.,
Feeley, M. N., Kim, E., Colic, M., Dede, M., Doench, J. G., Hart, T., Discovery of novel tumor
suppressors from CRISPR screens reveals lipid-sensitive subtype of AML. bioRxiv, 2020: p.
2020.10.08.332023. Copyright permissions are not required. This article is available under a
Creative Commons International License – https://creativecommons.org/licenses/by/4.0/).
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To evaluate the effectiveness of this shuffled Z-score approach, we used
COSMIC (Bamford et al., 2004; Sondka et al., 2018) tumor suppressor genes as a
positive reference set, and we combined COSMIC-defined oncogenes (with dualannotated TSG removed) with our previously specified set of nonessential genes as
a negative reference set (Bamford et al., 2004; Hart et al., 2014; Hart et al., 2015).
Since there is no consistent expectation for the presence of PS genes across cell
lines, we analyzed all 563 cell lines from the Avana 2019q2 data release collectively
(Dempster, Rossen, et al., 2019; DepMap, 2019; Meyers et al., 2017), calculating
gene-level scores on each cell line individually and then combining all scores into one
master list. The shuffled Z-score approach outperforms all other methods by a
substantial margin, identifying more than 500 TSG/cell line instances at a 10% false
discovery rate (FDR) (Figure 3.3B). This is roughly 50% more than the closest
alternatives, JACKS (Allen et al., 2019) and a nonparametric rank-based approach.
BAGEL (Hart & Moffat, 2016; E. Kim & Hart, 2020), a supervised classifier of essential
genes, performed worst at detecting PS genes, and the raw mean logFC approach
also fared poorly, highlighting the need for variance normalization across experiments.

3.2.3 Examining COSMIC TSG Proliferation Suppressor Hits and
Orthogonal Genomic Evidence
We applied this 10% FDR cutoff, corresponding to a shuffled logFC z-score >=
5.24, and examined the genes which are frequently hits in the Avana dataset.
Common tumor suppressor genes PTEN and TP53 are each hits in ~15% of all cell
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line screens with other well-known tumor suppressor genes appearing less frequently
(Figure 3.4A). Interestingly, this finding did not appear to be biased toward particular
tissues: in every lineage, most cell lines carried at least one PS gene (Figure 3.4C).
In total, we identify proliferation suppressor genes in 501/563 total screens (89.0%).

9. Figure 3.4: Overview of PS gene hits within the Avana 2019q2 set of screens . A) COSMIC
TSGs and the percent of cell lines in which they are detected as PS genes. B) Heatmap of
COSMIC (Bamford et al., 2004; Sondka et al., 2018) TSGs detected as PS in 563 cell lines.
Green indicates that the gene is detected as a PS gene, white indicates that the gene did not
have a sufficient PS score. Heatmap is row ordered based on A, and column ordered based
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on detected genes. Annotation bars include TP53 and PTEN loss of function (LOF) non-silent
mutation annotations, and PTEN copy number (CN) loss from CCLE (Ghandi et al., 2019).
Figure adapted from Lenoir, W. F., Morgado, M., DeWeirdt, P. C., McLaughlin, M., Griffith,
A. L., Sangree, A. K., Feeley, M. N., Kim, E., Colic, M., Dede, M., Doench, J. G., Hart, T.,
Discovery of novel tumor suppressors from CRISPR screens reveals lipid-sensitive subtype
of AML. bioRxiv, 2020: p. 2020.10.08.332023. Copyright permissions are not required. This
article

is

available

under

a

Creative

Commons

International

License

–

https://creativecommons.org/licenses/by/4.0/).

Among 288 COSMIC TSGs (Bamford et al., 2004; Sondka et al., 2018) for
which we have fitness profiles, we find that 58 (20.1%) of these genes occur as a
proliferation suppressor at least once (Table 3.1), and make up 16.6% of total
proliferation suppressor hit call observations (Figure 3.5A-B) vs. just 1.65% of all
fitness profiles, a 10-fold enrichment. Surprisingly, all of the TSG proliferation calls
come from just 249 of the 563 cell lines (49.7%) in which proliferation suppressor hit
calls were identified (Figure 3.4B).

We examined the set of TSG PS hits to orthogonal CCLE (Ghandi et al., 2019)
genomic data, in the form of mutation annotations and expression metrics, as further
validation of our analysis approach. When identified as a proliferation suppressor hit,
63% of the 58 TSGs demonstrate higher (Figure 3.5B) mRNA expression relative to
backgrounds where the TSG is not a proliferation suppressor hit (Table 3.1). Similarly,
we observe that 84.5% of the 58 TSGs, when identified as a proliferation suppressor
hit, demonstrate lower rates of non-silent mutations compared to backgrounds where
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the TSG is not considered a proliferation suppressor hit (Figure 3.5D). Together,
these observations confirm the reliability of our approach to detect genes with the
proliferation suppressor knockout phenotype, and that these genes – analogous to
essential genes – must be expressed and must not harbor a loss-of-function mutation
in order to elicit this phenotype.

10. Figure 3.5: Analysis of COSMIC (Bamford et al., 2004; Sondka et al., 2018) TSG PS Hits.
A) Percentage and (B) number of COSMIC TSG observations to corresponding to increased
shuffled Z-Scores. Plots are made using 0.25 bins. Black line indicates the 10% FDR Z-score
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cutoff used for PS identification.

C) Mean mRNA expression and (D) mean non-silent

mutation rate comparison of the 58 TSGs in backgrounds detected as PS genes and the all
other remaining backgrounds. Figure adapted from Lenoir, W. F., Morgado, M., DeWeirdt,
P. C., McLaughlin, M., Griffith, A. L., Sangree, A. K., Feeley, M. N., Kim, E., Colic, M., Dede,
M., Doench, J. G., Hart, T., Discovery of novel tumor suppressors from CRISPR screens
reveals lipid-sensitive subtype of AML. bioRxiv, 2020: p. 2020.10.08.332023. Copyright
permissions are not required. This article is available under a Creative Commons International
License – https://creativecommons.org/licenses/by/4.0/).

GENE

Count

PS Mean Exp

Other_Mean_Exp

PS_Mut

Other_Mut

ARID1A

2

5.73

4.85

0.00

0.17

ARNT

9

4.43

4.43

0.00

0.03

ATM

2

4.28

4.26

0.00

0.17

AXIN1

4

4.08

4.10

0.00

0.04

BAX

4

7.03

7.26

0.00

0.01

CASP8

1

4.94

4.34

0.00

0.05

CBFB

7

5.24

5.49

0.00

0.00

CCNC

1

5.09

5.54

0.00

0.00

CDKN1A

25

7.22

5.00

0.00

0.03

CDKN1B

2

5.07

4.82

0.00

0.02

CDKN2A

1

5.08

3.78

0.00

0.12

CDKN2C

13

5.71

4.34

0.00

0.02

CHEK2

8

3.88

4.34

0.00

0.03

CNBP

6

8.30

8.29

0.00

0.01

CREBBP

4

3.87

3.99

0.25

0.14

CUL3

2

5.56

5.66

0.00

0.03

CUX1

1

4.36

4.87

0.00

0.12

DNMT3A

1

3.51

3.28

0.00

0.05

ELF3

1

6.80

3.78

0.00

0.03

EP300

13

3.63

3.93

0.15

0.14

FBXO11

2

4.31

4.82

0.00

0.03

FBXW7

1

3.49

3.44

0.00

0.08

FLCN

1

5.86

4.21

0.00

0.03

FOXO3

1

4.73

3.45

0.00

0.02
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JAK1

3

5.54

5.24

0.00

0.06

KEAP1

33

5.53

5.54

0.03

0.08

LZTR1

6

5.01

4.85

0.00

0.05

MEN1

3

4.44

4.91

0.00

0.03

MYH9

2

6.75

7.37

0.00

0.09

NF1

9

3.99

4.02

0.11

0.13

NF2

52

4.67

4.24

0.04

0.04

NOTCH1

1

3.98

2.84

0.00

0.12

NOTCH2

2

3.99

4.45

0.00

0.07

PBRM1

2

5.01

4.08

0.00

0.07

PIK3R1

3

4.32

3.03

0.00

0.04

PML

1

3.93

4.40

0.00

0.05

PPP2R1A

1

5.50

6.86

0.00

0.04

PRKAR1A

1

7.05

6.77

0.00

0.02

PTEN

92

4.52

4.26

0.02

0.16

PTPRC

5

3.34

0.66

0.00

0.07

RB1

8

3.87

4.00

0.13

0.08

RPL22

1

9.66

9.29

0.00

0.05

RPL5

1

11.06

10.31

0.00

0.02

RUNX1

2

NaN

NaN

0.00

0.04

SMAD3

2

5.44

4.65

0.00

0.01

SMAD4

2

4.12

4.31

0.00

0.07

SPEN

1

3.79

4.76

0.00

0.15

STK11

4

5.22

5.02

0.00

0.05

SUFU

1

3.45

2.56

0.00

0.02

SUZ12

2

4.24

4.65

0.00

0.05

TENT5C

2

6.17

0.91

0.00

0.02

TET2

1

2.44

2.23

1.00

0.06

TGFBR2

2

4.23

3.99

0.00

0.03

TNFAIP3

1

4.07

3.16

0.00

0.03

TP53

79

5.38

4.98

0.09

0.79

TSC1

51

3.58

3.40

0.02

0.03

TSC2

49

5.07

4.93

0.04

0.08

WT1

1

3.51

0.96

0.00

0.03

3. Table 3.1: Statistics of 58 COSMIC TSGs when observed as a PS, vs other available data
points. Includes number of times TSG is observed as a PS gene (count), mean TPM
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expression when observed as a PS gene and additional backgrounds (PS Mean Exp, Other
Mean Exp), and non-silent mutation rate as a PS gene and additional backgrounds (PS Mut,
Other Mut). Table adapted from Lenoir, W. F., Morgado, M., DeWeirdt, P. C., McLaughlin,
M., Griffith, A. L., Sangree, A. K., Feeley, M. N., Kim, E., Colic, M., Dede, M., Doench, J. G.,
Hart, T., Discovery of novel tumor suppressors from CRISPR screens reveals lipid-sensitive
subtype of AML. bioRxiv, 2020: p. 2020.10.08.332023. Copyright permissions are not
required. This article is available under a Creative Commons International License –
https://creativecommons.org/licenses/by/4.0/).

We attempted to corroborate our findings using a second CRISPR dataset of
342 cell line screens from Behan et al. (Behan et al., 2019), including >150 screens
in the same cell lines as in the Avana data. However, these screens were terminated
at an earlier time point than the Avana data (14 vs. 21 days), giving less time for both
positive and negative selection signals to appear. The relatively weak fitness
enhancement introduced by PS gene knockout often precludes detection in a shorter
experiment. In the example F5 cell line (Figure 3.1A), a 2.5-fold change over a 21day time course corresponds to a fitness increase of only ~12% for rapidly growing
cells, or a doubling time decrease from 24 to 21 hours. In a 14-day experiment, this
increased proliferation rate would result in an observed log fold change of only ~1.7,
well within the expected noise from genes with no knockout phenotype (see 3.2.4
Methods). As a result, when we compared cell lines screened by both groups, the
Avana data yielded many more TSG hits (Figure 3.6A). However, hits at our 10%
FDR threshold across all Avana screens are strongly biased toward positive Z-scores
in the Sanger data (Figure 3.6B), consistent with a weaker signal of positive selection
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as a result of the shorter assays rather than a more general inconsistency (Dempster,
Pacini, et al., 2019).

11. Figure 3.6: Comparing PS hits observed in the Avana (Dempster, Rossen, et al., 2019;
DepMap, 2019; Meyers et al., 2017) dataset against genetic screens in matching Sanger
(Behan et al., 2019) cell lines. A) Precision comparison of genetic fitness metrics, and the
corresponding number of COSMIC (Bamford et al., 2004; Sondka et al., 2018) TSGs detected.
The Sanger dataset is indicated in black, with the Avana dataset indicated in red. (B) Avana
PS hits, Sanger vs Avana shuffled Z-scores. Dashed line indicates Sanger shuffled Z-score
set at 0, with the solid line indicating the Sanger shuffled Z-score = Avana shuffled Z-score (x
= y). Figure adapted from adapted from adapted from Lenoir, W. F., Morgado, M., DeWeirdt,
P. C., McLaughlin, M., Griffith, A. L., Sangree, A. K., Feeley, M. N., Kim, E., Colic, M., Dede,
M., Doench, J. G., Hart, T., Discovery of novel tumor suppressors from CRISPR screens
reveals lipid-sensitive subtype of AML. bioRxiv, 2020: p. 2020.10.08.332023. Copyright
permissions are not required. This article is available under a Creative Commons International
License – https://creativecommons.org/licenses/by/4.0/).
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3.2.4 Methods
Analysis was conducted in this section was done in R version 3.5.1
(Grolemund, 2016; R. C. Team, 2018). R packages tidyverse (Wickham et al., 2019),
data.table (Srinivasan, 2019), and knitr (Xie, 2014, 2015; Xie et al., 2020) were used
for figure generation, data manipulation, and general R functions; mixtools (Benaglia,
Chauveau, Hunter, & Young, 2009), permute (Simpson, Team, Bates, & Oksanen,
2019), and PRROC (Grau, Grosse, & Keilwagen, 2015; Keilwagen, Grosse, & Grau,
2014) were used for data simulations present in figures and evaluation; biomaRt
(Durinck et al., 2005; Durinck, Spellman, Birney, & Huber, 2009), and org.Hs.eg.db
(Carlson, 2018) were used in integrating data types; cowplot (Wilke, 2019),
ggbeeswarm

(Clarke

&

Sherrill-Mix,

2017),

annotate

(Gentleman,

2019),

RColorBrewer (Neuwirth, 2014), ComplexHeatmap (Gu, Eils, & Schlesner, 2016),
gplots (Warnes et al., 2020), ggpubr (Kassambara, 2020), grid (R. C. Team, 2018),
circlize (Gu, Gu, Eils, Schlesner, & Brors, 2014), ggthemes (Arnold et al., 2019), and
ggplot2 (Wickham, 2016) were used for figure aesthetics and generation.

Processing DepMap Screen and CCLE Genomics Data
Raw read count data and a map of guide RNAs were downloaded from the
Cancer Dependency Map (DepMap) database (www.depmap.org) (Dempster,
Rossen, et al., 2019; Meyers et al., 2017) and Project Score database
(https://depmap.sanger.ac.uk/) (Behan et al., 2019). Avana data version 2019q2
(DepMap, 2019) was used for this analysis. To avoid genetic interaction effects, we
discarded sgRNAs targeting multiple protein coding genes annotated as public or
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update pending in The Consensus Coding Sequence (CCDS, release 22) (Pujar et
al., 2018). Gene names in the guide RNA maps of Avana and Project Score were
updated using human gene information obtained from ncbi ftp. Then, read count data
for each replicate was passed through CRISPRcleanR (Iorio et al., 2018) with location
information of sgRNAs for the Avana CRISPR library based on GENCODE (Frankish
et al., 2019) to correct depletion effects caused by copy-number amplification.
Following this correction, each guide’s log 2 fold-change was calculated. For Project
Score data, we used only the gene location information of KY library v1.0 which is built
in CRISPRcleanR. Normalized TPM RNA-seq data, and mutation annotations for
CCLE (Ghandi et al., 2019) cells were also downloaded from DepMap. Ensembl gene
id in RNA-seq data was converted to gene symbol using cross reference downloaded
from Emsembl Biomart (Zerbino et al., 2018).

Shuffled Z-Score Metric
Shuffled z-score metric was generated using R version 3.5.1 base stat
packages (R. C. Team, 2018). To calculate the shuffle z-score, individual guide log2
fold-changes were shuffled creating a new set of log 2 fold-change for each individual
gene. Mean log2 fold-change values were calculated per gene, thus creating a new
null distribution of mean log2 fold-change for each screen. The mean and standard
deviation of this null distribution were recorded. In total the shuffling and generation of
the screen null distribution was calculated 1,000 times. The average of the 1,000
generated null distributions mean and standard deviation, with the uncorrected original
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gene log2 fold-change, was used to calculate the corresponding shuffled z-score. The
original and shuffled Z-score formula is as follows:
𝑆ℎ𝑢𝑓𝑓𝑙𝑒𝑑 𝐺𝑒𝑛𝑒 𝑍 − 𝑆𝑐𝑜𝑟𝑒 =

𝑥 − 𝜇𝑛𝑢𝑙𝑙
𝜎𝑛𝑢𝑙𝑙

Where x is the original gene log2 fold-change, 𝜇𝑛𝑢𝑙𝑙 is the averaged null
distribution mean, and 𝜎𝑛𝑢𝑙𝑙 is the averaged null distribution standard deviation. This
metric was calculated for the DepMap 18Q4 (Broad, 2018) screen data for algorithm
comparisons, DepMap 19Q2 screen data for all additional analyses, and the Sanger’s
DepMap screen set for Figure 3.6. This metric was additionally calculated for screen
sets coming from the Wang et al. (Wang et al., 2015; T. Wang et al., 2017), however
the metric was calculated on non-processed fold-change values for Figure 4.1.

Comparisons of Fitness Scoring Metrics
The following describes our comparative analysis of screening algorithms
observed in Figure 3.2 and 3.3. JACKS (Allen et al., 2019) and BAGEL (Hart & Moffat,
2016; E. Kim & Hart, 2020), software was downloaded from their corresponding
GitHub

official

distribution

sites:

https://github.com/felicityallen/JACKS,

and

https://github.com/hart-lab/bagel. We ran JACKS and BAGEL with raw fold change
data of DepMap 18Q4 version (Broad, 2018), gene guide map and replicate
information.

We

obtained

DepMap

18Q4

CERES

scores

from

‘dependency_score.csv’ downloaded from DepMap depository. Ranking was
performed per screen and based on mean log2 fold-change values per gene.
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We used the cancer gene census (CGC) list from COSMIC (Bamford et al.,
2004; Sondka et al., 2018) in order to compare fitness methods that can detect
proliferation suppressor activity. Tumor suppressor genes (TSGs) from CGC
represent a gene set of well-known proliferation suppressors. We separated the CGC
gene list in two gene sets, genes with any tumor suppressor role in cancer
representing true positive proliferation suppressor observations, and genes with any
oncogene role in cancer representing false positives. Additionally, we added nonessential genes (Hart et al., 2014; Hart et al., 2015) to the false positive list as these
genes are not expected to demonstrate any phenotype. With these compiled lists, we
evaluated each metric’s fitness scores, to see which metric would best separate the
true and false positive gene lists. The R package PRROC was used for fitness scoring
evaluation (Grau et al., 2015; Keilwagen et al., 2014).

Direct Proliferation Suppressor Comparisons of Avana and Sanger Screen
Datasets
The CRISPRcleanR (Iorio et al., 2018) corrected fold-change Sanger screen
set (Behan et al., 2019) was pushed through identical pipelines used to calculate the
shuffled z-score metric. Quality analysis of the shuffled z-score metric for both data
sets was pushed using identical gene sets described in the “Comparisons of Fitness
Scoring Metrics” section. This analysis was restricted to only overlapping cell lines,
153 total, in both datasets.

Theoretical Fold-Change and Growth Rate Quantification
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To assess hypothetical differences of proliferation suppressor fitness scoring
metrics based on standard sampling times of screen collection taken from the Sanger
and Avana databases (Behan et al., 2019; Dempster, Rossen, et al., 2019; Meyers et
al., 2017; Tsherniak et al., 2017), we calculated theoretical cell population differences
of wild-type and knocked out proliferation suppressor cell lines. The following formula
can be used to calculate cell populations based on doubling rate per day:
𝑋𝑓 = 𝑋𝑖 ∗ 2𝑘∗𝑡
In this formula Xf is the final population number of cells, Xi is the initial population of
cells, k is growth rate of the cells, and t is time in days. In order to compare cells we
can assume that these formulas are consistent with both wild-type cells and knocked
out proliferation suppressor cells. With, knocked out proliferation suppressor cells the
assumption is that these cells would grow faster compared to wild-type conditions and
thus kps > kwt, where kps is the growth rate for proliferation suppressor knocked out
cells, and kwt is the growth rate of wild type cells. These two independent growth rates
are related as:
𝑘𝑝𝑠 = 𝑘𝑤𝑡 + ∆𝑘
k represents the change in growth rate resulting from genetic knockout, and is
assumed to be positive. The growth rate formula for wild-type and proliferation
suppressor cells is thus:
𝑋𝑤𝑡 = 𝑋𝑖 ∗ 2𝑘𝑤𝑡∗𝑡 , 𝑋𝑝𝑠 = 𝑋𝑖 ∗ 2(𝑘𝑤𝑡+∆𝑘)∗𝑡
We then solved for k, with Log2(Xps/Xwt) as Log2(FC), representing the fold-change
difference between the cell populations at time t:
𝐿𝑜𝑔2 𝐹𝐶 = 𝐿𝑜𝑔2 (

𝑋𝑝𝑠
)
𝑋𝑤𝑡
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𝐿𝑜𝑔2 𝐹𝐶 = 𝐿𝑜𝑔2 (

𝑋𝑖 ∗ 2(𝑘𝑤𝑡+∆𝑘)∗𝑡
)
𝑋𝑖 ∗ 2𝑘𝑤𝑡∗𝑡

2(𝑘𝑤𝑡+∆𝑘)∗𝑡
𝐿𝑜𝑔2 𝐹𝐶 = 𝐿𝑜𝑔2 (
)
2𝑘𝑤𝑡∗𝑡
𝐿𝑜𝑔2 𝐹𝐶 = ((𝑘𝑤𝑡 + ∆𝑘) ∗ 𝑡) − (𝑘𝑤𝑡 ∗ 𝑡)
𝐿𝑜𝑔2 𝐹𝐶/𝑡 = 𝑘𝑤𝑡 + ∆𝑘 − 𝑘𝑤𝑡
𝐿𝑜𝑔2 𝐹𝐶/𝑡 = ∆𝑘

We next set Log2(FC) to 2.5, which represents a sizable gain in fitness from a knocked
out proliferation suppressor, and t = 21 days, representing the time in which the Avana
screens were sampled:
∆𝑘 =

2.5
= 0.12
21

Using the calculated k at 0.12, we can calculate the hypothetical Log2(FC) that would
be expected at t = 14 days, representing the time in which the Sanger screens were
sampled:
𝐿𝑜𝑔2 𝐹𝐶 = ∆𝑘 ∗ 𝑡
𝐿𝑜𝑔2 𝐹𝐶 = 0.12 ∗ 14 = 1.7
The resulting theoretical measurements demonstrate that k can be identical between
two samples, however the time in which the sample was taken will influence the ratio
between the two measured cell populations. Taken together, this suggests that
samples at shorter time points will demonstrate smaller quantified population size
differences between wild-type and proliferation suppressor knocked out cells
compared to samples taken at longer time points.
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3.3 Proliferation Suppressor Co-Occurrence Network
Identifies Pathways Controlling Cell Growth
3.3.1 Initial Co-Occurrence Network Observations
Although known TSGs act as PS genes in only a subset of cell lines, we
observed genes with similar functional annotations frequently occurring together
(Figure 3.4B). Co-occurring proliferation suppressor gene observations suggest
genes that are suppressing cellular growth in matching cell backgrounds. PTEN cooccurs with mTOR regulators NF2 (James et al., 2009) (P < 2x10-6, Fisher’s exact
test) and the TSC1/TSC2 complex (P-values both < 2x10-13) (J. Huang, Dibble,
Matsuzaki, & Manning, 2008), as well as Programmed Cell Death 10 (PDCD10)
(Marchi et al., 2015), a proposed tumor suppressor (Hart et al., 2015; Y. Zhu et al.,
2016) (Figure 3.7A). The TP53 regulatory cluster (TP53, CDKN1A, CHECK2,
TP53BP1) also exhibited a strong co-occurrence pattern that was independent of the
mTOR regulatory cluster (Figure 3.7A). mTOR (Pópulo, Lopes, & Soares, 2012) and
cell cycle checkpoint genes (Evan & Vousden, 2001; Massagué, 2004) have been
heavily linked to cancer development, given their roles in growth and proliferation, and
thus have been the focus of studies characterizing patient genomic profiles to identify
common pathway alterations (Donehower et al., 2019; Y. Zhang et al., 2017).
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The modularity of mTOR regulators and TP53 regulators demonstrates
pathway-level proliferation suppressor activity, which serves as a positive control
given their prominent role in cancer suppression. This observation is parallel to the
coessentiality phenomenon observed previously where correlated fitness profiles
indicate that genes operate in the same biochemical pathway or biological process
(Amici et al., 2019; Boyle et al., 2018; Hart, Koh, et al., 2017; E. Kim et al., 2019; Pan
et al., 2018). While these studies do contain tumor suppressors within their individual
network models of gene fitness, they are frequently predicated on instances where
tumor suppressors are essential for cellular fitness. Additionally, the sparseness of PS
data and the smaller effect sizes, relative to essential genes, render correlation
networks relatively poor at identifying modules of genes with proliferation suppressor
activity. As these studies modeled a completely distinct phenotype from the PS
phenotype, it is thus expected that they are lacking in gene connections that are only
observable when considering PS status.
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12. Figure 3.7: Defining co-occurrence relationships of genetic PS observations using the
Fisher’s exact test of independence. A) Heatmap displaying genetic relationships between
cell cycle genes and MTOR regulators. Top left half of heatmap displays FDR scores from
corresponding p-values from the Fisher’s exact test comparing the co-occurrence of PS
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observations of genes. Bottom right half of the heatmap displays number of PS occurrences.
The dendrogram is based on Euclidean distance of FDR scores. B) Pipeline used to derive
co-occurrence network. C) Selected gene clusters and corresponding heatmaps of cooccurrence patterns. Heatmap has annotation bar corresponding to observed tissue type.
Figure adapted from Lenoir, W. F., Morgado, M., DeWeirdt, P. C., McLaughlin, M., Griffith,
A. L., Sangree, A. K., Feeley, M. N., Kim, E., Colic, M., Dede, M., Doench, J. G., Hart, T.,
Discovery of novel tumor suppressors from CRISPR screens reveals lipid-sensitive subtype
of AML. bioRxiv, 2020: p. 2020.10.08.332023. Copyright permissions are not required. This
article

is

available

under

a

Creative

Commons

International

License

–

https://creativecommons.org/licenses/by/4.0/).

3.3.2 Proliferation Suppressor Co-Occurrence Network Identifies
Known Cell Proliferation Pathways
In order to identify genetic modules that specifically capture the functional PS
status, we developed a PS network based on Fisher’s exact test of independence
statistical overrepresentation of co-occurring PS genes (Figure 3.7B); see Methods
(3.3.4) for details. Network design through Fisher exact tests have proven before to
be useful in inferring relationships of 2 x 2 contingency tables between unique
observations (Mehta & Patel, 1983). This approach yields a sparse network of 103
genes containing 157 edges in disconnected clusters; only 9 clusters have 3 or more
genes (Figure 3.7C and 3.8C). Of these 157 edges, 31 (20.1%, Empirical P<10-4) are
present in the HumanNet (Hwang et al., 2019) functional interaction network (Figure
3.8A-B).
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The network recovers the PTEN and TP53 modules as well as the Hippo
pathway, the aryl hydrocarbon receptor complex (AHR/ARNT), the mTOR-repressing
GATOR1 complex, the STAGA chromatin remodeling complex, TYK2-STAT
signaling, and the gamma-secretase complex (Figure 3.7C), all of which have been
associated with tumor suppressor activity. The functional coherence and biological
relevance of the PS co-occurrence network further validates the approach taken, and
establishes this dataset as a resource for exploring putative tumor suppressor activity
in cell lines and tumors.
While 103 of observed gene nodes are represented in the network diagram,
there are 201 remaining gene proliferation suppressor observations that were not
observed to have edges. It is important to note that in many cases, it is likely that
known members of proliferation suppressor pathways may already be inactive. This
is evident in the three gene-node cluster of JAK-STAT signaling (Rawlings, Rosler, &
Harrison, 2004) that identifies STAT2, TYK2, and IRF9 (Rengachari et al., 2018)
(Figure 3.7C). Notably, JAK1 is missing from this gene collection, however, we do
see that JAK1 does appear to act as a proliferation suppressor at a lower rate within
similar cell backgrounds. This network design of PS co-occurrence, demonstrating
pathways of genes known to interact, provides further validation of the applied
systematic analyses, and further establishes a resource of modeling that can be used
for genetic studies of these pathways.
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13. Figure 3.8: Network figures continued. A) Empirical validation of observed edge coverage.
Histogram displays the number of edges observed in HumanNet (Hwang et al., 2019) from
random selections of available genes. Black line corresponds to edges observed in Kim et al.
(E. Kim et al., 2019) co-essentiality network (Figure 1.1). Red line corresponds to actual
number of PS co-occurrence edges observed in HumanNet. B) Number of edges observed
in HumanNet through increased cutoffs of shuffled Z-scores. Red dot indicates implemented
network. C) Remaining gene clusters from co-occurrence network. Figure adapted from
Lenoir, W. F., Morgado, M., DeWeirdt, P. C., McLaughlin, M., Griffith, A. L., Sangree, A. K.,
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Feeley, M. N., Kim, E., Colic, M., Dede, M., Doench, J. G., Hart, T., Discovery of novel tumor
suppressors from CRISPR screens reveals lipid-sensitive subtype of AML. bioRxiv, 2020: p.
2020.10.08.332023. Copyright permissions are not required. This article is available under a
Creative Commons International License – https://creativecommons.org/licenses/by/4.0/).

3.3.3 Network Cluster Reveal Candidate Hippo Pathway Genes
In assessing gene edges (Figure 3.7C and 3.8C), we have previously
discussed PTEN, observed to have edges with other mTOR related regulators KEAP1
through its association with NRF2, TSC1, TSC2, and NF2. Given that NF2 is a
regulator in the hippo pathway (Sourbier et al., 2018), and other CRISPR screening
studies have been able to identify hippo pathway-related conclusions (Quinton &
Ganem, 2019; Suemura et al., 2019), we expected to observe hippo related genes
within this cluster. We observed the hippo pathway genes and regulators TAOK1,
NF2, LATS2, and AMOTL2 (Yu & Guan, 2013). Additionally, PTEN, MAP4K4, and
PDCD10 have all been indicated in literature to have an interaction with the hippo
pathway; PTEN through YAP1 as a regulator (Tumaneng et al., 2012), the MAP4K
gene family directly activating LATS1/2 (Meng et al., 2015), and PDCD10, also known
as CCM3, of the striatin interacting phosphatase and kinase complex (STRIPAK)
initiating the hippo cascade (R. Chen, Xie, Meng, Ma, & Guan, 2019; Sakuma &
Chihara, 2017). Of the remaining gene edges in this cluster, their exact roles are not
confirmed. PLEKHA1 and PTEN have been shown to have an interaction through
affinity purification mass-spectrometry (AP-MS) (St-Denis et al., 2016). KEAP1 has
been shown to be co-essential with PDCD10, and though its fitness scores are anti-
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correlated with its binding partner NRF2 (Amici et al., 2019), NRF2 has been shown
to have a regulator role of mTOR (Bendavit, Aboulkassim, Hilmi, Shah, & Batist,
2016). KIRREL1 has been noted to have a high scoring protein interaction to LATS1
(Couzens et al., 2013; Oughtred et al., 2019). Signaling of NRP1’s binding partner
VEGF (Mamluk et al., 2002; Soker, Takashima, Miao, Neufeld, & Klagsbrun, 1998)
has been shown to be altered by YAP/TAZ (X. Wang et al., 2017). Cumulatively, this
suggests that every gene in this cluster has commonality in that they are in some form
related to the hippo pathway or mTOR regulation.

KIRREL1 and NRP1 are both surprising examples of proliferation suppressors
in that NRP1 through its binding partner with VEGF (Mamluk et al., 2002; Soker et al.,
1998) have been noted to promote cancer cell survival (Grun, Adhikary, & Eckert,
2018) and are a potential therapeutic target (Barr et al., 2005), while overexpression
of KIRREL1 has been noted to suggest poor prognosis for cancer patients (J. Chen
et al., 2018; Lundgren et al., 2019; M. J. Zhang, Hong, & Li, 2018). In which context
these genes serve as proliferation suppressors is not entirely clear, however we do
observe similar expression patterns of these genes to the likes of PTEN and TP53
(Figure 3.9).

65

14. Figure 3.9: Demonstrating expression patterns against PS status within two genes not
previously described as TSGs, (A) NRP1 and (B) KIRREL1, and two well established TSGs,
(C) TP53 and (D) PTEN. Figure not in print.

3.3.4 Methods
Co-Occurrence Network
The co-occurrence network was developed based on FDR scores from Fisher exact
tests of all gene by gene comparisons that were identified as a proliferation suppressor
more than once (314 genes total). Fisher’s exact test and Benjamini & Hochberg FDR
p-value adjustment were done using base R stat packages (R. C. Team, 2018).
Figure 3.7A was created with heatmap.2 function from the R gplots (Warnes et al.,
2020) package, with the dendrogram created through base R (Grolemund, 2016; R.
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C. Team, 2018) functions of Euclidean distance, and complete agglomeration
methods clustering of the Fisher’s exact test score between gene pairs. Smaller
heatmaps displayed in Figure 3.7B were made using the R ComplexHeatmap library
(Gu et al., 2016). Network visualization was completed using Cytoscape (Shannon et
al., 2003).

Network creation followed the corresponding steps:
1) Identify all proliferation suppressor observations (Z > 5.24).
2) Filter for gene proliferation suppressor observations that occurred at least 2
or more times, selecting for a total of 314 out of 17,407 genes available
(1.8% total available genes).
3) Create a binary (1 = proliferation suppressor, 0 = not proliferation
suppressor) matrix of all 314 genes in all cell lines.
4) Conduct Fisher’s exact test of every possible 2 x 2 contingency table of the
314 selected genes (n= 49,141 tests).
5) Adjust the corresponding p-values to FDR values, using a cutoff of 0.01 (1%
FDR) to define edges.

By assessing gene edges through Fisher exact-tests, we observed gene associations
that are based on the relative proportion of co-occurrences between two genes.

Proliferation Suppressor Network Enrichment
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To test network enrichment of observed edges (Figure 3.7 and 3.8), we took
10,000 random samples of 157 (total number of edges in the co-occurrence network)
gene pairs from the 49,141 available all by all gene pair Fisher’s exact test set. We
then compared each sample to see the frequency of gene pairs observed to have
some interaction within HumanNet (Hwang et al., 2019), omitting genetic interactions
observed solely in the co-essentiality network component (E. Kim et al., 2019) which
were derived from the same data set. Additionally, we compared our selected shuffled
Z-Score cutoff against other various Z-Score cutoffs to ensure that we observed
appropriate edge representation from HumanNet (Figure 3.8A-B). Networks were
made using identical pipelines and Fisher’s exact test set cutoffs with Z-Score cutoffs
between 3.5 and 8 at 0.25 increments.

3.4 Conclusions and Discussion
CRISPR screens have had a profound impact on cancer functional genomics.
While research has been mainly focused on essential gene phenotypes, there is still
much clinically relevant biology that can be uncovered by examining other phenotypes
from a genetic screen. The analysis conducted in this chapter establishes
methodology that can identify the “proliferation suppressor” fitness phenotype from
whole-genome CRISPR knockout genetic screens, which is defined as cells observed
to have higher fitness following specific genetic knockout. This represents, to our
knowledge, the first systematic study of this phenotype in the ~1,000 published
screens (Behan et al., 2019; Dempster, Rossen, et al., 2019; Meyers et al., 2017;
Tsherniak et al., 2017).
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The activity of PS genes is inherently context-dependent, rendering global
classification difficult. As with context-dependent essential genes, the strongest signal
is attained when comparing knockout phenotype with underlying mutation state. For
example, wildtype and mutant alleles of classic tumor suppressor examples TP53 and
PTEN are present in large numbers of cell lines, enabling relatively easy discrimination
of PS behavior in wildtype backgrounds, but most mutations are much more rare,
reducing statistical power. This suggests that there is a limited amount of cell line
availability that can detect TSGs as a proliferation suppressor. Further this raises the
point of the remaining COSMIC (Bamford et al., 2004; Sondka et al., 2018) TSGs that
are never detected. For this we posit four potential explanations:

1) The COSMIC TSG already exhibits a loss of function. Alluding to the
assumption in the previous paragraph, a TSG needs to be wild-type or active in order
to be detected. One such example is the tumor suppressor VHL, which is never
detected as a proliferation suppressor gene. VHL has quite opposite behavior from
other detected TSGs in that it is observed as consistently essential across all
backgrounds (Lenoir et al., 2017). In kidney specific cell lines however, VHL is highly
mutated and has a distinguishable nonessential fitness distribution in kidney cells
versus all other tissues (Figure 3.10) (Dempster, Rossen, et al., 2019; Ghandi et al.,
2019; Meyers et al., 2017; Tsherniak et al., 2017), which corresponds with the fact
that VHL behaves as a TSG in renal cell carcinoma (Bamford et al., 2004). This
suggests that VHL exhibits null fitness effects on kidney cells, where it normally would
operate as a TSG.
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15. Figure 3.10: VHL Shuffled Z-Score. VHL is noted as a TSG but is never identified as PS
gene. VHL demonstrates distinct fitness scoring in kidney cancer screens, but never is close
to being scored as PS gene. Figure not in print.

2) COSMIC TSGs can be context-dependent and thus are inherently rare. If a
TSG is specific to a background, then it requires that background to be reflected in the
cell data in order to be detected.

3) The COSMIC TSG is hidden as a proliferation suppressor due to CRISPR
technology limits. While CRISPR technology is a rapid advancement from previous
available tools, there have been several examples of how the technology is limited
(Dede, McLaughlin, Kim, & Hart, 2020; Iorio et al., 2018). Recent literature has shown
that single gene knockouts are limited by genetic buffering and that knockouts of a
single gene from a paralog pair is largely undetected (Dede et al., 2020; Kegel & Ryan,
2019). This phenomenon should extend to proliferation suppressor status as paralogs
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exist in the COSMIC TSG set. For example, COSMIC TSGs ARID1A and AXIN1 are
both independently identified as proliferation suppressors in 2 and 4 cell lines
respectively, while their paralog partners ARID1B and AXIN2 are never detected. For
a single paralog to be detected as a proliferation suppressor, it requires the gene to
have wild-type functional status, the partner paralog gene to have a loss of function
status, and corresponding directly to the TSG cell-type specificity, if any.

4) The COSMIC TSG is a fringe case and is limited by the method. As
previously mentioned, the cutoff 90% precision score used is a shuffled z-score of
5.24 (Figure 3.3B and 3.5A-B). Adjusting the score cutoff to a shuffled z-score of 4,
and precision score of 69.5%, further identifies 62 additional COSMIC TSGs, more
than doubling the number of unique genes observed.

Though we concede certain COSMIC TSGs are missing, we also affirm the
utility and conclusions from this technique due to the 10-fold increase in
representation, which is expected due to TSG’s fundamental role in suppressing
cancer cell proliferation. Further, the remaining proliferation suppressor observations
that are not TSGs, contain genes that would be expected proliferation suppressors.
For example, both TP53BP1 and autophagy regulator AMBRA1, are observed as a
proliferation suppressor in 4 and 23 screens respectively. Neither are a COSMIC TSG,
but both have strong evidence in literature indicating their roles in cancer proliferation
suppression (Bi, Huang, Liu, Zhang, & Ma, 2015; Cianfanelli et al., 2015; Meitinger et
al., 2016).
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In summary, this analysis identifies genes behaving consistently as
proliferation suppressors within cancer cell lines, which have the potential to be tumor
suppressor candidates. Our model-based approach enables the discovery of the PS
phenotype as an outlier from null-phenotype knockouts. Using this approach, we
recover COSMIC-annotated TSGs exhibiting the PS phenotype when wildtype alleles
are expressed at nominal levels. When examining genes that co-occurred as
proliferation suppressors, we found co-functional gene clusters similar to previous
studies (Boyle et al., 2018; E. Kim et al., 2019; Pan et al., 2018). Co-occurrence of
proliferation suppressors follows the principles of modular biology, with genes in the
same pathway acting as proliferation suppressors in the same cell lines. We observe
background-specific putative tumor suppressor activity for the PTEN pathway, P53
regulation, mTOR signaling, chromatin remodeling, and others. From our results, we
identify several proliferation genes, such as KIRREL1 and NRP1, which have similar
expression signatures to TP53 and PTEN, that are found to occur frequently with
hippo pathway genes. Further examination of proliferation suppressors could help
reveal additional cancer-related biology and could provide insight into the specific
nature of observed context-essential genes.
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Chapter 4 – Lipid Metabolism Proliferation
Suppressor Subtypes within Acute Myeloid
Leukemia Cell Lines
4.1 Background
The analyses contained in Chapter 3 depicted the proliferation suppressor
phenotype that could be recovered from a genetic fitness screen. While no tissue
appeared to be overrepresented (Figure 3.4C) for PS identification, a fatty acid
synthesis (FAS) cluster involved with lipid metabolism observed in figure 3.7 shows
a strong enrichment for acute myeloid leukemia (AML) cell lines (P = 1.1x10-5).

AML, like most cancers, typically relies on increased glucose consumption for
energy and diversion of glycolytic intermediates for the generation of biomass required
for cell proliferation. Membrane biomass is generated by phospholipid biosynthesis
that uses fatty acids (FA) as building blocks, with FA pools replenished by some
combination of triglyceride catabolism, transporter-mediated uptake, and de novo
synthesis via the ACLY/ACACA/FASN palmitate production pathway using citrate
precursor diverted from the TCA cycle. Indeed the role of lipid metabolism in AML
progression is indicated by changes in serum lipid content (Khalid, Siddiqui, Huang,
Shamsi, & Musharraf, 2018) in particular for long-chain saturated fatty acids that are
the terminal product of the FAS pipeline. Inhibition of FA synthesis is therefore an
appealing chemotherapeutic intervention (Flavin, Peluso, Nguyen, & Loda, 2010;
Punekar & Cho, 2019) and FASN inhibitors are currently undergoing clinical trials for
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treatment of solid tumors and metabolic diseases ("FASN Clinical Trials," 2020). The
observation that knocking out FAS pathway genes results in faster proliferation in
some AML cells, and their signature as putative tumor suppressor genes, is therefore
very unexpected, and in our view warrants further study.

In the following chapter, I will discuss analyses pertaining to investigation of the
FAS PS pathway cluster specific to AML, with the goal of identifying patterns and
subtypes of underlying metabolic rewiring. The majority of analyses found in this
chapter are present in the following preprint manuscript, currently under review:
Lenoir, W.F., et al., Discovery of novel tumor suppressors from CRISPR
screens reveals lipid-sensitive subtype of AML. bioRxiv, 2020: p. 2020.10.08.332023.

4.2 Variation in Fatty Acid Metabolism Pathways in AML
Cells

4.2.1 The FASN Proliferation Suppressor Observation
As mentioned in the background, we observed a large module containing
elements of several gene members of fatty acid and lipid biosynthesis pathways
(Figure 3.7). The specific pathway genes that we observe related to FASN include
ACACA, CHP1, and GPAT4, all of which have been implicated to have a role in fatty
acid utilization (Bayraktar et al., 2020; Zhu et al., 2019), in addition to the other
metabolic genes observed in this cluster are GPI, LSS, ERO1A, SLC2A1, and PGP.
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In subsequent analyses of FASN’s fitness score, the gene with the highest shuffled Zscores in this particular cluster, in matching cell lines coming from a separate leukemia
screen set using a different CRISPR guide target library coming from Wang et al.
(Wang et al., 2015; Wang et al., 2014; T. Wang et al., 2017), we observed identical
trends of FASN and related pathway genes demonstrating equivalent effects on
cellular fitness (Figure 4.1).

16. Figure 4.1: FASN’s Shuffled Z-Score in two sets of CRISPR genetic fitness screens, (A)
AML cell lines coming from the Avana set of screens (Dempster, Rossen, et al., 2019;
DepMap, 2019; Meyers et al., 2017), and (B) the Wang et al. set of screens (Wang et al.,
2015; Wang et al., 2014; T. Wang et al., 2017). Cell lines in green represent cell lines where
FASN is observed to behave as PS in Avana. Identical cells in the Wang screen set are
highlighted green as well. Figure not in print.

The shuffled Z-scores observed in Figure 4.1 are of different scale due to
experimental procedures, including different guide composition targeting FASN,
however the pattern of FASN’s fitness scores are similar. This indicates data
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agreement with FASN’s fitness scores in that FASN tends to behave more as a PS in
these cell lines, relative to all other available cell lines.

4.2.2 Computational Evidence of Metabolic Rewiring in Select AML
Cells
To learn whether additional elements of lipid metabolism were associated with
the FAS cluster, we examined the differential correlation of shuffled Z-scores in AML
cells. As mentioned in chapter 1, we and others have shown that genes with correlated
gene knockout fitness profiles in CRISPR screens are likely to be involved in the same
biological pathway or process (“co-functional”) (Boyle et al., 2018; E. Kim et al., 2019;
Rauscher et al., 2018; T. Wang et al., 2017), analogous to correlated genetic
interaction profiles in yeast (Costanzo et al., 2010; Costanzo et al., 2016; Roguev et
al., 2008). Strikingly, all gene pairs within the fully connected clique in the FAS cluster
(containing genes FASN, ACACA, GPAT4, CHP1, and GPI, Figure 3.7) had a median
Pearson correlation coefficient (PCC) of 0.90 in the 15 AML cell lines (range 0.870.97, Figure 4.2A, red), compared to median correlation of 0.18 in the remaining 548
cell lines (range -0.04-0.58, with the highest correlation between FASN and ACACA,
adjacent enzymes in the linear palmitate synthesis pathway; Figure 4.2A, gray).
These high differential Pearson correlation coefficients (dPCC) suggest that variation
in lipid metabolism is pronounced in AML cells (K.-C. Li, 2002).

We sought to explore whether this difference in correlation identified other
genes that might give insight into metabolic rewiring in AML. Calculating a global
difference between PCC of all gene pairs in AML and in the remaining >500 cell lines
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yielded many gene pairs whose dPCC appeared indistinguishable from random
sampling (Figure 4.3). To filter these, we calculated empirical P-values for each gene
pair. We randomly selected 15 cell lines from the pool of all screens, calculated PCC
for all gene pairs in the selected and remaining lines, and calculated dPCC from these
PCC values (Figure 4.2B). We repeated this process 1000 times to generate an
empirically-derived null distribution of dPCC values for each gene pair, against which
a P-value could be computed (Figure 4.2C-D).

17. Figure 4.2: Differential Network Analysis of genetic fitness correlations of the FAS cluster.
A) Five FAS cluster genes and their corresponding Pearson correlation of fitness scores in
AML cell lines (red) and all other cell lines (gray). B) Significance testing of differential PCC
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(dPCC) involves building a null distribution by randomly selecting 15 cell lines, and calculating
PCC between all gene pairs in the selected cells and the remaining cells. C) After 1,000
repeats, a null distribution is generated for each pair, and a P-value is calculated for the
observed AML-vs-other dPCC. D) dPCC density volcano plot. E) Heatmap of 61 genes with
significant change (p < 0.001, |Z| > 3) in AML cells. Highlighted genes include FAS cluster
genes and related fatty acid metabolism genes. Clustering indicates the putative Fatty Acid
Synthesis/Tumor Suppressor (FASTS) subtype. Green boxes indicate genes that are
preferentially essential (top) or nonessential (bottom) in FASTS. Orange, genes directly
involved in fatty acid synthesis. Figure adapted from Lenoir, W. F., Morgado, M., DeWeirdt,
P. C., McLaughlin, M., Griffith, A. L., Sangree, A. K., Feeley, M. N., Kim, E., Colic, M., Dede,
M., Doench, J. G., Hart, T., Discovery of novel tumor suppressors from CRISPR screens
reveals lipid-sensitive subtype of AML. bioRxiv, 2020: p. 2020.10.08.332023. Copyright
permissions are not required. This article is available under a Creative Commons International
License – https://creativecommons.org/licenses/by/4.0/).

Expanding the set to a filtered list of genes whose correlation with a gene in the
FASN cluster showed significant change in AML cells (P<0.001; see Methods) yielded
a total of 61 genes, including the 5 genes in the clique (Figure 4.2E) and the remaining
genes in the co-occurrence network cluster (LSS, ERO1A, SLC2A1, PGP) plus
Holocarboxylase Synthetase (HLCS), which biotinylates and activates acetyl-CoAcarboxylase. Interestingly, about a third of the genes showed significantly increased
anticorrelation with the FAS cluster, indicating genes preferentially essential where
the FAS genes act as proliferation suppressors (Figure 4.2E). These genes include
fatty acid desaturase (SCD), which operates directly downstream from FASN to
generate monounsaturated fatty acid species, and Sterol Regulatory Element Binding
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Transcription Factor 1 (SREBF1), the master regulatory factor for lipid homeostasis in
cells. Other lipid pathways are also represented, including plasmanylethanolamine
desaturase (TMEM189), critical for plasmalogen synthesis (Gallego-García et al.,
2019), and ceramide synthase 2 (CERS2), involved in de novo ceramide biosynthesis
(Mullen, Hannun, & Obeid, 2012), an important precursor for sphingomyelin in cell
membranes.

Clustering the AML cells lines according to these high dPCC genes reveals two
distinct subsets of cells. The FAS cluster and its correlates show strong proliferation
suppressor phenotype in four cell lines, NB4, MV411, MOLM13, and THP1. The
remaining eleven AML cell lines show negligible to weakly essential phenotypes when
these genes are knocked out. The anticorrelated genes, including SCD and SREBF1,
show heightened essentiality in these same cell lines. Together these observed shifts
in gene knockout fitness indicate that this subset of AML cells has a specific metabolic
rewiring. Because these cells share a genetic signature among fatty acid synthesis
pathway genes that is consistent with tumor suppressors, we call these cell lines Fatty
Acid Synthesis/Tumor Suppressor (FASTS) cells (Figure 4.2E).
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18. Figure 4.3: Examples of high dPCC resulting from data noise. A) EVPL vs MYCN label
shuffled Z-scores. Red indicates AML only observations, while gray indicates observations in
all other cells. B) same as (A) for ATOH8 vs. KNCK13 label shuffled Z-scores. Figure adapted
from Lenoir, W. F., Morgado, M., DeWeirdt, P. C., McLaughlin, M., Griffith, A. L., Sangree,
A. K., Feeley, M. N., Kim, E., Colic, M., Dede, M., Doench, J. G., Hart, T., Discovery of novel
tumor suppressors from CRISPR screens reveals lipid-sensitive subtype of AML. bioRxiv,
2020: p. 2020.10.08.332023. Copyright permissions are not required. This article is available
under
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Creative

Commons
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License

–

https://creativecommons.org/licenses/by/4.0/).

4.2.3 Methods
Differential Pearson Correlation Coefficient (dPCC) Analysis
dPCC correlation analysis was conducted in collaboration with postdoctoral lab
member Eiru Kim, Ph.D. and Traver Hart, Ph.D. Analysis including empirical
calculations were conducted in Python 3.8.2 (Foundation), using the packages SciPy
(Virtanen et al., 2020), NumPy (Harris et al., 2020), Matplotlib (Hunter, 2007), and
pandas (McKinney, 2010).

80
Differential Pearson correlation coefficient (dPCC) analysis was conducted in
order to identify genetic fitness distinctions between AML cells and all other cells
(Figure 4.2). Initial correlations (Figure 4.2A) of FASTS cluster genes, GPI, FASN,
CHP1, GPAT4, and ACACA were calculated with R version 3.5.1 base stat packages
(T. R. D. C. Team, 2016). and plotted in ggplot2 (Wickham, 2016).

Following this observation, a follow up dPCC analysis was conducted on the
FASTS cluster genes to assess dPCC quality. Tissue types that had less than 9 cell
lines available were removed, leaving dPCC analysis conducted in the remaining 550
cell lines. Following this filtering step, two gene-by-gene correlation matrices were
calculated. The first correlation matrix calculated all gene by gene pairs in only the
available AML cell lines (n=15). The second matrix calculated all gene by gene pairs
in the remaining 530 cell lines, with 5 additional blood lineage cell lines removed. The
dPCC matrix is therefore the AML correlation matrix minus the non-AML correlation
matrix.

Each gene-pair has a unique joint distribution of shuffled Z scores; thus, the
significance of each dPCC score must be calculated individually. To do this, we
generated null distributions for dPCC for each gene pair. We took random selections
without replacement of 15 cell lines (matching the n of AML cells), calculated all gene
x gene correlations for this selection and the remainder, and calculated dPCC. We
repeated this sampling and calculation 1,000 times to generate a unique null
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distribution for each gene pair and calculated an appropriate P-value (right tailed for
positive dPCC, left tailed for negative dPCC).

Genes which showed significant AML-specific change in correlation (dPCC
P<0.001) with a gene in the connected clique in the co-occurrence cluster (CHP1,
GPAT4, ACACA, FASN, GPI) were selected for further analysis (Figure 4.2E). Figure
4.2E was made using the R ComplexHeatmap library(Gu et al., 2016). Figure 4.2CD plots were made using the Python package Matplotlib (Hunter, 2007).

4.3 Orthogonal Evidence of Rewired Lipid Metabolism
4.3.1 Cas12a-mediated Genetic Interaction Screens Confirm
Rewired Lipid Metabolism
The following work in section was done in conjunction with group members coming
from the laboratories of both Dr. Traver Hart, and Dr. John Doench’s of the Broad
Institute. With members of my lab, we worked together to design the genetic screen
conducted in this section. Dr. Doench’s group performed the screen. Members from
both groups analyzed the results coming from the screen.

We sought to confirm whether gene knockout confers improved cell fitness, and
to gather some insight into why some AML cells show the FASTS phenotype and
others do not. We designed a CRISPR screen that measures the genetic interactions
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between eight selected “query genes” and ~100 other genes (“array genes”). The
query genes include FASN and ACACA, from the cluster of proliferation-suppressor
genes, as well as lipid homeostasis transcription factor SREBF1, anticorrelated with
the FAS cluster in the differential network analysis, and uncharacterized gene
c12orf49, previously implicated in lipid metabolism by coessentiality (E. Kim et al.,
2019) and a recent genetic interaction study (Bayraktar et al., 2020). Additional query
genes include control tumor suppressor genes TP53 and PTEN and control contextdependent essential genes GPX4 and PSTK (Figure 4.4A). The array genes include
two to three genes each from several metabolic pathways, including various branches
of lipid biosynthesis, glycolysis and glutaminolysis, oxphos, peroxisomal and
mitochondrial fatty acid oxidation. We include the query genes in the array gene set
(Figure 4.4A) to test for screen artifacts and further add control essential and
nonessential genes to measure overall screen efficacy.

We used the enCas12a CRISPR endonuclease system to carry out multiplex
gene knockouts (Kleinstiver et al., 2019). We used a dual-guide enCas12a design, as
described in DeWeirdt et al. (DeWeirdt et al., 2020), that allows for construction of
specific guide pairs through pooled oligonucleotide synthesis (Figure 4.4B). The
library robustly measures single knockout fitness by pairing three Cas12a crRNA per
target gene each with five crRNA targeting nonessential genes (Hart et al., 2014; Hart
et al., 2015) (n=15 constructs for single knockout fitness), and efficiently assays
double knockout fitness by measuring all guides targeting query-array gene pairs
(n=9) (Figure 4.4C). Using this efficient design and the endogenous multiplexing
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capability of enCas12a, we were able to synthesize a library targeting 800 gene pairs
with a single 12k oligonucleotide array.

19. Figure 4.4: Genetic interactions reveal a rewired lipid biosynthesis pathway in FASTS
cells. Figure made by Peter DeWeirdt, used with permission. A) Genetic interaction screen
targets 8 query genes and 100 array genes, for a total of 800 pairwise knockouts. B) Library
design uses a dual-guide enCa12a expression vector which targets the query gene in the “A”
position and array gene in the “B” position. C) Overall library design includes three
crRNA/gene plus control crRNA targeting nonessential genes. Single-knockout constructs
(target gene paired with nonessential controls) allow accurate measurement of single
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knockout fitness. D) Considering single knockout fitness of query genes in the “A” and “B”
position of the crRNA expression vector shows no position effects in the two cell lines
screened (MOLM-13, NOMO-1). LFC, log fold change. E) Single knockout fitness (Z-score of
mean LFC) is highly consistent between MOLM-13 and NOMO-1, but reveals backgroundspecific PS genes. F) Enrichment among GI for coessential and same-gene genetic
interactions. Same-gene interactions among genes that show single knockout fitness
phenotypes are expected, reflecting quality of GI observations. G) Global comparison of
MOLM-13, NOMO-1 genetic interaction Z scores. H) Network view of interactions in each
background shows rewiring in MOLM-13 FASTS cells. Figure adapted from Lenoir, W. F.,
Morgado, M., DeWeirdt, P. C., McLaughlin, M., Griffith, A. L., Sangree, A. K., Feeley, M. N.,
Kim, E., Colic, M., Dede, M., Doench, J. G., Hart, T., Discovery of novel tumor suppressors
from CRISPR screens reveals lipid-sensitive subtype of AML. bioRxiv, 2020: p.
2020.10.08.332023. Copyright permissions are not required. This article is available under a
Creative Commons International License – https://creativecommons.org/licenses/by/4.0/).

The screen conducted used one AML cell line from the FASTS subset,
MOLM13, and a second one with no FAS phenotype, NOMO1, collecting samples at
14 and 21 days after transduction with a five-day puromycin selection. Importantly, by
comparing the mean log fold change of query gene knockouts in the “A” position vs.
the same genes in the “B” position of the dual knockout vector, we find no positional
bias in the multiplex knockout constructs (Figure 4.4D), consistent with our previous
findings (Beltrao, Cagney, & Krogan, 2010; Dede et al., 2020). Single knockout fitness
measurements effectively segregated known essential genes from nonessentials,
confirming the efficacy of the primary screens. Context-dependent fitness profiles are
consistent with the cell genotypes, with PTEN and TSC1 showing positive selection in
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PTENwt NOMO1 cells and TP53 being a strong PS gene in P53 wt MOLM13 cells.
Strikingly, CHP1 and GPAT4 are the next two top hits in MOLM13, confirming their
proliferation suppressor phenotype (Figure 4.4E), while neither shows a phenotype in
NOMO1. Together these observations validate the enCas12a-mediated multiplex
perturbation platform, confirm the ability of CRISPR knockout screens to detect
proliferation suppressors, and corroborate the background-specific fitness enhancing
effects of genes from the FAS cluster.

To measure genetic interactions from the resulting screens, a linear regression
for each guide between the combination LFCs and the single guide LFCs, Z-scoring
the residuals from this line, and combining across all guides targeting the same gene
pair. Here, positive genetic interaction Z-scores reflect greater fitness than expected
and negative Z-scores represent lower than expected based on the single gene
knockouts independently, similar to the methodology applied in a recent survey of
genetic interactions in cancer cells using multiplex CRISPR perturbation (Horlbeck et
al., 2018). Gene self-interactions (when the same gene is in the A and B position,
Figure 4.4D) should therefore be negative for proliferation suppressors and positive
for essentials (Figure 4.4F-G). Overall, genetic interaction Z-scores in the two cell
lines showed moderate correlation (Figure 4.4G) and previously reported synthetic
interactions between C12orf49 and low-density lipoprotein receptor LDLR (Aregger et
al., 2020) and between SREBF1 and its paralog SREBF2 (Aregger et al., 2020) are
identified in both cell lines.
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In contrast with the interactions found in both cell lines, background-specific
genetic interactions reflect the genotypic and phenotypic differences between the
cells. The negative interaction between tumor suppressor PTEN and mTOR repressor
TSC1 in PTENwt NOMO1 cells is consistent with their epistatic roles in the mTOR
regulatory pathway. Both genes show positive knockout fitness in NOMO1 (Figure
4.4E) but their dual knockout does not provide an additive growth effect, resulting in a
suppressor interaction with a negative Z-score (Figure 4.4G-H). Similarly, suppressor
genetic interactions between ACACA and downstream proliferation suppressor genes
CHP1 and GPAT4 are pronounced in MOLM13 cells, consistent with epistatic
relationships in a linear biochemical pathway (Figure 4.4H). These interactions are
not replicated with query gene FASN, but both FASN and ACACA show negative
interactions with fatty acid transport gene FABP5 and positive interactions with
SREBF1 and SCD, the primary desaturase of long-chain saturated fatty acids. All of
these interactions are absent in NOMO1, demonstrating the rewiring of the lipid
biosynthesis genetic interaction network between these two cell types (Figure 4.4H).

4.3.2 FASTS Signature Predicts Sensitivity to Saturated Fatty Acids
The following work was done in collaboration with experimental team members
Micaela Morgado, Ph.D., and Megan McLaughlin from the lab of Dr. Traver Hart.

The significant differences in the single- and double-knockout fitness
signatures between the two cell lines suggests a major rewiring of lipid metabolism in
these cells. CHP1 and GPAT4 are reciprocal top correlates in the Avana coessentiality
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network (r=0.43, P=2.5x10-34), strongly predicting gene co-functionality (E. Kim et al.,
2019). Two recent studies characterized the role of lysophosphatidic acid
acyltransferase GPAT4 in adding saturated acyl moieties to glycerol 3-phosphate,
generating lysophosphatidic acid (LPA) and phosphatidic acid (PA), the precursors for
cellular phospholipids and triglycerides, and further discovered CHP1 as a key
regulatory factor for GPAT4 activity (Piccolis et al., 2019; Zhu et al., 2019). Within
hematological cancer cell lines, the coessentiality network is significantly restructured,
with the ACACA/FASN module correlated with SCD in most backgrounds (r=0.33) but
strongly anticorrelated (r=-0.63) in blood cancers (Figure 4.3E). The magnitude of this
change in correlation is ranked #7 out of 164 million gene pairs, with the other six
comprising interactions that are specific to other contexts, e.g. BRAF-SOX10 are
anticorrelated in blood (r= -0.41) but highly correlated ex-blood (r=0.59) due to their
co-essentiality in BRAFV600E melanoma cells. In contrast, ACACA and FASN are
weakly correlated with CHP1 in most tissues but strongly correlated in AML, with
underlying covariation largely driven by the PS phenotype in FASTS cells (Figure
4.3E). This pathway sign reversal is confirmed in the single knockout fitness observed
in our screens: SCD is strongly essential in MOLM13 but not in NOMO1 (Figure 4.4E).

Collectively these observations make a strong prediction about the metabolic
processing of specific lipid species. Faster proliferation upon knockout of genes
related to saturated fatty acid processing, coupled with increased dependency on fatty
acid desaturase (Figure 4.5A), suggests that these cells are at or near their carrying
capacity for saturated fatty acids.
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20. Figure 4.5: FASTS cells are sensitive to saturated FA. A) Schematic of the fatty
acid/glycerolipid synthesis pathway. Blue, PS genes in FASTS cells. Red, essential genes.
Pathway analysis suggests saturated fatty acids are a critical node. B) Apoptosis of FASTS
cells in response to media supplemented with 200 µm fatty acids. All three cell lines show
marked sensitivity to palmitate. C) Apoptosis of other AML cells in response to fatty acids
shows no response to palmitate. D) Triacylglycerol (TAG) species metabolite differences. The
x axis represents the median difference of log10 normalized peak area of the metabolite in
FASTS cells vs all other AML cells. The y axis represents the number of saturated bonds
present. Each dot represents a unique metabolite. (B) and (C) made by Micaela Morgado,
Ph.D., used with permission. Figure adapted from Lenoir, W. F., Morgado, M., DeWeirdt, P.
C., McLaughlin, M., Griffith, A. L., Sangree, A. K., Feeley, M. N., Kim, E., Colic, M., Dede, M.,
Doench, J. G., Hart, T., Discovery of novel tumor suppressors from CRISPR screens reveals
lipid-sensitive subtype of AML. bioRxiv, 2020: p. 2020.10.08.332023. Copyright permissions
are not required. This article is available under a Creative Commons International License –
https://creativecommons.org/licenses/by/4.0/).
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To test this prediction, we exposed three FASTS cell lines and four other AML
cell lines to various species of saturated and unsaturated fatty acids. FASTS cells
showed significantly increased apoptosis in the presence of 200 µm palmitate (Figure
4.5B-C) while no other species of saturated or unsaturated fatty acid showed similar
differential sensitivity. In addition, analysis of metabolic profiles of cells in the Cancer
Cell Line Encyclopedia (Ghandi et al., 2019; H. Li et al., 2019) showed that saturated
acyl chains are markedly overrepresented in triacylglycerol (TAG) in FASTS cells
(Figure 4.5D), in contrast with other lipid species measured (Figure 4.6). Palmitateinduced lipotoxicity has been studied in many contexts – and importantly, the role of
GPAT4 and CHP1 in mediating lipotoxicity was well described recently (Piccolis et al.,
2019; Zhu et al., 2019) – but, to our knowledge, this is the first instance of a genetic
signature that predicts liposensitivity.
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21. Figure 4.6: Additional metabolite comparisons. A) Lysophosphatidylethanolamine (LPE)
species metabolite difference. The x axis represents the median difference of log10
normalized peak area of the metabolite in FASTS cells vs all other AML cells. The y axis
represents the number of saturated bonds present. Each dot represents a unique metabolite.
B) same for diacylglycerol (DAG), (C) lysophosphatidylcholine (LPC), (D) sphingomyelin
(SM), (E) cholesterol ester (CE), and (F) phosphatidylcholine (PC) species. Figure adapted
from Lenoir, W. F., Morgado, M., DeWeirdt, P. C., McLaughlin, M., Griffith, A. L., Sangree,
A. K., Feeley, M. N., Kim, E., Colic, M., Dede, M., Doench, J. G., Hart, T., Discovery of novel
tumor suppressors from CRISPR screens reveals lipid-sensitive subtype of AML. bioRxiv,
2020: p. 2020.10.08.332023. Copyright permissions are not required. This article is available
under
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4.3.3 Clinical Relevancy of Observed Phenotype
To explore whether the FASTS phenotype has clinical relevance, we compared
our results with patient survival information from public databases. Using genetic
characterization data from CCLE (Ghandi et al., 2019), we did not find any lesion
which segregated FASTS cells from other CD33+ AML cells (Figure 4.7A), so no
mutation is nominated to drive a FASTS phenotype in vivo. Instead, we explored
whether variation in gene expression was associated with patient outcomes. We
included genes in the core FASTS module as well as genes with strong genetic
interactions with ACACA/FASN in our screen (Figure 4.7A). To select an appropriate
cohort for genomic analysis, we first considered patient age. Although AML is present
across every decade of life, patients from whom FASTS cell lines were derived are all
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under 30 years of age (sources of other AML cells ranged from 7 to 68 years; Figure
4.7B). With this in mind, we explored data from the TARGET-AML (Meshinchi &
Arceci) project, which focuses on childhood cancers (Figure 4.7C). Using TARGET
data, we calculated hazard ratios using univariate Cox proportional-hazards modeling
with continuous mRNA expression values for our genes of interest as independent
variables. We observed that both CHP1 and GPAT4 show significant, negative hazard
ratios (HR), consistent with a tumor suppressor signature (Figure 4.7D), and that no
other gene from our set shows a negative HR. Indeed, tumors in the top quartile of
gene expression showed significantly improved survival for both CHP1 (P-value
0.007, Figure 4.7E) and GPAT4 (P-value 0.035, Figure 4.7F). These findings are not
replicated for CHP1 and GPAT4 in the TCGA (Cancer Genome Atlas Research et al.,
2013) or OHSU (Tyner et al., 2018) tumor genomics data sets, suggesting the FASTS
phenotype might be restricted to juvenile leukemias.

22. Figure 4.7: Prognostic signature of FASTS module. A) Heatmap of shuffled Z scores for
genes implicated in the genetic interaction network. Top, common AML lesions. B) Shuffled
Z-score of FASN in AML cell lines vs. age of patient from which cell lines were derived. Blue,
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FASTS cells. C) Age distribution of AML patients in three genomics cohorts. (d) Hazard ratios
(95% CI; univariate Cox proportional hazards test) for expression of genes in (a), using
genomics and survival data from TARGET. E) Kaplan-Meier survival analysis of AML patients
in TARGET, comparing top quartile of CHP1 expression vs. others. F) Same, with GPAT4.
Figure adapted from Lenoir, W. F., Morgado, M., DeWeirdt, P. C., McLaughlin, M., Griffith,
A. L., Sangree, A. K., Feeley, M. N., Kim, E., Colic, M., Dede, M., Doench, J. G., Hart, T.,
Discovery of novel tumor suppressors from CRISPR screens reveals lipid-sensitive subtype
of AML. bioRxiv, 2020: p. 2020.10.08.332023. Copyright permissions are not required. This
article

is
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4.3.4 Methods

Metabolomics Analysis
This section describes the methods used within Figure 4.5D and 4.6.
Metabolomics data acquired from Supplementary table 1 of Li et al. (H. Li et al., 2019)
For analysis, normalized data (“1-clean data”) and coefficient of variation for each
metabolite (“1-CV”) was used. Normalized data was filtered to select only AML cells
that were present in Avana 2019q2 (DepMap, 2019) screen set. Following filtering,
the median of species present was taken, grouped by whether the measurement was
from a FASTS AML or other AML cell line. The difference in median, representing the
log ratio, was taken for each metabolite. Metabolites that had differences in medians
less than the coefficient of variation were omitted from the plots. Acyl group and
number of unsaturated bonds were obtained directly from the provided nomenclature.
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AML Patient Survival Analysis
This section describes the methods used within Figure 4.7 and 4.8. The results
published here are in part based upon data generated by the Therapeutically
Applicable Research to Generate Effective Treatments (TARGET) initiative,
phs000218, managed by the NCI. The data used for this analysis are available at
dbGaP Study Accession: phs000465.v19.p8. Information about TARGET can be
found at http://ocg.cancer.gov/programs/target.

Genes chosen for analysis were all genes shown to have an interaction with
ACACA in Figure 4H and FASN. Gene annotations noted in the Figure 6A heatmap
include any non-silent mutation, copy number loss for TP53 & KMT2A, and copy
number gain for KRAS, NRAS, and FLT3. FLT3-ITD annotations were included in the
FLT3 annotation row bar. Mutation annotations come from CCLE 71, copy number calls
come from the cBioPortal (Cerami et al., 2012; Gao et al., 2013) database, and FLTITD annotations come from the DSMZ catalogue ("German Collection of
Microorganisms and Cell Cultures GmbH: Welcome to the Leibniz Institute DSMZ,").

TARGET-AML (Meshinchi & Arceci) data including age, genetic expression
(HTseq FPKM UQ), time to event, and survival event outcomes, and TCGA ("Genomic
and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia," 2013)
patient ages were downloaded directly from the Xena (Goldman et al., 2020)
database. The OHSU BeatAML (Tyner et al., 2018) age data was directly downloaded
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from the Vizome database. Age of patient derived cell lines were obtained from the
Cellosaurus database (Bairoch, 2018). Hazard ratios calculated from Cox proportional
hazards modeling were done using the R survival (Therneau & Grambsch, 2000;
Therneau, until, 2009), Elizabeth, & Cynthia, 2020) package, and Kaplan-Meier plots
were created using the R survminer (Kassambara, Kosinski, Biecek, & Fabian, 2020)
package.

P-values shown are based on log-rank and Schoenfeld tests calculated
internally by the survminer (Kassambara et al., 2020) package. For this analysis,
patient expression profiles were chosen from primary tumor samples, filtering out
samples from recurrent patients (42 such cases). Patient stratification is conducted
based on stratifying patient groups into lower genetic expression (patients with genetic
expression below the 75th percentile, n = 108), and higher genetic expression
(patients with 75th percentile and above, n = 37). Computed hazard ratios for all tested
genes all passed the cox proportion hazards assumption (Figure 4.8) by failing to
reject the Schoenfeld test null hypothesis.
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23. Figure 4.8: Testing the Cox Proportional Hazards Assumption. Assessing the Cox
proportional hazards assumption with Schoenfeld tests of all genes in Figure 6D; (A) FASN,
(B) CHP1, (C) GPAT4, (D) ACACA, (E) SQLE, (F) CPT2, (G) SCD, (H) CRLS1, (I) ACLY, (J)
SBREF1, (K) FABP5. Figure adapted from Lenoir, W. F., Morgado, M., DeWeirdt, P. C.,
McLaughlin, M., Griffith, A. L., Sangree, A. K., Feeley, M. N., Kim, E., Colic, M., Dede, M.,
Doench, J. G., Hart, T., Discovery of novel tumor suppressors from CRISPR screens reveals
lipid-sensitive subtype of AML. bioRxiv, 2020: p. 2020.10.08.332023. Copyright permissions
are not required. This article is available under a Creative Commons International License –
https://creativecommons.org/licenses/by/4.0/).
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4.4 Conclusions and Discussion
The co-occurrence network from Chapter 3 revealed a novel module
associated with glycerolipid biosynthesis, which exhibits the PS phenotype in a subset
of AML cells. Analysis of the rewiring of the lipid metabolism coessentiality network in
AML cells corroborated this discovery, and led us to define the Fatty Acid
Synthesis/Tumor Suppressor (FASTS) phenotype in four AML cell lines. A survey of
genetic interactions, using the enCas12a multiplex knockout platform, showed major
network rewiring between FASTS and other AML cells, and revealed strong genetic
interactions in FASTS cells with GPAT4, a key enzyme in the processing of saturated
fatty acids, and its regulator CHP1. Collectively these observations suggest that
FASTS cells are near some critical threshold for saturated fatty acid carrying capacity,
which we validated biochemically by treatment with fatty acids and bioinformatically
by comparison with CCLE metabolomic profiling.

Confirming the clinical relevance of an in vitro phenotype can be difficult. No
obvious mutation segregates FASTS cells from other AML cells, and with only four
cell lines showing the FASTS phenotype, we lack the statistical power to discover
associations in an unbiased way. However, by narrowing our search to strong hits
from the differential network analyses, we found a significant survival advantage in a
roughly age-matched cohort for GPAT4 and CHP1 overexpression. This finding is
consistent with a wholly novel tumor suppressor signature for our PS gene module.
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The combination of genetic, biochemical, and clinical support for the discovery
of a novel tumor suppressor module has several implications. First, it provides a
clinical signature that warrants further research as a prognostic marker as well as a
potential therapeutic target -- and a high-risk group for fatty acid synthesis inhibitors.
Second, it demonstrates the power of differential network analysis, and in particular
differential genetic interaction networks, to dissect the rewiring of molecular pathways
from modular phenotypes. And finally, it suggests that there still may be much to learn
from data-driven analyses of large-scale screen data, beyond the low-hanging fruit of
lesion/vulnerability associations.
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Chapter 5 – Compensatory Genetic Interactions for
the Fanconi Anemia Pathway

5.1 Background
Many oncology drugs have been developed to target recurrent mechanisms of
oncogenic drivers. A common problem with targeting oncogenic drivers however is
that cancer cells frequently adapt to these drugs and develop resistance to the
targeted oncogenes, or cancer cells rely on oncogenes that are currently undruggable.
These situations have driven researchers to identify alternative gene pathways that
can be targeted by therapeutics. One such strategy for precision medicine within
cancer therapy is synthetic lethality, defined in Chapter 1. Identifying genetic
dependencies that are specific to cell lines harboring loss of function TSGs, represent
candidate synthetic lethal targets in that they can indicate genes that are required for
cell survival in the absence of TSG caretaker functions.

The analysis conducted in Chapter 5, is currently under review, and was in
collaboration with postdoctoral fellow Rui Wang of the Department of Experimental
Radiation Oncology in MD Anderson, and Dr. Lei Li of Zhejiang University (previously
of the Department of Experimental Radiation Oncology in MD Anderson). We aimed
to identify genetic dependency distinctions between wild-type cells and cells with
functional loss of Fanconi anemia (FancA) genes. The FancA pathway of genes,
represents an ideal pathway of study to identify synthetic lethal relationships given its
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TSG caretaker functional roles through DNA damage repair (Pickering, Zhang,
Panneerselvam, & Fei, 2013). Many FancA pathway gene members, including one
gene specifically analyzed – FANCG, have been defined as TSGs within the Cancer
Gene Census by COSMIC (Sondka et al., 2018). Further, synthetic lethal relationships
with FancA are ideal therapeutic targets from a clinical perspective, considering that
FancA deficiency is observed to be frequently caused by somatic mutations within
cancer patients (Niraj, Farkkila, & D'Andrea, 2019).

5.2 Genetic Screening in Combination with Isogenic
Knockout of Fanconi Anemia Pathway Members

5.2.1 Genetic Screens in Combination with Isogenic Knockout
The approach taken to identify synthetic lethal candidates with FancA gene
pathway members was to conduct a three distinct genetic knockout fitness screens in
parallel within HCT116 cells. The first screen was conducted in wild-type conditions,
with the second and third screens conducted in mutant cell lines, containing knocked
out FancA members FANCL and FANCG (Y. Huang et al., 2014) through homologous
targeting. The screens were conducted using the TKOv3 guide RNA library (Hart,
Tong, et al., 2017). Following lentivirus infection, and cell selection, cell pellets for
sample analysis were collected before passaging, and following passaging of 13 and
14 doublings. These samplings represent three distinct time points; T0, T1, and T2.
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All samples were done in triplicate repeats, and with full experimental designed
observable in Figure 5.1A. Screen and data collection completed by Dr. Rui Wang.

5.2.2 Singular Value Decomposition To Identify Biological Variation
in Genetic Screens
In order to identify target synthetic lethal hits with the corresponding FA
deficient mutant screens, we used the matrix factorization technique singular value
decomposition (SVD). SVD has been used previously for identifying genetic
expression differences between backgrounds (Alter, Brown, & Botstein, 2000), and
analogous techniques have been proposed to identify synthetic lethal targets (Y. Liu,
Wu, Liu, Li, & Zheng, 2019), however to our knowledge, this method has not been
used previously to identify synthetic lethal candidates on genetic fitness screens with
single gene knockouts.

The raw reads generated from these screens were processed with the genetic
fitness classifier BAGEL (Hart & Moffat, 2016; E. Kim & Hart, 2020) software to
calculate gene-level fitness scores (BF), where positive scores indicate essential
genes and negative scores indicate no knockout phenotype. We compared the
screens to previously identified sets of known essential and nonessential fitness
genes (Hart et al., 2014; Hart et al., 2015) in order to assess sufficient screen
performance. BFs from the six samples were then combined into a single matrix and
quantile-normalized, and the resulting matrix was decomposed using SVD. The fourth
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component of the v matrix highlights variation between the FA knockout and wild-type
samples (Figure 5.1B) This observed variation represents genetic fitness differences
that exist between the FA knockouts and wild-type samples (Figure 5.1C). We were
specifically interested in genes that had high differential fitness scores by SVD that
also have a sign change in BF (Figure 5.1D), that is, genes that are essential in one
background and nonessential in the other. The z-score transformed eigenvalues in
the fourth component of matrix v, represent the genetic signal that is observed to
contribute to the sample’s separation, and thus lead to high differential fitness scores
between knockout and wild-type samples (Figure 5.1E).

24. Figure 5.1: Computational Assessment to Find Synthetic Lethal Candidates in
Combination with Isogenic Knockouts. A) Schematic experimental design using whole
genome fitness screens. Figure created by Rui Wang, Ph.D., used with permission. B)
Resulting SVD v matrix of processed quantile-normalized BAGEL essential scores (BF) of
FancA deficient and wild-type screens. Color similarity in matrix represents the direction and
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amount of signal that is contributing to the individual component. C) Histogram of component
4 scores coming from matrix u eigenvalues. Histogram represents genetic fitness signal
differences existing between the FancA knockouts and wild-type samples. Values less than 3 are colored blue, while greater than 3 are colored pink and correspond to the points on D.
D) Comparison of mean BF scores in the FANCL and FANC knockout screens versus wild
type screen. E) Table of the top 8 genes negative z-score eigenvalues coming from the fourth
component of matrix u. Blue highlighted rows represent genes that had a difference in
essential score (columns 3 & 4), representing phenotypic difference in the two sets of screens.
Figure currently not in print.

In order to further establish the compensatory function role of one of the top
synthetic lethal gene candidates POLI, a DNA polymerase gene involved in DNA
repair (Frank et al., 2001; Tissier et al., 2000), we examined the genetic fitness profiles
of 21 additional DNA polymerase genes in 425 screens from the Avana 2018q4 screen
set (Broad, 2018; Dempster, Rossen, et al., 2019; Meyers et al., 2017). Strikingly, we
found that POLI was never found to be essential in this screen set, while the other
remaining genes had fitness scores (BFs) that were similar to the published set. This
indicates, that we observe POLI to be necessary for cell survival in our tested FancA
deficient backgrounds (Figure 5.2).
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25. Figure 5.2: POLI essential fitness, specific to FancA deficient backgrounds. This figure
demonstrates genetic fitness scores (BFs) for 21 DNA polymerase genes. Black dots
correspond to screens coming from the Avana 2018q4 screen set (Broad, 2018; Dempster,
Rossen, et al., 2019; Meyers et al., 2017), and green dots correspond to the average BF score
for FancA deficient screens. Figure currently not in print.

5.2.3 Methods
SVD Analysis
SVD analysis was conducted using the MASS package version 7.3-50 in R
(Ripley, 2002). This method takes an m x n matrix made up of numerical values and
breaks it down into three unique matrices: u, v, and d representing specific features
of the input matrix. In this analysis, the input matrix is made up by m samples and n
genes. The output matrix v can be used to identify differences and consistencies
between samples in the input matrix, while matrix u can indicate which specific rows
(genes) are contributing to differences observed in matrix v.
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Fitness Scores and Quality Control
Screen quality control and assessment followed procedures demonstrated by
BAGEL software found at https://github.com/hart-lab/bagel (Hart et al., 2014; Hart &
Moffat, 2016). POL pathway gene data found on figure 5.1F comes from the Avana
2018q4 screen dataset (Broad, 2018; Dempster, Rossen, et al., 2019; Meyers et al.,
2017) and has followed quantile normalization pipelines following protocols from
(Lenoir et al., 2017).

5.3 Conclusion and Discussion
Given that many TSGs have crucial functions in maintenance of genome
integrity, it is perplexing to find cancer cells harboring loss of critically needed TSG
functions. If we examine TSG compensatory mechanisms in cells with loss of function
TSGs, we can potentially identify synthetic lethal targets. Whole-genome CRISPR
Cas9 knockout screens are an effective methodology for identifying synthetic lethal
relationships as we can make direct comparisons between distinct backgrounds and
demonstrate how cell dependencies change in the presence of a tested perturbation,
such as an isogenic knockout shown in this chapter.
In this chapter we demonstrate analysis that led to a discovery of cellular
dependency on POLI that occurs in deficient FancA backgrounds. Remarkably, POLI
did not demonstrate to be essential in a set of 425 other cells (Figure 5.2), suggesting
that the cellular dependency of POLI is rare and unexpected. Further this observation
indicates the necessity of perturbation experiments in order to reveal hidden genetic
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dependencies. Identification of genetic dependencies to loss of function TSG
backgrounds provides synthetic lethal targets that can be leveraged to specifically
eliminate cancer cells, such as POLI with FancA pathway deficiency.
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Chapter 6 - Final Remarks

The tidal wave of genomic data availability and tools has led to enormous
amounts of time and energy spent in research to understand underlying genetics of
diseases. Given this advance in technology, research in precision medicine aims to
unveil genetic targets that are in combination with underlying malignant genomics of
a patient. Despite the progress and enthusiasm of precision medicine and of genomic
tools made available in the last two decades, we have only seen an increase in
patients with metastatic cancer benefiting in genome based therapies from 0.7% in
2006 to 4.9% in 2018 (Marquart, Chen, & Prasad, 2018), representing a minority of
patients. This suggests that despite the success of advancement of genomic tools,
further studies are needed to comprehend genetics of underlying diseases in order to
improve precision medicine approaches.

In this dissertation, we analyzed genomic data to improve knowledge of cancer
systems. We established computational analyses to study gene relationships through
genetic screening technology. We demonstrated how introducing different
methodologies, and adapting existing datasets, in order to ask different questions of
interest can lead to discovery of new genetic relationships that have potential for
clinical impact.
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6.1 Chapter Summaries

6.1.1 Chapter 1 – Introduction and Fundamental Concepts

Chapter 1 reviewed a brief history of systems biology and a few current
available genomic technologies. This chapter further reviewed CRISPR technologies
and general applications of this technology. Researchers have rapidly invested time
and effort into CRISPR technology in order to learn new functional relationships of
genes. These relationships include genetic interactions, which have been specifically
focused on and studied to better understand connections of underlying cellular
machinery and processes.

6.1.2 Chapter 2 – Available Data and Integration of Genomic Metrics
with Genetic Fitness

Chapter 2 reviewed available genetic screening data and the implementation
of the PICKLES database. The PICKLES database is a database that includes genetic
screening data published in the last half-decade and additional genomic metrics. This
chapter demonstrated some appropriate techniques in terms of how to handle large
scale combinations of genetic fitness screens, in addition to utility of visualizing
genomic integration. Finally, this chapter discussed usage and general next steps of
this database.
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6.1.3 Chapter 3 – Identification of Proliferation Suppressor Genes
and Genetic Modules within Fitness Screens

Chapter 3 established methodologies that were used to identify proliferation
suppressor gene sets in genetic fitness screens. This gene type was observed to have
an enrichment of tumor suppressor genes, which was leveraged in order to identify a
high confidence threshold of a proliferation suppressor phenotype. Using this
threshold, we identified an assortment of genes acting as proliferation suppressors,
and developed a network that demonstrated co-occurrence of proliferation suppressor
genes. This co-occurrence network yielded pathway enrichment, providing
computational evidence that pathways of genes were actively suppressing fitness.

6.1.4 Chapter 4 – Lipid Metabolism Proliferation Suppressor
Subtypes within Acute Myeloid Leukemia Cell Lines
Chapter 4 expanded on a specific fatty acid synthesis proliferation suppressor
module that was observed specific to select acute myeloid leukemia cells. We chose
to further study this observation because this pathway is needed to generate biomass
for cell proliferation, and actively suppressing fitness suggests a counter intuitive role
in these cells. The analysis contained in this chapter demonstrated a confirmation of
this phenotype genetically through a double knockout enCas12a CRISPR screen,
computationally through analysis of public metabolomic data, and biochemically
through differential response of excess fatty acids through a growth assay. Finally, we
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observed that two genes specific to this pathway, CHP1 and GPAT4, display survival
advantage with higher expression in clinical data.

6.1.5 Chapter 5 – Compensatory Genetic Interactions for the
Fanconi Anemia Pathway

Chapter 5 reviewed detection of genetic interactions of Fanconi Anemia
pathway genes through computational assessment of whole genome fitness screens
in combination with isogenic knockouts. Through this methodology we were able to
detect POLI as a gene that provided compensatory functions that allowed cell survival
in Fanconi Anemia deficient backgrounds. One striking observation from this chapter
was that POLI was never observed to be required for cell fitness compared to a panel
of 425 other cell lines, highlighting the need for perturbation experiments.

6.2 Future Directions
The advancement of CRISPR as a technology has provided a profound wealth
of information. There have been massive datasets that have aimed to connect genetic
dependencies to corresponding backgrounds, but many of these studies have
struggled to identify the specific genomic context in which a genetic dependency
exists. In order for scientists to improve upon comprehension of cellular complexities
and identification of context specific genetic dependency, research will need to utilize
more advanced CRISPR systems, such as base editors and systems able to target
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multiple loci simultaneously, to interrogate genetic connections. Additionally, there
should be more concentrated effort on dissecting data to select for specific
backgrounds. The analyses demonstrated in Chapter 4 are an example of why
background selection is important in the case of select FAS genes.

Though this FAS pathway represents a promising avenue for therapeutics,
many clinical trials have failed due to drug resistance caused by adaptive metabolic
mechanisms. In the last couple of years there have been efforts to understand
adaptive metabolism by modeling genetic dependency adaptations when presented
with metabolic perturbations (Aregger et al., 2020; Piccolis et al., 2019). In one such
study published by Aregger et al. (Aregger et al., 2020), the authors completed a
whole-genome CRISPR Cas9 knockout screen in HAP1 cells with removed FAS
genes coding DNA. From this study, the authors demonstrated genetic interactions
with FAS that provided insight into compensatory mechanisms that occur in the
absence or inhibition of FAS genes. Within our analyses through the enCas12a
system, we observe that some interactions are similar to verified interactions from
Aregger et al., however, we also observe that in distinct backgrounds certain
interactions are fundamentally different. This indicates that the genetic interactions
observed are context specific, thus suggesting that we require additional analysis in
order to understand this adaptive metabolism that influences drug efficacy.
Together this suggests that there is still much complex biology to be learned.
Technological advancements are fundamental in detecting novel features of cellular
biology, but have consequentially unveiled new questions for researchers to consider.
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Critical thinking of the mountain of publicly available genomic data, paired with
innovative methodologies will be required in order to further identify targetable disease
vulnerabilities.

112

Bibliography
Aguirre, A. J., Meyers, R. M., Weir, B. A., Vazquez, F., Zhang, C.-Z., Ben-David, U., Cook, A.,
Ha, G., Harrington, W. F., Doshi, M. B., Kost-Alimova, M., Gill, S., Xu, H., Ali, L. D.,
Jiang, G., Pantel, S., Lee, Y., Goodale, A., Cherniack, A. D., Oh, C., Kryukov, G.,
Cowley, G. S., Garraway, L. A., Stegmaier, K., Roberts, C. W., Golub, T. R., Meyerson,
M., Root, D. E., Tsherniak, A., & Hahn, W. C. (2016). Genomic Copy Number Dictates
a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discovery, 6(8),
914-929. doi:10.1158/2159-8290.CD-16-0154
Allen, F., Behan, F., Khodak, A., Iorio, F., Yusa, K., Garnett, M., & Parts, L. (2019). JACKS: joint
analysis of CRISPR/Cas9 knockout screens. Genome Research, 29(3), 464-471.
doi:10.1101/gr.238923.118
Alter, O., Brown, P. O., & Botstein, D. (2000). Singular value decomposition for genomewide expression data processing and modeling. Proc Natl Acad Sci U S A, 97(18),
10101-10106. doi:10.1073/pnas.97.18.10101
Amici, D. R., Jackson, J. M., Metz, K. A., Ansel, D. J., Smith, R. S., Brockway, S., Takagishi, S.
R., Srivastava, S., O’Hara, B. P., Cho, B.-K., Goo, Y. A., Kelleher, N. L., Ben-Sahra, I.,
Foltz, D. R., & Mendillo, M. L. (2019). Coessential Genetic Networks Reveal the
Organization and Constituents of a Dynamic Cellular Stress Response. bioRxiv,
847996. doi:10.1101/847996
Aregger, M., Lawson, K. A., Billmann, M., Costanzo, M., Tong, A. H. Y., Chan, K., Rahman, M.,
Brown, K. R., Ross, C., Usaj, M., Nedyalkova, L., Sizova, O., Habsid, A., Pawling, J., Lin,
Z.-Y., Abdouni, H., Wong, C. J., Weiss, A., Mero, P., Dennis, J. W., Gingras, A.-C.,

113
Myers, C. L., Andrews, B. J., Boone, C., & Moffat, J. (2020). Systematic mapping of
genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a
regulator of lipid metabolism. Nature Metabolism. doi:10.1038/s42255-020-0211-z
Arnold, J. B., Daroczi, G., Werth, B., Weitzner, B., Kunst, J., Auguie, B., Rudis, B., package.),
H. W. C. f. t. g., package), J. T. C. f. t. l., & London, J. (2019). ggthemes: Extra Themes,
Scales and Geoms for 'ggplot2' (Version 4.2.0).
Bairoch, A. (2018). The Cellosaurus, a Cell-Line Knowledge Resource. Journal of
Biomolecular Techniques : JBT, 29(2), 25-38. doi:10.7171/jbt.18-2902-002
Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A.,
Teague, J., Futreal, P. A., Stratton, M. R., & Wooster, R. (2004). The COSMIC
(Catalogue of Somatic Mutations in Cancer) database and website. British Journal of
Cancer, 91(2), 355-358. doi:10.1038/sj.bjc.6601894
Barabasi, A. L., Gulbahce, N., & Loscalzo, J. (2011). Network medicine: a network-based
approach to human disease. Nat Rev Genet, 12(1), 56-68. doi:10.1038/nrg2918
Barr, M. P., Byrne, A. M., Duffy, A. M., Condron, C. M., Devocelle, M., Harriott, P., BouchierHayes, D. J., & Harmey, J. H. (2005). A peptide corresponding to the neuropilin-1binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast
tumour cells. Br J Cancer, 92(2), 328-333. doi:10.1038/sj.bjc.6602308
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C.
J., Lehar, J., Kryukov, G. V., Sonkin, D., Reddy, A., Liu, M., Murray, L., Berger, M. F.,
Monahan, J. E., Morais, P., Meltzer, J., Korejwa, A., Jane-Valbuena, J., Mapa, F. A.,
Thibault, J., Bric-Furlong, E., Raman, P., Shipway, A., Engels, I. H., Cheng, J., Yu, G. K.,

114
Yu, J., Aspesi, P., Jr., de Silva, M., Jagtap, K., Jones, M. D., Wang, L., Hatton, C.,
Palescandolo, E., Gupta, S., Mahan, S., Sougnez, C., Onofrio, R. C., Liefeld, T.,
MacConaill, L., Winckler, W., Reich, M., Li, N., Mesirov, J. P., Gabriel, S. B., Getz, G.,
Ardlie, K., Chan, V., Myer, V. E., Weber, B. L., Porter, J., Warmuth, M., Finan, P.,
Harris, J. L., Meyerson, M., Golub, T. R., Morrissey, M. P., Sellers, W. R., Schlegel, R.,
& Garraway, L. A. (2012). The Cancer Cell Line Encyclopedia enables predictive
modelling of anticancer drug sensitivity. Nature, 483(7391), 603-607.
doi:10.1038/nature11003
Bayraktar, E. C., La, K., Karpman, K., Unlu, G., Ozerdem, C., Ritter, D. J., Alwaseem, H.,
Molina, H., Hoffmann, H.-H., Millner, A., Atilla-Gokcumen, G. E., Gamazon, E. R.,
Rushing, A. R., Knapik, E. W., Basu, S., & Birsoy, K. (2020). Metabolic coessentiality
mapping identifies C12orf49 as a regulator of SREBP processing and cholesterol
metabolism. Nature Metabolism, 2(6), 487-498. doi:10.1038/s42255-020-0206-9
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao,
Y., Sassi, F., Pinnelli, M., Ansari, R., Harper, S., Jackson, D. A., McRae, R., Pooley, R.,
Wilkinson, P., van der Meer, D., Dow, D., Buser-Doepner, C., Bertotti, A., Trusolino,
L., Stronach, E. A., Saez-Rodriguez, J., Yusa, K., & Garnett, M. J. (2019). Prioritization
of cancer therapeutic targets using CRISPR-Cas9 screens. Nature, 568(7753), 511516. doi:10.1038/s41586-019-1103-9
Beltrao, P., Cagney, G., & Krogan, N. J. (2010). Quantitative genetic interactions reveal
biological modularity. Cell, 141(5), 739-745. doi:10.1016/j.cell.2010.05.019

115
Benaglia, T., Chauveau, D., Hunter, D., & Young, D. (2009). mixtools: An R Package for
Analyzing Finite Mixture Models. Journal of Statistical Software, 32.
doi:10.18637/jss.v032.i06
Bendavit, G., Aboulkassim, T., Hilmi, K., Shah, S., & Batist, G. (2016). Nrf2 Transcription
Factor Can Directly Regulate mTOR: LINKING CYTOPROTECTIVE GENE EXPRESSION
TO A MAJOR METABOLIC REGULATOR THAT GENERATES REDOX ACTIVITY. J Biol
Chem, 291(49), 25476-25488. doi:10.1074/jbc.M116.760249
Bi, J., Huang, A., Liu, T., Zhang, T., & Ma, H. (2015). Expression of DNA damage checkpoint
53BP1 is correlated with prognosis, cell proliferation and apoptosis in colorectal
cancer. Int J Clin Exp Pathol, 8(6), 6070-6082. Retrieved from
https://www.ncbi.nlm.nih.gov/pubmed/26261485
Bodapati, S., Daley, T. P., Lin, X., Zou, J., & Qi, L. S. (2020). A benchmark of algorithms for the
analysis of pooled CRISPR screens. Genome Biol, 21(1), 62. doi:10.1186/s13059-02001972-x
Boyle, E. A., Pritchard, J. K., & Greenleaf, W. J. (2018). High-resolution mapping of cancer
cell networks using co-functional interactions. Molecular Systems Biology, 14(12),
e8594. doi:10.15252/msb.20188594
Broad, D. (2018). DepMap Achilles 18Q4 public.
Brown, K. R., Mair, B., Soste, M., & Moffat, J. (2019). CRISPR screens are feasible in TP53
wild-type cells. Molecular Systems Biology, 15(8), e8679.
doi:10.15252/msb.20188679

116
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth,
M., Curtin, N. J., & Helleday, T. (2005). Specific killing of BRCA2-deficient tumours
with inhibitors of poly(ADP-ribose) polymerase. Nature, 434(7035), 913-917.
doi:10.1038/nature03443
Campbell, T. M., Castro, M. A., Ponder, B. A., & Meyer, K. B. (2016). Identification of PostTranscriptional Modulators of Breast Cancer Transcription Factor Activity Using
MINDy. PLoS One, 11(12), e0168770. doi:10.1371/journal.pone.0168770
Cancer, D. S. (2018). Broad Institute Cancer Dependency Map, CRISPR Avana dataset 18Q1
(Avana_public_18Q1).
Cancer Genome Atlas Research, N., Ley, T. J., Miller, C., Ding, L., Raphael, B. J., Mungall, A. J.,
Robertson, A., Hoadley, K., Triche, T. J., Jr., Laird, P. W., Baty, J. D., Fulton, L. L.,
Fulton, R., Heath, S. E., Kalicki-Veizer, J., Kandoth, C., Klco, J. M., Koboldt, D. C.,
Kanchi, K. L., Kulkarni, S., Lamprecht, T. L., Larson, D. E., Lin, L., Lu, C., McLellan, M.
D., McMichael, J. F., Payton, J., Schmidt, H., Spencer, D. H., Tomasson, M. H., Wallis,
J. W., Wartman, L. D., Watson, M. A., Welch, J., Wendl, M. C., Ally, A., Balasundaram,
M., Birol, I., Butterfield, Y., Chiu, R., Chu, A., Chuah, E., Chun, H. J., Corbett, R.,
Dhalla, N., Guin, R., He, A., Hirst, C., Hirst, M., Holt, R. A., Jones, S., Karsan, A., Lee,
D., Li, H. I., Marra, M. A., Mayo, M., Moore, R. A., Mungall, K., Parker, J., Pleasance,
E., Plettner, P., Schein, J., Stoll, D., Swanson, L., Tam, A., Thiessen, N., Varhol, R.,
Wye, N., Zhao, Y., Gabriel, S., Getz, G., Sougnez, C., Zou, L., Leiserson, M. D., Vandin,
F., Wu, H. T., Applebaum, F., Baylin, S. B., Akbani, R., Broom, B. M., Chen, K., Motter,
T. C., Nguyen, K., Weinstein, J. N., Zhang, N., Ferguson, M. L., Adams, C., Black, A.,

117
Bowen, J., Gastier-Foster, J., Grossman, T., Lichtenberg, T., Wise, L., Davidsen, T.,
Demchok, J. A., Shaw, K. R., Sheth, M., Sofia, H. J., Yang, L., Downing, J. R., & Eley, G.
(2013). Genomic and epigenomic landscapes of adult de novo acute myeloid
leukemia. N Engl J Med, 368(22), 2059-2074. doi:10.1056/NEJMoa1301689
Carlson, M. (2018). org.Hs.eg.db: Genome wide annotation for Human.
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne,
C. J., Heuer, M. L., Larsson, E., Antipin, Y., Reva, B., Goldberg, A. P., Sander, C., &
Schultz, N. (2012). The cBio Cancer Genomics Portal: An Open Platform for Exploring
Multidimensional Cancer Genomics Data. Cancer Discovery, 2(5), 401-404.
doi:10.1158/2159-8290.CD-12-0095
Chen, J., Wang, X., Hu, B., He, Y., Qian, X., & Wang, W. (2018). Candidate genes in gastric
cancer identified by constructing a weighted gene co-expression network. PeerJ, 6,
e4692. doi:10.7717/peerj.4692
Chen, R., Xie, R., Meng, Z., Ma, S., & Guan, K. L. (2019). STRIPAK integrates upstream signals
to initiate the Hippo kinase cascade. Nat Cell Biol, 21(12), 1565-1577.
doi:10.1038/s41556-019-0426-y
Cianfanelli, V., Fuoco, C., Lorente, M., Salazar, M., Quondamatteo, F., Gherardini, P. F., De
Zio, D., Nazio, F., Antonioli, M., D'Orazio, M., Skobo, T., Bordi, M., Rohde, M., Dalla
Valle, L., Helmer-Citterich, M., Gretzmeier, C., Dengjel, J., Fimia, G. M., Piacentini,
M., Di Bartolomeo, S., Velasco, G., & Cecconi, F. (2015). AMBRA1 links autophagy to
cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and
degradation. Nat Cell Biol, 17(1), 20-30. doi:10.1038/ncb3072

118
Clarke, E., & Sherrill-Mix, S. (2017). ggbeeswarm: Categorical Scatter (Violin Point) Plots
(Version 0.6.0).
Colic, M., Wang, G., Zimmermann, M., Mascall, K., McLaughlin, M., Bertolet, L., Lenoir, W.
F., Moffat, J., Angers, S., Durocher, D., & Hart, T. (2019). Identifying chemogenetic
interactions from CRISPR screens with drugZ. Genome Medicine, 11(1), 52.
doi:10.1186/s13073-019-0665-3
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W.,
Marraffini, L. A., & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas
systems. Science (New York, N.Y.), 339(6121), 819-823. doi:10.1126/science.1231143
Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J.
L. Y., Toufighi, K., Mostafavi, S., Prinz, J., St Onge, R. P., VanderSluis, B., Makhnevych,
T., Vizeacoumar, F. J., Alizadeh, S., Bahr, S., Brost, R. L., Chen, Y., Cokol, M.,
Deshpande, R., Li, Z., Lin, Z.-Y., Liang, W., Marback, M., Paw, J., San Luis, B.-J.,
Shuteriqi, E., Tong, A. H. Y., van Dyk, N., Wallace, I. M., Whitney, J. A., Weirauch, M.
T., Zhong, G., Zhu, H., Houry, W. A., Brudno, M., Ragibizadeh, S., Papp, B., Pál, C.,
Roth, F. P., Giaever, G., Nislow, C., Troyanskaya, O. G., Bussey, H., Bader, G. D.,
Gingras, A.-C., Morris, Q. D., Kim, P. M., Kaiser, C. A., Myers, C. L., Andrews, B. J., &
Boone, C. (2010). The genetic landscape of a cell. Science (New York, N.Y.),
327(5964), 425-431. doi:10.1126/science.1180823
Costanzo, M., VanderSluis, B., Koch, E. N., Baryshnikova, A., Pons, C., Tan, G., Wang, W.,
Usaj, M., Hanchard, J., Lee, S. D., Pelechano, V., Styles, E. B., Billmann, M., van
Leeuwen, J., van Dyk, N., Lin, Z.-Y., Kuzmin, E., Nelson, J., Piotrowski, J. S., Srikumar,

119
T., Bahr, S., Chen, Y., Deshpande, R., Kurat, C. F., Li, S. C., Li, Z., Usaj, M. M., Okada,
H., Pascoe, N., San Luis, B.-J., Sharifpoor, S., Shuteriqi, E., Simpkins, S. W., Snider, J.,
Suresh, H. G., Tan, Y., Zhu, H., Malod-Dognin, N., Janjic, V., Przulj, N., Troyanskaya, O.
G., Stagljar, I., Xia, T., Ohya, Y., Gingras, A.-C., Raught, B., Boutros, M., Steinmetz, L.
M., Moore, C. L., Rosebrock, A. P., Caudy, A. A., Myers, C. L., Andrews, B., & Boone,
C. (2016). A global genetic interaction network maps a wiring diagram of cellular
function. Science (New York, N.Y.), 353(6306). doi:10.1126/science.aaf1420
Couzens, A. L., Knight, J. D., Kean, M. J., Teo, G., Weiss, A., Dunham, W. H., Lin, Z. Y.,
Bagshaw, R. D., Sicheri, F., Pawson, T., Wrana, J. L., Choi, H., & Gingras, A. C. (2013).
Protein interaction network of the mammalian Hippo pathway reveals mechanisms
of kinase-phosphatase interactions. Sci Signal, 6(302), rs15.
doi:10.1126/scisignal.2004712
Dede, M., McLaughlin, M., Kim, E., & Hart, T. (2020). Multiplex enCas12a screens detect
functional buffering among paralogs otherwise masked in monogenic Cas9 knockout
screens. Genome Biology, 21(1), 262. doi:10.1186/s13059-020-02173-2
Dempster, J. M., Pacini, C., Pantel, S., Behan, F. M., Green, T., Krill-Burger, J., Beaver, C. M.,
Younger, S. T., Zhivich, V., Najgebauer, H., Allen, F., Gonçalves, E., Shepherd, R.,
Doench, J. G., Yusa, K., Vazquez, F., Parts, L., Boehm, J. S., Golub, T. R., Hahn, W. C.,
Root, D. E., Garnett, M. J., Tsherniak, A., & Iorio, F. (2019). Agreement between two
large pan-cancer CRISPR-Cas9 gene dependency data sets. Nature Communications,
10(1), 5817. doi:10.1038/s41467-019-13805-y

120
Dempster, J. M., Rossen, J., Kazachkova, M., Pan, J., Kugener, G., Root, D. E., & Tsherniak, A.
(2019). Extracting Biological Insights from the Project Achilles Genome-Scale CRISPR
Screens in Cancer Cell Lines. bioRxiv, 720243. doi:10.1101/720243
DepMap, B. (2019). DepMap 19Q2 Public. In.
DeWeirdt, P. C., Sanson, K. R., Sangree, A. K., Hegde, M., Hanna, R. E., Feeley, M. N., Griffith,
A. L., Teng, T., Borys, S. M., Strand, C., Joung, J. K., Kleinstiver, B. P., Pan, X., Huang,
A., & Doench, J. G. (2020). Optimization of AsCas12a for combinatorial genetic
screens in human cells. Nature Biotechnology, 1-11. doi:10.1038/s41587-020-0600-6
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I.,
Tothova, Z., Wilen, C., Orchard, R., Virgin, H. W., Listgarten, J., & Root, D. E. (2016).
Optimized sgRNA design to maximize activity and minimize off-target effects of
CRISPR-Cas9. Nature Biotechnology, 34(2), 184-191. doi:10.1038/nbt.3437
Donehower, L. A., Soussi, T., Korkut, A., Liu, Y., Schultz, A., Cardenas, M., Li, X., Babur, O.,
Hsu, T.-K., Lichtarge, O., Weinstein, J. N., Akbani, R., & Wheeler, D. A. (2019).
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome
Atlas. Cell Reports, 28(5), 1370-1384.e1375. doi:10.1016/j.celrep.2019.07.001
Doudna, J. A., & Charpentier, E. (2014). Genome editing. The new frontier of genome
engineering with CRISPR-Cas9. Science, 346(6213), 1258096.
doi:10.1126/science.1258096
Druker, H., Zelley, K., McGee, R. B., Scollon, S. R., Kohlmann, W. K., Schneider, K. A., & Wolfe
Schneider, K. (2017). Genetic Counselor Recommendations for Cancer Predisposition

121
Evaluation and Surveillance in the Pediatric Oncology Patient. Clin Cancer Res,
23(13), e91-e97. doi:10.1158/1078-0432.CCR-17-0834
Du, D., Roguev, A., Gordon, D. E., Chen, M., Chen, S.-H., Shales, M., Shen, J. P., Ideker, T.,
Mali, P., Qi, L. S., & Krogan, N. J. (2017). Genetic interaction mapping in mammalian
cells using CRISPR interference. Nature Methods, 14(6), 577-580.
doi:10.1038/nmeth.4286
Durinck, S., Moreau, Y., Kasprzyk, A., Davis, S., De Moor, B., Brazma, A., & Huber, W. (2005).
BioMart and Bioconductor: a powerful link between biological databases and
microarray data analysis. Bioinformatics (Oxford, England), 21(16), 3439-3440.
doi:10.1093/bioinformatics/bti525
Durinck, S., Spellman, P. T., Birney, E., & Huber, W. (2009). Mapping identifiers for the
integration of genomic datasets with the R/Bioconductor package biomaRt. Nature
Protocols, 4(8), 1184-1191. doi:10.1038/nprot.2009.97
Echeverri, C. J., Beachy, P. A., Baum, B., Boutros, M., Buchholz, F., Chanda, S. K., Downward,
J., Ellenberg, J., Fraser, A. G., Hacohen, N., Hahn, W. C., Jackson, A. L., Kiger, A.,
Linsley, P. S., Lum, L., Ma, Y., Mathey-Prevot, B., Root, D. E., Sabatini, D. M., Taipale,
J., Perrimon, N., & Bernards, R. (2006). Minimizing the risk of reporting false
positives in large-scale RNAi screens. Nat Methods, 3(10), 777-779.
doi:10.1038/nmeth1006-777
Echeverri, C. J., & Perrimon, N. (2006). High-throughput RNAi screening in cultured cells: a
user's guide. Nat Rev Genet, 7(5), 373-384. doi:10.1038/nrg1836

122
Evan, G. I., & Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature,
411(6835), 342-348. doi:10.1038/35077213
Evers, B., Jastrzebski, K., Heijmans, J. P., Grernrum, W., Beijersbergen, R. L., & Bernards, R.
(2016). CRISPR knockout screening outperforms shRNA and CRISPRi in identifying
essential genes. Nat Biotechnol, 34(6), 631-633. doi:10.1038/nbt.3536
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., Santarosa,
M., Dillon, K. J., Hickson, I., Knights, C., Martin, N. M., Jackson, S. P., Smith, G. C., &
Ashworth, A. (2005). Targeting the DNA repair defect in BRCA mutant cells as a
therapeutic strategy. Nature, 434(7035), 917-921. doi:10.1038/nature03445
Flavin, R., Peluso, S., Nguyen, P. L., & Loda, M. (2010). Fatty acid synthase as a potential
therapeutic target in cancer. Future Oncology, 6(4), 551-562. doi:10.2217/fon.10.11
Foundation, P. S. Python Language Reference, version 3.8.2.
Frank, E. G., Tissier, A., McDonald, J. P., Rapic-Otrin, V., Zeng, X., Gearhart, P. J., &
Woodgate, R. (2001). Altered nucleotide misinsertion fidelity associated with
poliota-dependent replication at the end of a DNA template. EMBO J, 20(11), 29142922. doi:10.1093/emboj/20.11.2914
Frankish, A., Diekhans, M., Ferreira, A.-M., Johnson, R., Jungreis, I., Loveland, J., Mudge, J.
M., Sisu, C., Wright, J., Armstrong, J., Barnes, I., Berry, A., Bignell, A., Carbonell Sala,
S., Chrast, J., Cunningham, F., Di Domenico, T., Donaldson, S., Fiddes, I. T., García
Girón, C., Gonzalez, J. M., Grego, T., Hardy, M., Hourlier, T., Hunt, T., Izuogu, O. G.,
Lagarde, J., Martin, F. J., Martínez, L., Mohanan, S., Muir, P., Navarro, F. C. P., Parker,
A., Pei, B., Pozo, F., Ruffier, M., Schmitt, B. M., Stapleton, E., Suner, M.-M., Sycheva,

123
I., Uszczynska-Ratajczak, B., Xu, J., Yates, A., Zerbino, D., Zhang, Y., Aken, B.,
Choudhary, J. S., Gerstein, M., Guigó, R., Hubbard, T. J. P., Kellis, M., Paten, B.,
Reymond, A., Tress, M. L., & Flicek, P. (2019). GENCODE reference annotation for the
human and mouse genomes. Nucleic Acids Research, 47(D1), D766-D773.
doi:10.1093/nar/gky955
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., &
Stratton, M. R. (2004). A census of human cancer genes. Nat Rev Cancer, 4(3), 177183. doi:10.1038/nrc1299
Gallego-García, A., Monera-Girona, A. J., Pajares-Martínez, E., Bastida-Martínez, E., PérezCastaño, R., Iniesta, A. A., Fontes, M., Padmanabhan, S., & Elías-Arnanz, M. (2019). A
bacterial light response reveals an orphan desaturase for human plasmalogen
synthesis. Science (New York, N.Y.), 366(6461), 128-132.
doi:10.1126/science.aay1436
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen,
A., Sinha, R., Larsson, E., Cerami, E., Sander, C., & Schultz, N. (2013). Integrative
analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Science Signaling, 6(269), pl1. doi:10.1126/scisignal.2004088
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. (2013).
New England Journal of Medicine, 368(22), 2059-2074.
doi:10.1056/NEJMoa1301689
Gentleman, R. (2019). annotate: Annotation for microarrays.

124
German Collection of Microorganisms and Cell Cultures GmbH: Welcome to the Leibniz
Institute DSMZ.
Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R.,
Barretina, J., Gelfand, E. T., Bielski, C. M., Li, H., Hu, K., Andreev-Drakhlin, A. Y., Kim,
J., Hess, J. M., Haas, B. J., Aguet, F., Weir, B. A., Rothberg, M. V., Paolella, B. R.,
Lawrence, M. S., Akbani, R., Lu, Y., Tiv, H. L., Gokhale, P. C., de Weck, A., Mansour, A.
A., Oh, C., Shih, J., Hadi, K., Rosen, Y., Bistline, J., Venkatesan, K., Reddy, A., Sonkin,
D., Liu, M., Lehar, J., Korn, J. M., Porter, D. A., Jones, M. D., Golji, J., Caponigro, G.,
Taylor, J. E., Dunning, C. M., Creech, A. L., Warren, A. C., McFarland, J. M.,
Zamanighomi, M., Kauffmann, A., Stransky, N., Imielinski, M., Maruvka, Y. E.,
Cherniack, A. D., Tsherniak, A., Vazquez, F., Jaffe, J. D., Lane, A. A., Weinstock, D. M.,
Johannessen, C. M., Morrissey, M. P., Stegmeier, F., Schlegel, R., Hahn, W. C., Getz,
G., Mills, G. B., Boehm, J. S., Golub, T. R., Garraway, L. A., & Sellers, W. R. (2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature,
569(7757), 503-508. doi:10.1038/s41586-019-1186-3
Gilbert, L. A., Horlbeck, M. A., Adamson, B., Villalta, J. E., Chen, Y., Whitehead, E. H.,
Guimaraes, C., Panning, B., Ploegh, H. L., Bassik, M. C., Qi, L. S., Kampmann, M., &
Weissman, J. S. (2014). Genome-Scale CRISPR-Mediated Control of Gene Repression
and Activation. Cell, 159(3), 647-661. doi:10.1016/j.cell.2014.09.029
Goldman, M. J., Craft, B., Hastie, M., Repečka, K., McDade, F., Kamath, A., Banerjee, A., Luo,
Y., Rogers, D., Brooks, A. N., Zhu, J., & Haussler, D. (2020). Visualizing and

125
interpreting cancer genomics data via the Xena platform. Nature Biotechnology,
38(6), 675-678. doi:10.1038/s41587-020-0546-8
Grau, J., Grosse, I., & Keilwagen, J. (2015). PRROC: computing and visualizing precision-recall
and receiver operating characteristic curves in R. Bioinformatics, 31(15), 2595-2597.
doi:10.1093/bioinformatics/btv153
Grolemund, H. W. G. (2016). R for Data Science(pp. 1 online resource). Retrieved from
http://proquest.safaribooksonline.com/9781491910382
Grun, D., Adhikary, G., & Eckert, R. L. (2018). NRP-1 interacts with GIPC1 and alpha6/beta4integrins to increase YAP1/Np63alpha-dependent epidermal cancer stem cell
survival. Oncogene, 37(34), 4711-4722. doi:10.1038/s41388-018-0290-4
Gu, Z., Eils, R., & Schlesner, M. (2016). Complex heatmaps reveal patterns and correlations
in multidimensional genomic data. Bioinformatics (Oxford, England), 32(18), 28472849. doi:10.1093/bioinformatics/btw313
Gu, Z., Gu, L., Eils, R., Schlesner, M., & Brors, B. (2014). circlize Implements and enhances
circular visualization in R. Bioinformatics (Oxford, England), 30(19), 2811-2812.
doi:10.1093/bioinformatics/btu393
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell,
144(5), 646-674. doi:10.1016/j.cell.2011.02.013
Harris, C. R., Millman, K. J., van der Walt, S. J., Gommers, R., Virtanen, P., Cournapeau, D.,
Wieser, E., Taylor, J., Berg, S., Smith, N. J., Kern, R., Picus, M., Hoyer, S., van Kerkwijk,
M. H., Brett, M., Haldane, A., del Río, J. F., Wiebe, M., Peterson, P., GérardMarchant, P., Sheppard, K., Reddy, T., Weckesser, W., Abbasi, H., Gohlke, C., &

126
Oliphant, T. E. (2020). Array programming with NumPy. Nature, 585(7825), 357-362.
doi:10.1038/s41586-020-2649-2
Hart, T., Brown, K. R., Sircoulomb, F., Rottapel, R., & Moffat, J. (2014). Measuring error rates
in genomic perturbation screens: gold standards for human functional genomics.
Molecular Systems Biology, 10(7), 733. doi:10.15252/msb.20145216
Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., Mis, M.,
Zimmermann, M., Fradet-Turcotte, A., Sun, S., Mero, P., Dirks, P., Sidhu, S., Roth, F.
P., Rissland, O. S., Durocher, D., Angers, S., & Moffat, J. (2015). High-Resolution
CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell,
163(6), 1515-1526. doi:10.1016/j.cell.2015.11.015
Hart, T., Koh, C., & Moffat, J. (2017). Coessentiality And Cofunctionality: A Network
Approach To Learning Genetic Vulnerabilities From Cancer Cell Line Fitness Screens.
bioRxiv.
Hart, T., & Moffat, J. (2016). BAGEL: a computational framework for identifying essential
genes from pooled library screens. BMC Bioinformatics, 17(1), 164.
doi:10.1186/s12859-016-1015-8
Hart, T., Tong, A. H. Y., Chan, K., Van Leeuwen, J., Seetharaman, A., Aregger, M.,
Chandrashekhar, M., Hustedt, N., Seth, S., Noonan, A., Habsid, A., Sizova, O.,
Nedyalkova, L., Climie, R., Tworzyanski, L., Lawson, K., Sartori, M. A., Alibeh, S., Tieu,
D., Masud, S., Mero, P., Weiss, A., Brown, K. R., Usaj, M., Billmann, M., Rahman, M.,
Constanzo, M., Myers, C. L., Andrews, B. J., Boone, C., Durocher, D., & Moffat, J.

127
(2017). Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens.
G3 (Bethesda, Md.), 7(8), 2719-2727. doi:10.1534/g3.117.041277
Hartwell, L. H., Hopfield, J. J., Leibler, S., & Murray, A. W. (1999). From molecular to modular
cell biology. Nature, 402(6761 Suppl), C47-52. doi:10.1038/35011540
Henkel, L., Rauscher, B., & Boutros, M. (2019). Context-dependent genetic interactions in
cancer. Curr Opin Genet Dev, 54, 73-82. doi:10.1016/j.gde.2019.03.004
Hilton, I. B., D'Ippolito, A. M., Vockley, C. M., Thakore, P. I., Crawford, G. E., Reddy, T. E., &
Gersbach, C. A. (2015). Epigenome editing by a CRISPR-Cas9-based acetyltransferase
activates genes from promoters and enhancers. Nat Biotechnol, 33(5), 510-517.
doi:10.1038/nbt.3199
Horlbeck, M. A., Xu, A., Wang, M., Bennett, N. K., Park, C. Y., Bogdanoff, D., Adamson, B.,
Chow, E. D., Kampmann, M., Peterson, T. R., Nakamura, K., Fischbach, M. A.,
Weissman, J. S., & Gilbert, L. A. (2018). Mapping the Genetic Landscape of Human
Cells. Cell, 174(4), 953-967.e922. doi:10.1016/j.cell.2018.06.010
Huang, J., Dibble, C. C., Matsuzaki, M., & Manning, B. D. (2008). The TSC1-TSC2 complex is
required for proper activation of mTOR complex 2. Molecular and Cellular Biology,
28(12), 4104-4115. doi:10.1128/MCB.00289-08
Huang, J. Z., Chen, M., Zeng, M., Xu, S. H., Zou, F. Y., Chen, D., & Yan, G. R. (2016). Downregulation of TRPS1 stimulates epithelial-mesenchymal transition and metastasis
through repression of FOXA1. J Pathol, 239(2), 186-196. doi:10.1002/path.4716

128
Huang, Y., Leung, J. W., Lowery, M., Matsushita, N., Wang, Y., Shen, X., Huong, D., Takata,
M., Chen, J., & Li, L. (2014). Modularized functions of the Fanconi anemia core
complex. Cell Rep, 7(6), 1849-1857. doi:10.1016/j.celrep.2014.04.029
Hunter, J. D. (2007). Matplotlib: A 2D Graphics Environment. Computing in Science
Engineering, 9(3), 90-95. doi:10.1109/MCSE.2007.55
Hwang, S., Kim, C. Y., Yang, S., Kim, E., Hart, T., Marcotte, E. M., & Lee, I. (2019). HumanNet
v2: human gene networks for disease research. Nucleic Acids Research, 47(D1),
D573-D580. doi:10.1093/nar/gky1126
Ideker, T., Galitski, T., & Hood, L. (2001). A new approach to decoding life: systems biology.
Annu Rev Genomics Hum Genet, 2, 343-372. doi:10.1146/annurev.genom.2.1.343
Iorio, F., Behan, F. M., Gonçalves, E., Bhosle, S. G., Chen, E., Shepherd, R., Beaver, C., Ansari,
R., Pooley, R., Wilkinson, P., Harper, S., Butler, A. P., Stronach, E. A., Saez-Rodriguez,
J., Yusa, K., & Garnett, M. J. (2018). Unsupervised correction of gene-independent
cell responses to CRISPR-Cas9 targeting. BMC Genomics, 19(1), 604.
doi:10.1186/s12864-018-4989-y
Jain, I. H., Calvo, S. E., Markhard, A. L., Skinner, O. S., To, T. L., Ast, T., & Mootha, V. K.
(2020). Genetic Screen for Cell Fitness in High or Low Oxygen Highlights
Mitochondrial and Lipid Metabolism. Cell, 181(3), 716-727 e711.
doi:10.1016/j.cell.2020.03.029
James, M. F., Han, S., Polizzano, C., Plotkin, S. R., Manning, B. D., Stemmer-Rachamimov, A.
O., Gusella, J. F., & Ramesh, V. (2009). NF2/merlin is a novel negative regulator of
mTOR complex 1, and activation of mTORC1 is associated with meningioma and

129
schwannoma growth. Molecular and Cellular Biology, 29(15), 4250-4261.
doi:10.1128/MCB.01581-08
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A
Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial
Immunity. Science, 337(6096), 816-821. doi:10.1126/science.1225829
Kaelin, W. G., Jr. (2012). Molecular biology. Use and abuse of RNAi to study mammalian
gene function. Science, 337(6093), 421-422. doi:10.1126/science.1225787
Kassambara, A. (2020). ggpubr: 'ggplot2' Based Publication Ready Plots. Retrieved from
https://CRAN.R-project.org/package=ggpubr
Kassambara, A., Kosinski, M., Biecek, P., & Fabian, S. (2020). survminer: Drawing Survival
Curves using 'ggplot2' (Version 0.4.8).
Kegel, B. D., & Ryan, C. J. (2019). Paralog buffering contributes to the variable essentiality of
genes in cancer cell lines. PLOS Genetics, 15(10), e1008466.
doi:10.1371/journal.pgen.1008466
Keilwagen, J., Grosse, I., & Grau, J. (2014). Area under Precision-Recall Curves for Weighted
and Unweighted Data. PLoS One, 9(3), e92209. doi:10.1371/journal.pone.0092209
Khalid, A., Siddiqui, A. J., Huang, J.-H., Shamsi, T., & Musharraf, S. G. (2018). Alteration of
Serum Free Fatty Acids are Indicators for Progression of Pre-leukaemia Diseases to
Leukaemia. Scientific Reports, 8(1), 14883. doi:10.1038/s41598-018-33224-1
Kim, E., Dede, M., Lenoir, W. F., Wang, G., Srinivasan, S., Colic, M., & Hart, T. (2019). A
network of human functional gene interactions from knockout fitness screens in
cancer cells. Life Science Alliance, 2(2). doi:10.26508/lsa.201800278

130
Kim, E., & Hart, T. (2020). Improved analysis of CRISPR fitness screens and reduced offtarget effects with the BAGEL2 gene essentiality classifier. bioRxiv,
2020.2005.2030.125526. doi:10.1101/2020.05.30.125526
Kim, H. K., Song, M., Lee, J., Menon, A. V., Jung, S., Kang, Y.-M., Choi, J. W., Woo, E., Koh, H.
C., Nam, J.-W., & Kim, H. (2017). In vivo high-throughput profiling of CRISPR–Cpf1
activity. Nature Methods, 14(2), 153-159. doi:10.1038/nmeth.4104
Kleinstiver, B. P., Sousa, A. A., Walton, R. T., Tak, Y. E., Hsu, J. Y., Clement, K., Welch, M. M.,
Horng, J. E., Malagon-Lopez, J., Scarfò, I., Maus, M. V., Pinello, L., Aryee, M. J., &
Joung, J. K. (2019). Engineered CRISPR-Cas12a variants with increased activities and
improved targeting ranges for gene, epigenetic and base editing. Nature
Biotechnology, 37(3), 276-282. doi:10.1038/s41587-018-0011-0
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016). Programmable editing
of a target base in genomic DNA without double-stranded DNA cleavage. Nature,
533(7603), 420-424. doi:10.1038/nature17946
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu,
P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., Nureki, O., & Zhang, F. (2015).
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.
Nature, 517(7536), 583-588. doi:10.1038/nature14136
Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K.,
Dewar, K., Doyle, M., FitzHugh, W., Funke, R., Gage, D., Harris, K., Heaford, A.,
Howland, J., Kann, L., Lehoczky, J., LeVine, R., McEwan, P., McKernan, K., Meldrim, J.,
Mesirov, J. P., Miranda, C., Morris, W., Naylor, J., Raymond, C., Rosetti, M., Santos,

131
R., Sheridan, A., Sougnez, C., Stange-Thomann, Y., Stojanovic, N., Subramanian, A.,
Wyman, D., Rogers, J., Sulston, J., Ainscough, R., Beck, S., Bentley, D., Burton, J.,
Clee, C., Carter, N., Coulson, A., Deadman, R., Deloukas, P., Dunham, A., Dunham, I.,
Durbin, R., French, L., Grafham, D., Gregory, S., Hubbard, T., Humphray, S., Hunt, A.,
Jones, M., Lloyd, C., McMurray, A., Matthews, L., Mercer, S., Milne, S., Mullikin, J. C.,
Mungall, A., Plumb, R., Ross, M., Shownkeen, R., Sims, S., Waterston, R. H., Wilson,
R. K., Hillier, L. W., McPherson, J. D., Marra, M. A., Mardis, E. R., Fulton, L. A.,
Chinwalla, A. T., Pepin, K. H., Gish, W. R., Chissoe, S. L., Wendl, M. C., Delehaunty, K.
D., Miner, T. L., Delehaunty, A., Kramer, J. B., Cook, L. L., Fulton, R. S., Johnson, D. L.,
Minx, P. J., Clifton, S. W., Hawkins, T., Branscomb, E., Predki, P., Richardson, P.,
Wenning, S., Slezak, T., Doggett, N., Cheng, J. F., Olsen, A., Lucas, S., Elkin, C.,
Uberbacher, E., Frazier, M., Gibbs, R. A., Muzny, D. M., Scherer, S. E., Bouck, J. B.,
Sodergren, E. J., Worley, K. C., Rives, C. M., Gorrell, J. H., Metzker, M. L., Naylor, S. L.,
Kucherlapati, R. S., Nelson, D. L., Weinstock, G. M., Sakaki, Y., Fujiyama, A., Hattori,
M., Yada, T., Toyoda, A., Itoh, T., Kawagoe, C., Watanabe, H., Totoki, Y., Taylor, T.,
Weissenbach, J., Heilig, R., Saurin, W., Artiguenave, F., Brottier, P., Bruls, T., Pelletier,
E., Robert, C., Wincker, P., Smith, D. R., Doucette-Stamm, L., Rubenfield, M.,
Weinstock, K., Lee, H. M., Dubois, J., Rosenthal, A., Platzer, M., Nyakatura, G.,
Taudien, S., Rump, A., Yang, H., Yu, J., Wang, J., Huang, G., Gu, J., Hood, L., Rowen, L.,
Madan, A., Qin, S., Davis, R. W., Federspiel, N. A., Abola, A. P., Proctor, M. J., Myers,
R. M., Schmutz, J., Dickson, M., Grimwood, J., Cox, D. R., Olson, M. V., Kaul, R.,
Raymond, C., Shimizu, N., Kawasaki, K., Minoshima, S., Evans, G. A., Athanasiou, M.,

132
Schultz, R., Roe, B. A., Chen, F., Pan, H., Ramser, J., Lehrach, H., Reinhardt, R.,
McCombie, W. R., de la Bastide, M., Dedhia, N., Blocker, H., Hornischer, K., Nordsiek,
G., Agarwala, R., Aravind, L., Bailey, J. A., Bateman, A., Batzoglou, S., Birney, E., Bork,
P., Brown, D. G., Burge, C. B., Cerutti, L., Chen, H. C., Church, D., Clamp, M., Copley,
R. R., Doerks, T., Eddy, S. R., Eichler, E. E., Furey, T. S., Galagan, J., Gilbert, J. G.,
Harmon, C., Hayashizaki, Y., Haussler, D., Hermjakob, H., Hokamp, K., Jang, W.,
Johnson, L. S., Jones, T. A., Kasif, S., Kaspryzk, A., Kennedy, S., Kent, W. J., Kitts, P.,
Koonin, E. V., Korf, I., Kulp, D., Lancet, D., Lowe, T. M., McLysaght, A., Mikkelsen, T.,
Moran, J. V., Mulder, N., Pollara, V. J., Ponting, C. P., Schuler, G., Schultz, J., Slater,
G., Smit, A. F., Stupka, E., Szustakowki, J., Thierry-Mieg, D., Thierry-Mieg, J., Wagner,
L., Wallis, J., Wheeler, R., Williams, A., Wolf, Y. I., Wolfe, K. H., Yang, S. P., Yeh, R. F.,
Collins, F., Guyer, M. S., Peterson, J., Felsenfeld, A., Wetterstrand, K. A., Patrinos, A.,
Morgan, M. J., de Jong, P., Catanese, J. J., Osoegawa, K., Shizuya, H., Choi, S., Chen,
Y. J., Szustakowki, J., & International Human Genome Sequencing, C. (2001). Initial
sequencing and analysis of the human genome. Nature, 409(6822), 860-921.
doi:10.1038/35057062
Lee, J. Y., Park, Y. J., Oh, N., Kwack, K. B., & Park, K. S. (2017). A transcriptional complex
composed of ER(alpha), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast
cancer cells. Oncotarget, 8(26), 42752-42760. doi:10.18632/oncotarget.17459
Lenoir, W. F., Lim, T. L., & Hart, T. (2017). PICKLES: the database of pooled in-vitro CRISPR
knockout library essentiality screens. Nucleic Acids Res. doi:10.1093/nar/gkx993

133
Li, H., Ning, S., Ghandi, M., Kryukov, G. V., Gopal, S., Deik, A., Souza, A., Pierce, K., Keskula,
P., Hernandez, D., Ann, J., Shkoza, D., Apfel, V., Zou, Y., Vazquez, F., Barretina, J.,
Pagliarini, R. A., Galli, G. G., Root, D. E., Hahn, W. C., Tsherniak, A., Giannakis, M.,
Schreiber, S. L., Clish, C. B., Garraway, L. A., & Sellers, W. R. (2019). The landscape of
cancer cell line metabolism. Nature Medicine, 25(5), 850-860. doi:10.1038/s41591019-0404-8
Li, K.-C. (2002). Genome-wide coexpression dynamics: Theory and application. Proceedings
of the National Academy of Sciences of the United States of America, 99(26), 1687516880. doi:10.1073/pnas.252466999
Lin, A., Giuliano, C. J., Palladino, A., John, K. M., Abramowicz, C., Yuan, M. L., Sausville, E. L.,
Lukow, D. A., Liu, L., Chait, A. R., Galluzzo, Z. C., Tucker, C., & Sheltzer, J. M. (2019).
Off-target toxicity is a common mechanism of action of cancer drugs undergoing
clinical trials. Sci Transl Med, 11(509). doi:10.1126/scitranslmed.aaw8412
Liu, J., Srinivasan, S., Li, C.-Y., Ho, I.-L., Rose, J., Shaheen, M., Wang, G., Yao, W., Deem, A.,
Bristow, C., Hart, T., & Draetta, G. (2019). Pooled library screening with multiplexed
Cpf1 library. Nature Communications, 10(1), 3144. doi:10.1038/s41467-019-10963-x
Liu, S. J., Horlbeck, M. A., Cho, S. W., Birk, H. S., Malatesta, M., He, D., Attenello, F. J.,
Villalta, J. E., Cho, M. Y., Chen, Y., Mandegar, M. A., Olvera, M. P., Gilbert, L. A.,
Conklin, B. R., Chang, H. Y., Weissman, J. S., & Lim, D. A. (2017). CRISPRi-based
genome-scale identification of functional long noncoding RNA loci in human cells.
Science, 355(6320). doi:10.1126/science.aah7111

134
Liu, Y., Wu, M., Liu, C., Li, X., & Zheng, J. (2019). SL 2 MF: Predicting Synthetic Lethality in
Human Cancers via Logistic Matrix Factorization. IEEE/ACM Trans Comput Biol
Bioinform. doi:10.1109/TCBB.2019.2909908
Luna, A. (2018). cytoscape/r-cytoscape.js: r-cytoscape.js 0.0.7 (Version v0.0.7): Zenodo.
Retrieved from https://doi.org/10.5281/zenodo.1345344
Lundgren, S., Fagerstrom-Vahman, H., Zhang, C., Ben-Dror, L., Mardinoglu, A., Uhlen, M.,
Nodin, B., & Jirstrom, K. (2019). Discovery of KIRREL as a biomarker for prognostic
stratification of patients with thin melanoma. Biomark Res, 7, 1.
doi:10.1186/s40364-018-0153-8
Mali, P., Esvelt, K. M., & Church, G. M. (2013). Cas9 as a versatile tool for engineering
biology. Nature Methods, 10(10), 957-963. doi:10.1038/nmeth.2649
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G.
M. (2013). RNA-Guided Human Genome Engineering via Cas9. Science (New York,
N.Y.), 339(6121), 823-826. doi:10.1126/science.1232033
Mamluk, R., Gechtman, Z., Kutcher, M. E., Gasiunas, N., Gallagher, J., & Klagsbrun, M.
(2002). Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth
factor-2, and heparin via its b1b2 domain. J Biol Chem, 277(27), 24818-24825.
doi:10.1074/jbc.M200730200
Marchi, S., Corricelli, M., Trapani, E., Bravi, L., Pittaro, A., Delle Monache, S., Ferroni, L.,
Patergnani, S., Missiroli, S., Goitre, L., Trabalzini, L., Rimessi, A., Giorgi, C., Zavan, B.,
Cassoni, P., Dejana, E., Retta, S. F., & Pinton, P. (2015). Defective autophagy is a key

135
feature of cerebral cavernous malformations. EMBO molecular medicine, 7(11),
1403-1417. doi:10.15252/emmm.201505316
Marcotte, R., Brown, K. R., Suarez, F., Sayad, A., Karamboulas, K., Krzyzanowski, P. M.,
Sircoulomb, F., Medrano, M., Fedyshyn, Y., Koh, J. L. Y., van Dyk, D., Fedyshyn, B.,
Luhova, M., Brito, G. C., Vizeacoumar, F. J., Vizeacoumar, F. S., Datti, A., Kasimer, D.,
Buzina, A., Mero, P., Misquitta, C., Normand, J., Haider, M., Ketela, T., Wrana, J. L.,
Rottapel, R., Neel, B. G., & Moffat, J. (2012). Essential gene profiles in breast,
pancreatic, and ovarian cancer cells. Cancer Discov, 2(2), 172-189.
doi:10.1158/2159-8290.CD-11-0224
Marcotte, R., Sayad, A., Brown, K. R., Sanchez-Garcia, F., Reimand, J., Haider, M., Virtanen,
C., Bradner, J. E., Bader, G. D., Mills, G. B., Pe'er, D., Moffat, J., & Neel, B. G. (2016).
Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and
Resistance. Cell, 164(1-2), 293-309. doi:10.1016/j.cell.2015.11.062
Marquart, J., Chen, E. Y., & Prasad, V. (2018). Estimation of the Percentage of US Patients
With Cancer Who Benefit From Genome-Driven Oncology. JAMA Oncol, 4(8), 10931098. doi:10.1001/jamaoncol.2018.1660
Massagué, J. (2004). G1 cell-cycle control and cancer. Nature, 432(7015), 298-306.
doi:10.1038/nature03094
McDonald, E. R., 3rd, de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R.,
Belur, D., Castelletti, D., Frias, E., Gampa, K., Golji, J., Kao, I., Li, L., Megel, P., Perkins,
T. A., Ramadan, N., Ruddy, D. A., Silver, S. J., Sovath, S., Stump, M., Weber, O.,
Widmer, R., Yu, J., Yu, K., Yue, Y., Abramowski, D., Ackley, E., Barrett, R., Berger, J.,

136
Bernard, J. L., Billig, R., Brachmann, S. M., Buxton, F., Caothien, R., Caushi, J. X.,
Chung, F. S., Cortes-Cros, M., deBeaumont, R. S., Delaunay, C., Desplat, A., Duong,
W., Dwoske, D. A., Eldridge, R. S., Farsidjani, A., Feng, F., Feng, J., Flemming, D.,
Forrester, W., Galli, G. G., Gao, Z., Gauter, F., Gibaja, V., Haas, K., Hattenberger, M.,
Hood, T., Hurov, K. E., Jagani, Z., Jenal, M., Johnson, J. A., Jones, M. D., Kapoor, A.,
Korn, J., Liu, J., Liu, Q., Liu, S., Liu, Y., Loo, A. T., Macchi, K. J., Martin, T., McAllister,
G., Meyer, A., Molle, S., Pagliarini, R. A., Phadke, T., Repko, B., Schouwey, T.,
Shanahan, F., Shen, Q., Stamm, C., Stephan, C., Stucke, V. M., Tiedt, R., Varadarajan,
M., Venkatesan, K., Vitari, A. C., Wallroth, M., Weiler, J., Zhang, J., Mickanin, C.,
Myer, V. E., Porter, J. A., Lai, A., Bitter, H., Lees, E., Keen, N., Kauffmann, A.,
Stegmeier, F., Hofmann, F., Schmelzle, T., & Sellers, W. R. (2017). Project DRIVE: A
Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered
by Large-Scale, Deep RNAi Screening. Cell, 170(3), 577-592 e510.
doi:10.1016/j.cell.2017.07.005
McKinney, W. (2010). Data Structures for Statistical Computing in Python. Proceedings of
the 9th Python in Science Conference, 56-61. doi:10.25080/Majora-92bf1922-00a
McPherson, W. C. a. J. C. a. J. A. a. Y. X. a. J. shiny: Web Application Framework for R.
Retrieved from http://shiny.rstudio.com
Medrano, M., Communal, L., Brown, K. R., Iwanicki, M., Normand, J., Paterson, J.,
Sircoulomb, F., Krzyzanowski, P., Novak, M., Doodnauth, S. A., Saiz, F. S., Cullis, J., AlAwar, R., Neel, B. G., McPherson, J., Drapkin, R., Ailles, L., Mes-Massons, A. M., &
Rottapel, R. (2017). Interrogation of Functional Cell-Surface Markers Identifies

137
CD151 Dependency in High-Grade Serous Ovarian Cancer. Cell Rep, 18(10), 23432358. doi:10.1016/j.celrep.2017.02.028
Mehta, C. R., & Patel, N. R. (1983). A Network Algorithm for Performing Fisher's Exact Test
in r × c Contingency Tables. Journal of the American Statistical Association, 78(382),
427-434. doi:10.2307/2288652
Meitinger, F., Anzola, J. V., Kaulich, M., Richardson, A., Stender, J. D., Benner, C., Glass, C. K.,
Dowdy, S. F., Desai, A., Shiau, A. K., & Oegema, K. (2016). 53BP1 and USP28 mediate
p53 activation and G1 arrest after centrosome loss or extended mitotic duration. J
Cell Biol, 214(2), 155-166. doi:10.1083/jcb.201604081
Menche, J., Sharma, A., Kitsak, M., Ghiassian, S. D., Vidal, M., Loscalzo, J., & Barabasi, A. L.
(2015). Disease networks. Uncovering disease-disease relationships through the
incomplete interactome. Science, 347(6224), 1257601. doi:10.1126/science.1257601
Meng, Z., Moroishi, T., Mottier-Pavie, V., Plouffe, S. W., Hansen, C. G., Hong, A. W., Park, H.
W., Mo, J. S., Lu, W., Lu, S., Flores, F., Yu, F. X., Halder, G., & Guan, K. L. (2015).
MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo
pathway. Nat Commun, 6, 8357. doi:10.1038/ncomms9357
Meshinchi, S., & Arceci, R. TARGET: Acute Myeloid Leukemia (AML), dbGaP Study Accession:
phs000465.v19.p8.
Meyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H., Dharia, N.
V., Montgomery, P. G., Cowley, G. S., Pantel, S., Goodale, A., Lee, Y., Ali, L. D., Jiang,
G., Lubonja, R., Harrington, W. F., Strickland, M., Wu, T., Hawes, D. C., Zhivich, V. A.,
Wyatt, M. R., Kalani, Z., Chang, J. J., Okamoto, M., Stegmaier, K., Golub, T. R.,

138
Boehm, J. S., Vazquez, F., Root, D. E., Hahn, W. C., & Tsherniak, A. (2017).
Computational correction of copy number effect improves specificity of CRISPR-Cas9
essentiality screens in cancer cells. Nature Genetics, 49(12), 1779-1784.
doi:10.1038/ng.3984
Moffat, J., Grueneberg, D. A., Yang, X., Kim, S. Y., Kloepfer, A. M., Hinkle, G., Piqani, B.,
Eisenhaure, T. M., Luo, B., Grenier, J. K., Carpenter, A. E., Foo, S. Y., Stewart, S. A.,
Stockwell, B. R., Hacohen, N., Hahn, W. C., Lander, E. S., Sabatini, D. M., & Root, D. E.
(2006). A lentiviral RNAi library for human and mouse genes applied to an arrayed
viral high-content screen. Cell, 124(6), 1283-1298. doi:10.1016/j.cell.2006.01.040
Moffat, J., Reiling, J. H., & Sabatini, D. M. (2007). Off-target effects associated with long
dsRNAs in Drosophila RNAi screens. Trends Pharmacol Sci, 28(4), 149-151.
doi:10.1016/j.tips.2007.02.009
Mullen, T. D., Hannun, Y. A., & Obeid, L. M. (2012). Ceramide synthases at the centre of
sphingolipid metabolism and biology. The Biochemical journal, 441(3), 789-802.
doi:10.1042/BJ20111626
Neuwirth, E. (2014). RColorBrewer: ColorBrewer Palettes (Version 1.1-2).
Niraj, J., Farkkila, A., & D'Andrea, A. D. (2019). The Fanconi Anemia Pathway in Cancer. Annu
Rev Cancer Biol, 3, 457-478. doi:10.1146/annurev-cancerbio-030617-050422
Oughtred, R., Stark, C., Breitkreutz, B. J., Rust, J., Boucher, L., Chang, C., Kolas, N., O'Donnell,
L., Leung, G., McAdam, R., Zhang, F., Dolma, S., Willems, A., Coulombe-Huntington,
J., Chatr-Aryamontri, A., Dolinski, K., & Tyers, M. (2019). The BioGRID interaction

139
database: 2019 update. Nucleic Acids Res, 47(D1), D529-D541.
doi:10.1093/nar/gky1079
Pan, J., Meyers, R. M., Michel, B. C., Mashtalir, N., Sizemore, A. E., Wells, J. N., Cassel, S. H.,
Vazquez, F., Weir, B. A., Hahn, W. C., Marsh, J. A., Tsherniak, A., & Kadoch, C. (2018).
Interrogation of Mammalian Protein Complex Structure, Function, and Membership
Using Genome-Scale Fitness Screens. Cell Systems, 6(5), 555-568.e557.
doi:10.1016/j.cels.2018.04.011
Piccolis, M., Bond, L. M., Kampmann, M., Pulimeno, P., Chitraju, C., Jayson, C. B. K., Vaites, L.
P., Boland, S., Lai, Z. W., Gabriel, K. R., Elliott, S. D., Paulo, J. A., Harper, J. W.,
Weissman, J. S., Walther, T. C., & Farese, R. V. (2019). Probing the Global Cellular
Responses to Lipotoxicity Caused by Saturated Fatty Acids. Molecular Cell, 74(1), 3244.e38. doi:10.1016/j.molcel.2019.01.036
Pickering, A., Zhang, J., Panneerselvam, J., & Fei, P. (2013). Advances in the understanding
of the Fanconi anemia tumor suppressor pathway. Cancer Biol Ther, 14(12), 10891091. doi:10.4161/cbt.26380
Pópulo, H., Lopes, J. M., & Soares, P. (2012). The mTOR signalling pathway in human cancer.
International Journal of Molecular Sciences, 13(2), 1886-1918.
doi:10.3390/ijms13021886
Pujar, S., O'Leary, N. A., Farrell, C. M., Loveland, J. E., Mudge, J. M., Wallin, C., Girón, C. G.,
Diekhans, M., Barnes, I., Bennett, R., Berry, A. E., Cox, E., Davidson, C., Goldfarb, T.,
Gonzalez, J. M., Hunt, T., Jackson, J., Joardar, V., Kay, M. P., Kodali, V. K., Martin, F. J.,
McAndrews, M., McGarvey, K. M., Murphy, M., Rajput, B., Rangwala, S. H., Riddick,

140
L. D., Seal, R. L., Suner, M.-M., Webb, D., Zhu, S., Aken, B. L., Bruford, E. A., Bult, C. J.,
Frankish, A., Murphy, T., & Pruitt, K. D. (2018). Consensus coding sequence (CCDS)
database: a standardized set of human and mouse protein-coding regions supported
by expert curation. Nucleic Acids Research, 46(D1), D221-D228.
doi:10.1093/nar/gkx1031
Punekar, S., & Cho, D. C. (2019). Novel Therapeutics Affecting Metabolic Pathways.
American Society of Clinical Oncology Educational Book(39), e79-e87.
doi:10.1200/EDBK_238499
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A.
(2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control
of gene expression. Cell, 152(5), 1173-1183. doi:10.1016/j.cell.2013.02.022
Quinton, R. J., & Ganem, N. J. (2019). CRISPR-Mediated Approaches to Regulate YAP/TAZ
Levels. Methods Mol Biol, 1893, 203-214. doi:10.1007/978-1-4939-8910-2_16
Rauscher, B., Heigwer, F., Henkel, L., Hielscher, T., Voloshanenko, O., & Boutros, M. (2018).
Toward an integrated map of genetic interactions in cancer cells. Molecular Systems
Biology, 14(2), e7656. doi:10.15252/msb.20177656
Rawlings, J. S., Rosler, K. M., & Harrison, D. A. (2004). The JAK/STAT signaling pathway. J Cell
Sci, 117(Pt 8), 1281-1283. doi:10.1242/jcs.00963
Rengachari, S., Groiss, S., Devos, J. M., Caron, E., Grandvaux, N., & Panne, D. (2018).
Structural basis of STAT2 recognition by IRF9 reveals molecular insights into ISGF3
function. Proc Natl Acad Sci U S A, 115(4), E601-E609. doi:10.1073/pnas.1718426115
Ripley, W. N. V. a. B. D. (2002). Modern Applied Statistics with S (Fourth ed.): Springer.

141
Roguev, A., Bandyopadhyay, S., Zofall, M., Zhang, K., Fischer, T., Collins, S. R., Qu, H., Shales,
M., Park, H.-O., Hayles, J., Hoe, K.-L., Kim, D.-U., Ideker, T., Grewal, S. I., Weissman, J.
S., & Krogan, N. J. (2008). Conservation and rewiring of functional modules revealed
by an epistasis map in fission yeast. Science (New York, N.Y.), 322(5900), 405-410.
doi:10.1126/science.1162609
Ryan, C. J., Bajrami, I., & Lord, C. J. (2018). Synthetic Lethality and Cancer - Penetrance as
the Major Barrier. Trends Cancer, 4(10), 671-683. doi:10.1016/j.trecan.2018.08.003
Sakuma, C., & Chihara, T. (2017). Role of the STRIPAK complex and the Hippo pathway in
synaptic terminal formation. Neural Regen Res, 12(4), 578-579. doi:10.4103/16735374.205089
Sanjana, N. E., Shalem, O., & Zhang, F. (2014). Improved vectors and genome-wide libraries
for CRISPR screening. Nat Methods, 11(8), 783-784. doi:10.1038/nmeth.3047
Search of: FASN - List Results - ClinicalTrials.gov. (2020).
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelson, T., Heckl, D., Ebert,
B. L., Root, D. E., Doench, J. G., & Zhang, F. (2014). Genome-scale CRISPR-Cas9
knockout screening in human cells. Science, 343(6166), 84-87.
doi:10.1126/science.1247005
Shalem, O., Sanjana, N. E., & Zhang, F. (2015). High-throughput functional genomics using
CRISPR-Cas9. Nature Reviews. Genetics, 16(5), 299-311. doi:10.1038/nrg3899
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N.,
Schwikowski, B., & Ideker, T. (2003). Cytoscape: A Software Environment for

142
Integrated Models of Biomolecular Interaction Networks. Genome Research, 13(11),
2498-2504. doi:10.1101/gr.1239303
Shen, J. P., Zhao, D., Sasik, R., Luebeck, J., Birmingham, A., Bojorquez-Gomez, A., Licon, K.,
Klepper, K., Pekin, D., Beckett, A. N., Sanchez, K. S., Thomas, A., Kuo, C.-C., Du, D.,
Roguev, A., Lewis, N. E., Chang, A. N., Kreisberg, J. F., Krogan, N., Qi, L., Ideker, T., &
Mali, P. (2017). Combinatorial CRISPR–Cas9 screens for de novo mapping of genetic
interactions. Nature Methods, 14(6), 573-576. doi:10.1038/nmeth.4225
Shows, T. B., Alper, C. A., Bootsma, D., Dorf, M., Douglas, T., Huisman, T., Kit, S., Klinger, H.
P., Kozak, C., Lalley, P. A., Lindsley, D., McAlpine, P. J., McDougall, J. K., Meera Khan,
P., Meisler, M., Morton, N. E., Opitz, J. M., Partridge, C. W., Payne, R., Roderick, T. H.,
Rubinstein, P., Ruddle, F. H., Shaw, M., Spranger, J. W., & Weiss, K. (1980).
International System for Human Gene Nomenclature (1979) ISGN (1979). Birth
Defects Orig Artic Ser, 15(11), 96-116. Retrieved from
https://www.ncbi.nlm.nih.gov/pubmed/7213958
Simpson, G. L., Team, R. C., Bates, D. M., & Oksanen, J. (2019). permute: Functions for
Generating Restricted Permutations of Data (Version 0.9-5).
Smith, I., Greenside, P. G., Natoli, T., Lahr, D. L., Wadden, D., Tirosh, I., Narayan, R., Root, D.
E., Golub, T. R., Subramanian, A., & Doench, J. G. (2017). Evaluation of RNAi and
CRISPR technologies by large-scale gene expression profiling in the Connectivity
Map. PLoS Biol, 15(11), e2003213. doi:10.1371/journal.pbio.2003213

143
Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998). Neuropilin-1 is
expressed by endothelial and tumor cells as an isoform-specific receptor for vascular
endothelial growth factor. Cell, 92(6), 735-745. doi:10.1016/s0092-8674(00)81402-6
Solimini, N. L., Xu, Q., Mermel, C. H., Liang, A. C., Schlabach, M. R., Luo, J., Burrows, A. E.,
Anselmo, A. N., Bredemeyer, A. L., Li, M. Z., Beroukhim, R., Meyerson, M., & Elledge,
S. J. (2012). Recurrent hemizygous deletions in cancers may optimize proliferative
potential. Science, 337(6090), 104-109. doi:10.1126/science.1219580
Sondka, Z., Bamford, S., Cole, C. G., Ward, S. A., Dunham, I., & Forbes, S. A. (2018). The
COSMIC Cancer Gene Census: describing genetic dysfunction across all human
cancers. Nature Reviews Cancer, 18(11), 696-705. doi:10.1038/s41568-018-0060-1
Sonnichsen, B., Koski, L. B., Walsh, A., Marschall, P., Neumann, B., Brehm, M., Alleaume, A.
M., Artelt, J., Bettencourt, P., Cassin, E., Hewitson, M., Holz, C., Khan, M., Lazik, S.,
Martin, C., Nitzsche, B., Ruer, M., Stamford, J., Winzi, M., Heinkel, R., Roder, M.,
Finell, J., Hantsch, H., Jones, S. J., Jones, M., Piano, F., Gunsalus, K. C., Oegema, K.,
Gonczy, P., Coulson, A., Hyman, A. A., & Echeverri, C. J. (2005). Full-genome RNAi
profiling of early embryogenesis in Caenorhabditis elegans. Nature, 434(7032), 462469. doi:10.1038/nature03353
Sourbier, C., Liao, P. J., Ricketts, C. J., Wei, D., Yang, Y., Baranes, S. M., Gibbs, B. K.,
Ohanjanian, L., Spencer Krane, L., Scroggins, B. T., Keith Killian, J., Wei, M. H., Kijima,
T., Meltzer, P. S., Citrin, D. E., Neckers, L., Vocke, C. D., & Marston Linehan, W.
(2018). Targeting loss of the Hippo signaling pathway in NF2-deficient papillary
kidney cancers. Oncotarget, 9(12), 10723-10733. doi:10.18632/oncotarget.24112

144
Srinivasan, M. D. a. A. (2019). data.table: Extension of `data.frame`. Retrieved from
https://CRAN.R-project.org/package=data.table
St-Denis, N., Gupta, G. D., Lin, Z. Y., Gonzalez-Badillo, B., Veri, A. O., Knight, J. D. R.,
Rajendran, D., Couzens, A. L., Currie, K. W., Tkach, J. M., Cheung, S. W. T., Pelletier,
L., & Gingras, A. C. (2016). Phenotypic and Interaction Profiling of the Human
Phosphatases Identifies Diverse Mitotic Regulators. Cell Rep, 17(9), 2488-2501.
doi:10.1016/j.celrep.2016.10.078
Steinhart, Z., Pavlovic, Z., Chandrashekhar, M., Hart, T., Wang, X., Zhang, X., Robitaille, M.,
Brown, K. R., Jaksani, S., Overmeer, R., Boj, S. F., Adams, J., Pan, J., Clevers, H., Sidhu,
S., Moffat, J., & Angers, S. (2017). Genome-wide CRISPR screens reveal a Wnt-FZD5
signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.
Nat Med, 23(1), 60-68. doi:10.1038/nm.4219
Suemura, S., Kodama, T., Myojin, Y., Yamada, R., Shigekawa, M., Hikita, H., Sakamori, R.,
Tatsumi, T., & Takehara, T. (2019). CRISPR Loss-of-Function Screen Identifies the
Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular
Carcinoma. Cancers (Basel), 11(9). doi:10.3390/cancers11091362
Team, G. M. P. D. (2020). Google Analytics: Google LLC. Retrieved from
https://analytics.google.com/analytics/web/
Team, R. C. (2018). R: A Language and Environment for Statistical Computing. Vienna,
Austria: R Foundation for Statistical Computing. Retrieved from https://www.Rproject.org/
Team, T. R. D. C. (2016). R: A Language and Environment for Statistical Computing.

145
Theodorou, V., Stark, R., Menon, S., & Carroll, J. S. (2013). GATA3 acts upstream of FOXA1 in
mediating ESR1 binding by shaping enhancer accessibility. Genome Res, 23(1), 12-22.
doi:10.1101/gr.139469.112
Therneau, T. M., & Grambsch, P. M. (2000). Modeling Survival Data: Extending the Cox
Model. New York: Springer-Verlag.
Therneau, T. M., until, 2009), T. L. o. S.-R. p. a. R. m., Elizabeth, A., & Cynthia, C. (2020).
survival: Survival Analysis (Version 3.2-3).
Tissier, A., Frank, E. G., McDonald, J. P., Iwai, S., Hanaoka, F., & Woodgate, R. (2000).
Misinsertion and bypass of thymine-thymine dimers by human DNA polymerase
iota. EMBO J, 19(19), 5259-5266. doi:10.1093/emboj/19.19.5259
Tong, A. H., Lesage, G., Bader, G. D., Ding, H., Xu, H., Xin, X., Young, J., Berriz, G. F., Brost, R.
L., Chang, M., Chen, Y., Cheng, X., Chua, G., Friesen, H., Goldberg, D. S., Haynes, J.,
Humphries, C., He, G., Hussein, S., Ke, L., Krogan, N., Li, Z., Levinson, J. N., Lu, H.,
Menard, P., Munyana, C., Parsons, A. B., Ryan, O., Tonikian, R., Roberts, T., Sdicu, A.
M., Shapiro, J., Sheikh, B., Suter, B., Wong, S. L., Zhang, L. V., Zhu, H., Burd, C. G.,
Munro, S., Sander, C., Rine, J., Greenblatt, J., Peter, M., Bretscher, A., Bell, G., Roth,
F. P., Brown, G. W., Andrews, B., Bussey, H., & Boone, C. (2004). Global mapping of
the yeast genetic interaction network. Science, 303(5659), 808-813.
doi:10.1126/science.1091317
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S.,
Harrington, W. F., Pantel, S., Krill-Burger, J. M., Meyers, R. M., Ali, L., Goodale, A.,
Lee, Y., Jiang, G., Hsiao, J., Gerath, W. F. J., Howell, S., Merkel, E., Ghandi, M.,

146
Garraway, L. A., Root, D. E., Golub, T. R., Boehm, J. S., & Hahn, W. C. (2017). Defining
a Cancer Dependency Map. Cell, 170(3), 564-576.e516.
doi:10.1016/j.cell.2017.06.010
Tumaneng, K., Schlegelmilch, K., Russell, R. C., Yimlamai, D., Basnet, H., Mahadevan, N.,
Fitamant, J., Bardeesy, N., Camargo, F. D., & Guan, K. L. (2012). YAP mediates
crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR29. Nat Cell Biol, 14(12), 1322-1329. doi:10.1038/ncb2615
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N.,
Schultz, A. R., Traer, E., Abel, M., Agarwal, A., Blucher, A., Borate, U., Bryant, J.,
Burke, R., Carlos, A., Carpenter, R., Carroll, J., Chang, B. H., Coblentz, C., d’Almeida,
A., Cook, R., Danilov, A., Dao, K.-H. T., Degnin, M., Devine, D., Dibb, J., Edwards, D. K.,
Eide, C. A., English, I., Glover, J., Henson, R., Ho, H., Jemal, A., Johnson, K., Johnson,
R., Junio, B., Kaempf, A., Leonard, J., Lin, C., Liu, S. Q., Lo, P., Loriaux, M. M., Luty, S.,
Macey, T., MacManiman, J., Martinez, J., Mori, M., Nelson, D., Nichols, C., Peters, J.,
Ramsdill, J., Rofelty, A., Schuff, R., Searles, R., Segerdell, E., Smith, R. L., Spurgeon, S.
E., Sweeney, T., Thapa, A., Visser, C., Wagner, J., Watanabe-Smith, K., Werth, K.,
Wolf, J., White, L., Yates, A., Zhang, H., Cogle, C. R., Collins, R. H., Connolly, D. C.,
Deininger, M. W., Drusbosky, L., Hourigan, C. S., Jordan, C. T., Kropf, P., Lin, T. L.,
Martinez, M. E., Medeiros, B. C., Pallapati, R. R., Pollyea, D. A., Swords, R. T., Watts,
J. M., Weir, S. J., Wiest, D. L., Winters, R. M., McWeeney, S. K., & Druker, B. J. (2018).
Functional genomic landscape of acute myeloid leukaemia. Nature, 562(7728), 526531. doi:10.1038/s41586-018-0623-z

147
Tzelepis, K., Koike-Yusa, H., De Braekeleer, E., Li, Y., Metzakopian, E., Dovey, O. M., Mupo,
A., Grinkevich, V., Li, M., Mazan, M., Gozdecka, M., Ohnishi, S., Cooper, J., Patel, M.,
McKerrell, T., Chen, B., Domingues, A. F., Gallipoli, P., Teichmann, S., Ponstingl, H.,
McDermott, U., Saez-Rodriguez, J., Huntly, B. J. P., Iorio, F., Pina, C., Vassiliou, G. S.,
& Yusa, K. (2016). A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and
Therapeutic Targets in Acute Myeloid Leukemia. Cell Reports, 17(4), 1193-1205.
doi:10.1016/j.celrep.2016.09.079
Virtanen, P., Gommers, R., Oliphant, T. E., Haberland, M., Reddy, T., Cournapeau, D.,
Burovski, E., Peterson, P., Weckesser, W., Bright, J., van der Walt, S. J., Brett, M.,
Wilson, J., Millman, K. J., Mayorov, N., Nelson, A. R. J., Jones, E., Kern, R., Larson, E.,
Carey, C. J., Polat, İ., Feng, Y., Moore, E. W., VanderPlas, J., Laxalde, D., Perktold, J.,
Cimrman, R., Henriksen, I., Quintero, E. A., Harris, C. R., Archibald, A. M., Ribeiro, A.
H., Pedregosa, F., & van Mulbregt, P. (2020). SciPy 1.0: fundamental algorithms for
scientific computing in Python. Nature Methods, 17(3), 261-272.
doi:10.1038/s41592-019-0686-2
Wang, T., Birsoy, K., Hughes, N. W., Krupczak, K. M., Post, Y., Wei, J. J., Lander, E. S., &
Sabatini, D. M. (2015). Identification and characterization of essential genes in the
human genome. Science (New York, N.Y.), 350(6264), 1096-1101.
doi:10.1126/science.aac7041
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014). Genetic screens in human cells
using the CRISPR-Cas9 system. Science (New York, N.Y.), 343(6166), 80-84.
doi:10.1126/science.1246981

148
Wang, T., Yu, H., Hughes, N. W., Liu, B., Kendirli, A., Klein, K., Chen, W. W., Lander, E. S., &
Sabatini, D. M. (2017). Gene Essentiality Profiling Reveals Gene Networks and
Synthetic Lethal Interactions with Oncogenic Ras. Cell, 168(5), 890-903.e815.
doi:10.1016/j.cell.2017.01.013
Wang, X., Freire Valls, A., Schermann, G., Shen, Y., Moya, I. M., Castro, L., Urban, S., Solecki,
G. M., Winkler, F., Riedemann, L., Jain, R. K., Mazzone, M., Schmidt, T., Fischer, T.,
Halder, G., & Ruiz de Almodovar, C. (2017). YAP/TAZ Orchestrate VEGF Signaling
during Developmental Angiogenesis. Dev Cell, 42(5), 462-478 e467.
doi:10.1016/j.devcel.2017.08.002
Warnes, G. R., Bolker, B., Bonebakker, L., Gentleman, R., Huber, W., Liaw, A., Lumley, T.,
Maechler, M., Magnusson, A., Moeller, S., Schwartz, M., Venables, B., & Galili, T.
(2020). gplots: Various R Programming Tools for Plotting Data (Version 3.0.4).
Wickham, H. (2016). ggplot2: Elegant Graphics for Data Analysis: Springer.
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G.,
Hayes, A., Henry, L., Hester, J., Kuhn, M., Pedersen, T., Miller, E., Bache, S., Müller,
K., Ooms, J., Robinson, D., Seidel, D., Spinu, V., & Yutani, H. (2019). Welcome to the
Tidyverse. Journal of Open Source Software, 4, 1686. doi:10.21105/joss.01686
Wilke, C. O. (2019). cowplot: Streamlined Plot Theme and Plot Annotations for 'ggplot2'.
Retrieved from https://CRAN.R-project.org/package=cowplot
Xie, Y. (2014). knitr: A Comprehensive Tool for Reproducible Research in R: Chapman and
Hall/CRC.
Xie, Y. (2015, 2015). Dynamic Documents with R and knitr. Routledge & CRC Press.

149
Xie, Y., Zhang, B., Zvoleff, A., http://www.andre-simon.de), A. S. t. C. f. u. i. t. w. d. f. t. H. p.,
Atkins, A., Wolen, A., Manton, A., Yasumoto, A., Baumer, B., Diggs, B., Zhang, B.,
Pereira, C., Dervieux, C., Hugh-Jones, D., Robinson, D., Hemken, D., Murdoch, D.,
Campitelli, E., Hughes, E., Riederer, E., Hirschmann, F., Simeon, F., Fang, F.,
inst/misc/Sweavel.sty), F. E. H. J. t. S. p. a., Aden-Buie, G., Detrez, G., Wickham, H.,
Zhu, H., Jeon, H., Bengtsson, H., Yutani, H., Lyttle, I., Daniel, H., Burkhead, J.,
Manton, J., Lander, J., Punyon, J., Luraschi, J., Arnold, J., Bryan, J., inst/misc/doccoclassic.css), J. A. t. C. f. a., Stephens, J., Hester, J., Cheng, J., Ranke, J., Honaker, J.,
Muschelli, J., Keane, J., Allaire, J. J., Toloe, J., Sidi, J., Larmarange, J., Barnier, J.,
Zhong, K., Slowikowski, K., Forner, K., Smith, K. K., Mueller, K., Takahashi, K.,
Walthert, L., Gallindo, L., Hofert, M., Modrák, M., Chirico, M., Friendly, M.,
Bojanowski, M., Kuhlmann, M., Patrick, M., Caballero, N., Salkowski, N., Hansen, N.
R., Ross, N., Mahdi, O., Li, Q., Vaidyanathan, R., Cotton, R., Krzyzanowski, R.,
Francois, R., Williamson, R., Kostyshak, S., Meyer, S., Brouwer, S., Bernard, S. d.,
Rousseau, S., Wei, T., Assus, T., Lamadon, T., Leeper, T., Mastny, T., Torsney-Weir, T.,
Davis, T., Veitas, V., Zhu, W., Wu, W., & Foster, Z. (2020). knitr: A General-Purpose
Package for Dynamic Report Generation in R (Version 1.29).
Xue, W., Kitzing, T., Roessler, S., Zuber, J., Krasnitz, A., Schultz, N., Revill, K., Weissmueller,
S., Rappaport, A. R., Simon, J., Zhang, J., Luo, W., Hicks, J., Zender, L., Wang, X. W.,
Powers, S., Wigler, M., & Lowe, S. W. (2012). A cluster of cooperating tumorsuppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A,
109(21), 8212-8217. doi:10.1073/pnas.1206062109

150
Yu, F. X., & Guan, K. L. (2013). The Hippo pathway: regulators and regulations. Genes Dev,
27(4), 355-371. doi:10.1101/gad.210773.112
Zerbino, D. R., Achuthan, P., Akanni, W., Amode, M. R., Barrell, D., Bhai, J., Billis, K.,
Cummins, C., Gall, A., Girón, C. G., Gil, L., Gordon, L., Haggerty, L., Haskell, E.,
Hourlier, T., Izuogu, O. G., Janacek, S. H., Juettemann, T., To, J. K., Laird, M. R.,
Lavidas, I., Liu, Z., Loveland, J. E., Maurel, T., McLaren, W., Moore, B., Mudge, J.,
Murphy, D. N., Newman, V., Nuhn, M., Ogeh, D., Ong, C. K., Parker, A., Patricio, M.,
Riat, H. S., Schuilenburg, H., Sheppard, D., Sparrow, H., Taylor, K., Thormann, A.,
Vullo, A., Walts, B., Zadissa, A., Frankish, A., Hunt, S. E., Kostadima, M., Langridge, N.,
Martin, F. J., Muffato, M., Perry, E., Ruffier, M., Staines, D. M., Trevanion, S. J., Aken,
B. L., Cunningham, F., Yates, A., & Flicek, P. (2018). Ensembl 2018. Nucleic Acids
Research, 46(D1), D754-D761. doi:10.1093/nar/gkx1098
Zhang, M. J., Hong, Y. Y., & Li, N. (2018). Overexpression of Kin of IRRE-Like Protein 1
(KIRREL) in Gastric Cancer and Its Clinical Prognostic Significance. Med Sci Monit, 24,
2711-2719. doi:10.12659/MSM.910386
Zhang, Y., Ng, P. K.-S., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong,
K. J., Akbani, R., Hadjipanayis, A., Pantazi, A., Bristow, C. A., Lee, E., Mahadeshwar, H.
S., Tang, J., Zhang, J., Yang, L., Seth, S., Lee, S., Ren, X., Song, X., Sun, H., Seidman, J.,
Luquette, L. J., Xi, R., Chin, L., Protopopov, A., Westbrook, T. F., Shelley, C. S.,
Choueiri, T. K., Ittmann, M., Van Waes, C., Weinstein, J. N., Liang, H., Henske, E. P.,
Godwin, A. K., Park, P. J., Kucherlapati, R., Scott, K. L., Mills, G. B., Kwiatkowski, D. J.,
& Creighton, C. J. (2017). A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR

151
Pathway Alterations. Cancer Cell, 31(6), 820-832.e823.
doi:10.1016/j.ccell.2017.04.013
Zhu, S., Li, W., Liu, J., Chen, C. H., Liao, Q., Xu, P., Xu, H., Xiao, T., Cao, Z., Peng, J., Yuan, P.,
Brown, M., Liu, X. S., & Wei, W. (2016). Genome-scale deletion screening of human
long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat Biotechnol,
34(12), 1279-1286. doi:10.1038/nbt.3715
Zhu, X. G., Nicholson Puthenveedu, S., Shen, Y., La, K., Ozlu, C., Wang, T., Klompstra, D.,
Gultekin, Y., Chi, J., Fidelin, J., Peng, T., Molina, H., Hang, H. C., Min, W., & Birsoy, K.
(2019). CHP1 Regulates Compartmentalized Glycerolipid Synthesis by Activating
GPAT4. Molecular Cell, 74(1), 45-58.e47. doi:10.1016/j.molcel.2019.01.037
Zhu, Y., Zhao, K., Prinz, A., Keyvani, K., Lambertz, N., Kreitschmann-Andermahr, I., Lei, T., &
Sure, U. (2016). Loss of endothelial programmed cell death 10 activates glioblastoma
cells and promotes tumor growth. Neuro-Oncology, 18(4), 538-548.
doi:10.1093/neuonc/nov155

152

Vita
Walter Frank Lenoir IV was born and raised in Austin, Texas and is the son of
Gloria Cisneros Lenoir and Walter Frank Lenoir III. Frank completed high school
at the Library Arts and Science Academy in Austin, Texas in May 2011. In August
2011, Frank started his undergraduate degree at Virginia Tech in Blacksburg,
Virginia. Frank transferred to the University of Texas at Austin in 2012, and
completed his Bachelor of Science degree in Biochemistry, with a certificate in
Computational Science in May 2016. In August of 2016, he entered The
University of Texas MD Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences to pursue his Ph.D. in biomedical science – quantitative
sciences.

